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The eukaryotic genome is composed of chromatin, a complex polymer 
of genomic DNA, RNA, and closely associated proteins. Histone proteins form 
the core of the nucleosome, the fundamental repeating unit of chromatin. Variant 
histone proteins play critical roles in the epigenetic regulation of gene expression 
and in the development of multicellular organisms.
In this thesis, I describe the first genome-wide profiles of histone H3 
variants in pluripotent mammalian embryonic stem (ES) cells, and I establish the 
dependence and independence of these patterns on the histone chaperone Hira. 
To distinguish H3 variants, I use designed zinc finger nucleases (ZFNs) to rapidly 
knock epitope tags into a single allele of the endogenous histone H3.3B gene in 
mouse ES cells.
Genome-wide analysis reveals that H3.3 is enriched in specific patterns 
at active and repressed genes with high CpG content promoters, including 
developmentally repressed bivalent H3K4me3 / H3K27me3 genes in ES cells, 
in addition to transcribed non-coding regions, telomeres, ribosomal DNA (rDNA), 
and genic and intergenic transcription factor binding sites (TFBS). Transcriptional 
termination sites of highly transcribed genes are marked by peaks of H3.3 and 
phosphorylated RNA polymerase II. Differentiation of ES cells into neural precursor 
cells (NPCs) leads to specific changes in H3.3 localization, demonstrating that the 
localization of H3.3 is dependent on cellular state. Targeted gene editing of H3.3B 
to H3.2 or H3.1 using ZFNs demonstrates that these patterns are dependent on 
the amino acid sequence of endogenous H3.3. 
Using wild-type and Hira -/- ES cells, I show that the H3.3 chaperone Hira 
is required for H3.3 enrichment at active and repressed genes. Strikingly, Hira 
is not essential for deposition of H3.3 at rDNA, telomeres, and specific TFBS. 
Immunoaffinity purification and mass spectrometry reveal that the proteins Atrx 
and Daxx associate with H3.3 in a Hira-independent manner.  Using Atrxflox and 
Atrxnull mouse ES cells, I find that Atrx is specifically required for Hira-independent 
enrichment of H3.3 at telomeres and rDNA, and for repression of telomeric and 
ribosomal RNA. Overall, the data in this thesis demonstrate that multiple and 
distinct pathways are responsible for H3.3 deposition at specific genomic locations 
in mammalian cells.
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1CHAPTER 1
GENERAL INTRODUCTION
“The major problem, I think, is chromatin…you can inherit something beyond 
the DNA sequence.  That’s where the real excitement of genetics is now.” 
    ---James Watson (Watson, 2003).
One (mostly) identical genome, many cell types
One of the singular wonders of biology is the capacity of a single cell to give rise to 
a multicellular organism.  Every human begins life as an individual cell, the product 
of fusion of sperm and oocyte, formed with a unique combination of paternal and 
maternal genetic material. Despite the fact that a fully grown human being contains 
an estimated ten trillion different cells (Dobzhansky, 1970; Savage, 1977), organized 
into multiple organs and over four hundred spatially and functionally distinct cell 
types (Vickaryous and Hall, 2006), the vast majority of all of these cells contain 
identical genetic information (Gurdon and Melton, 2008) (Figure 1.1).
During the 1940s, scientists led by Avery, MacLeod, and McCarty here 
at the Rockefeller University demonstrated that genetic information is carried 
by DNA (Avery et al., 1979). However, it was not immediately clear that nearly 
every cell in a multicellular organism is genetically identical.  One possibility was 
that organismal development might permanently alter the genomes of different 
cell types, thereby rendering them genetically distinct from other tissues of the 
body (Gurdon and Byrne, 2003; Gurdon and Melton, 2008).  Beginning in the 
mid twentieth century, developmental biologists including Robert Briggs, Thomas 
King, and John Gurdon conducted a series of pioneering experiments involving 
the transplantation of differentiated frog cell nuclei from various embryonic and 
2Figure 1.1:  Mammalian development generates diverse cell types with identical genomes.
Sperm and oocyte contain distinct haploid genomes. Following fertilization, the paternal and 
maternal pronuclei fuse to form the new genome of the diploid zygote, the unicellular embryo. 
From this point on, most new and old cells of the developing mammal carry an identical diploid 
genome throughout the lifetime of the organism, despite a vast diversity of differentiated cellular 
phenotypes.  After repeated mitotic divisions of the zygote, the mammalian embryo becomes 
a morula (not shown), a ball of cells which begins at the 12-16 cell stage.  About 4 days after 
fertilization in humans, a fluid filled cavity forms in the morula, and the embryo is now known 
as a blastocyst. Cells differentiate into an outer extraembryonic layer known as the trophoblast 
(blue cells), which attaches to the endometrial epithelium and later gives rise to the placenta, and 
an inner layer known as the inner cell mass (ICM) (pink cells), which gives rise to the embryo 
itself. If the blastocyst stage embryo is harvested prior to implantation, pluripotent embryonic 
stem (ES) cells can be derived from the ICM. ES cells have the capacity to self-renew and 
maintain the pluripotent state in culture for extended periods of time. In addition, ES cells can 
differentiate into cells of all germ lineages (ectoderm, endoderm, mesoderm), including neural 
cells, cardiac cells, and pancreatic b-cells depicted below.  When injected back into blastocyst 
mouse embryos, ES cells contribute to the embryo to form chimeras, and can even give rise to 
the germline for passage to the next generation. See (Meissner et al., 2009; Moore et al., 2008).
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4adult tissues (including lung, heart, liver, and intestine) into enucleated frog eggs 
(Gurdon and Byrne, 2003).  Remarkably, Gurdon and colleagues found that some 
of the frog embryos generated from nuclei of fully differentiated somatic cells were 
able to develop into tadpoles and even into adult frogs (Gurdon and Byrne, 2003; 
Laskey and Gurdon, 1970).  These experiments were later successfully conducted 
in mammals with the infamous cloning of Dolly the sheep from the nucleus of a 
cultured adult mammary gland cell by Wilmut and colleagues (Campbell et al., 1996; 
Wilmut et al., 1997) (Figure 1.2).  Although this process of somatic cell nuclear 
transfer is not very efficient, particularly with nuclei from adult cells, the fact that 
even 1-2% of differentiated cell nuclei could develop into a fully formed vertebrate 
demonstrated that cell differentiation is reversible, and does not necessarily alter 
the genetic content of a cell (Gurdon and Byrne, 2003; Gurdon and Melton, 2008; 
Laskey and Gurdon, 1970).  Gurdon and colleagues therefore concluded that the 
genetic blueprint for normal cellular development is preserved in all somatic cells 
of an organism, even in terminally differentiated cells that would normally have no 
Somatic cell nuclear transfer (SCNT)
Single nucleus injected
to enucleated egg
Egg
Second meiotic prophase
Blastula
Fetus
Embryonic
stem cell
Fertile adult
Reprogrammed status
of transplanted nuclei
Pluripotent
Pluripotent
Totipotent
Adapted from Gurdon and Melton, Science 2008.
Somatic
cell
Figure 1.2:  Cell differentiation is reversible
Nuclear transfer experiments by John Gurdon, Ian Wilmut and colleagues demonstrate 
that cell differentiation is reversible (Gurdon and Byrne, 2003; Rossant, 2009). The 
nucleus of a differentiated somatic cell can be transferred to an unfertilized, enucleated 
egg. Some of the new embryos that are generated from nuclear transfer experiments 
can give rise to pluripotent embryonic stem cells, to a new fetus, or a fertile adult. 
5chance of passing on their genetic material.
There are of course a few exceptions to this general principle of the 
conversation of genetic identity during cellular differentiation.  Certain immune 
cells contain genes that are specifically mutated to increase the body’s ability to 
respond to the diverse array of pathogens present in our environment (Teng and 
Papavasiliou, 2007). Some cells such as red blood cells are so specialized that 
they no longer contain any stable genetic information at all, having ejected their 
DNA during terminal differentiation so as to be optimized for carrying oxygen from 
the lungs to various tissues of the body (Chasis and Mohandas, 2008).  However, 
other than a few important exceptions, the vast majority of the trillions of cells that 
make up the human body are genetically identical – unique and subtly different 
from the cells of another human being, but identical to one another.  Yet despite 
this genetic uniformity, the cells of our body are organized into tissues and cell 
types that are enormously different from one another in form and function (Ross 
et al., 2009; Vickaryous and Hall, 2006)  (Figure 1.1).  If their genetic content is 
identical, what makes one cell different from another?
A brief history of gene regulation
Some clues to the dizzying yet highly organized array of cellular diversity lie in 
biochemical studies. Despite generally identical DNA content, the RNA and protein 
content of different tissues can differ greatly (Alaiya et al., 2005; Cloonan et al., 
2008; Wang et al., 2009a).  While some proteins and RNA are common to many 
cell types, even the levels of these so-called ‘housekeeping’ genes and proteins 
can be highly variable (de Jonge et al., 2007). For example, two-dimensional 
electrophoresis studies of different tissue types clearly demonstrate that many 
proteins, even those common to multiple tissues, have dramatically different levels 
in distinct cell types (Alberts, 2002; Minden et al., 2009).  Moreover, patterns of 
6RNA and protein content are so characteristic of cell type that they can be used 
to identify cells of uncertain tissue origin (Alaiya et al., 2005; Bloom et al., 2004; 
Rosenfeld et al., 2008).  If different cells of an individual organism contain identical 
DNA, perhaps what makes one cell phenotypically different from one another 
therefore lies largely in the RNA and protein content of the cell.
Classic studies from Jacob and Monod in bacteria provided a model for 
basic genetic control mechanisms by which the biochemical composition (RNA 
and protein content) of a cell was determined by regulated transcription of DNA 
into RNA, offering a potential solution to the problem of how an identical cellular 
genome can give rise to such phenotypic diversity (Monod and Jacob, 1961).  The 
expression of specific genes can be regulated in a temporal and spatial manner 
that allows for cellular differentiation and organismal development.  In 1961, Jacob 
and Monod wrote:
It may be in the interpretation and analysis of differentiation that the new 
concepts derived from the study of microorganisms will prove of the greatest 
value.  One point at least already seems to be quite clear: namely that 
biochemical differentiation (reversible or not) of cells carrying an identical 
genome, does not constitute a “paradox,” as it appeared to do so for many 
years, to both embryologists and geneticists….The control mechanisms 
discovered in microorganisms govern the expression of genetic potentialities 
(Monod and Jacob, 1961).
Thus, the concept of regulated cellular gene expression in the development 
of higher eukaryotes was born in the field of bacterial genetics.  However, the 
mechanisms underlying the regulation of eukaryotic gene expression remained 
initially obscure.
In 1969, a key component of this puzzle for eukaryotes was solved with 
the landmark discovery of RNA polymerases by Robert Roeder (Roeder and 
Rutter, 1969).  As a graduate student in William Rutter’s lab, Roeder purified three 
DNA-dependent RNA polymerases, now known as RNA polymerase (RNAP) I, 
II, and III, and demonstrated that RNAPI was localized to the nucleolus (the site 
7of ribosomal DNA transcription), while RNAPII and RNAPII were restricted to the 
nucleoplasm (Roeder and Rutter, 1969, 1970).  The discovery that three different 
enzymes catalyzed the transcription of DNA into RNA was quite surprising, 
particularly given that most contemporary scientists believed that animal cells 
contained a single enzyme (Roeder, 2003).  In the following years, Roeder and 
colleagues demonstrated that each of the three RNAP enzymes was dedicated 
to the transcription of specific classes of genes (Abmayr and Workman, 2003; 
Roeder, 2003). Specifically, RNAPI catalyzed the synthesis of ribosomal RNA 
(rRNA), RNAPII catalyzed the synthesis of pre-messenger RNA (pre-mRNA), and 
RNAPIII catalyzed the synthesis of transfer RNA (tRNA) and 5S rRNA (Weinmann 
et al., 1974; Weinmann and Roeder, 1974).
With further biochemical studies, it soon became clear to Roeder and 
colleagues that the mechanisms underlying eukaryotic gene regulation must 
involve many more factors beyond the three different types of RNA polymerase. 
For example, each of the different types of polymerase was found to be composed 
of multiple subunits, most of which are unique to the specific type of polymerase 
(Sklar et al., 1975). In addition, transcription of mammalian gene sequences by the 
different RNA polymerases required multiple additional enzyme-specific recognition 
factors, and the gene regulation field spent many productive years defining the 
identity of these general transcription initiation factors, and the ordered assembly 
of functional transcription pre-initiation complexes (Matsui et al., 1980; Roeder, 
2003; Segall et al., 1980; Sikorski and Buratowski, 2009).  After the sequencing 
of the human genome, it was estimated that 200-300 genes code for proteins 
that make up the general transcriptional machinery (Lander et al., 2001; Venter et 
al., 2001).  However, these general transcription factors are promiscuous in their 
capacity to transcribe numerous genes (Luse et al., 1981; Sikorski and Buratowski, 
2009), and the identification of general transcriptional machinery therefore did not 
8solve the mystery of gene-specific and cell-type specific transcription that occurs 
during normal development and cellular differentiation.
To activate or repress the transcription of particular genes, cells utilize 
factors that recognize specific sequences of DNA.  Sequence-specific DNA 
binding proteins were initially identified in prokaryotes (Jacob and Monod, 1961). 
In 1980, the identification and purification of TFIIIA provided the first example of 
a sequence-specific DNA binding transcription factor in eukaryotes (Abmayr and 
Workman, 2003; Engelke et al., 1980; Roeder, 2003). Numerous sequence-specific 
DNA binding proteins have been subsequently identified, and ~1400 proteins are 
estimated to serve as transcription factors that bind to sequence-specific elements 
in humans (Farnham, 2009; Vaquerizas et al., 2009).  More recently, multiple groups 
have identified large subunit complexes that mediate physical and functional links 
between sequence-specific transcription factors and the general transcriptional 
machinery, with certain subunits capable of interacting with specific TFs (Biddick 
and Young, 2005; Kornberg, 2005; Malik and Roeder, 2005; Meisterernst et al., 
1991).  Many of the activities of these complexes converge on the post-translational 
modification of histones in chromatin (Black et al., 2006; Venters and Pugh, 2009), 
a subject that will be addressed in a following section (Figure 1.3).
Tissue and lineage-specific transcription factors can play critical roles in 
regulating and even defining cellular identity (Hemberger et al., 2009; Niwa et 
al., 2000). Recently, these lineage-defining properties of transcription factors have 
been used to switch and reprogram cells from one somatic lineage into differentiated 
cells of a different lineage and even to pluripotent cells (Gurdon and Melton, 2008; 
Jaenisch and Young, 2008; Yamanaka, 2009). For example, the expression of 
the muscle specific transcription factor myoD is sufficient to switch a variety of 
nonmuscle cell types into muscle (Weintraub et al., 1989).  Some developmentally 
important transcription factors often act in combination with other transcription 
9Figure 1.3:  Contemporary view of gene activation
General transcription factors and RNA polymerase II (RNAPII) (green ovals) bind to thousands of 
core promoter regions through recognition of common elements such as TATA boxes and initiators 
(INR), but this binding alone provides very low transcriptional activity. Transcription can be increased 
by (1) binding of a site-specific DNA binding factor (red trapezoid) to cis elements in the proximal 
promoter region and stabilizing the recruitment of the transcriptional machinery.  Promoter activity 
can be further stimulated (+) by site-specific factors (orange) binding to enhancers (2), but this 
step is not sufficient for high levels of transcription.  Cell-type specific enhancer factors (pink) can 
cooperate with site-specific factors to stimulate transcription by recruiting a coactivator (3) such as 
a histone modifying enzyme (for example, a histone acetyltransferase, HAT) that can create a more 
favorable environment for transcription (++). The bottom illustration represents long-distance looping 
of a distal enhancer element to promote transcription in the context of chromatin.  Nucleosomes 
are depicted, with the possible contribution of histone variants (light green) and specific histone 
tail modifications (small blue and pink spheres) to be discussed later.  The elongating RNAPII 
is phosphorylated on its C-terminal domain, and the pink strand represents the growing RNA 
transcript.  This figure has been adapted from (Farnham, 2009).
TF = transcription factor.  TFBS = transcription factor binding site.  TSS = transcription start site. 
TES = transcription end site.
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factors (Chen et al., 2008b; Farnham, 2009), a realization that was utilized in the 
landmark development of cellular reprogramming (Takahashi and Yamanaka, 2006). 
In 2006, Yamanaka and colleagues demonstrated that the retroviral introduction of 
genes encoding 4 transcription factors enriched in ES cells (Oct4, Sox2, Klf4, and 
c-Myc) enabled differentiated fibroblasts to take on a cellular phenotype similar to 
pluripotent ES cells, subsequently known as induced pluripotent stem (iPS) cells 
(Takahashi and Yamanaka, 2006; Yamanaka, 2009) (Figure 1.4). Along with the 
previous experiments of Gurdon and colleagues described above, such cellular 
Reprogramming
+ reprogramming factors
Induced pluripotent 
stem (iPS) cell
Developmental potental
of reprogrammed cells
Pluripotent
Somatic
cell
Neural cells Cardiac cells Hepatocytes Pancreatic
β-cells
Adapted from Yamanaka, Cell 2009.
Patient
Regenerative
medicine
Figure 1.4: Cellular reprogramming generates induced pluripotent stem cells from 
differentiated cells
Cellular reprogramming further demonstrates the reversibility of cell differentiation.  As originally 
developed by Yamanaka and colleagues in 2006, reprogramming factors (such as transcription 
factors Oct4, Sox2, Klf4, and c-myc) can be introduced in a variety of ways into a differentiated 
somatic cell.  After a period of time, a number of these somatic cells will take on the morphology and 
cellular phenotype of pluripotent ES cells, and such reprogrammed cells are subsequently known as 
induced pluripotent stem (iPS) cells.  Like ES cells, iPS cells have the capacity to differentiate into 
cells of all germ lineages.  Patient-derived iPS cells can be used to produce various differentiated 
somatic cells with the same genotype as the patient, and these cells therefore have great potential 
for use in cell transplantation therapy.  This figure and legend has been adapted from (Yamanaka, 
2009).
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reprogramming conclusively demonstrates that under specific conditions, cellular 
differentiation is reversible.  Moreover, cellular reprogramming also paves the way 
for the development of patient specific iPS cells that could be used for therapeutic 
purposes in regenerative medicine (Rossant, 2009; Yamanaka, 2009).
Although the advent of reprogramming has revolutionized the concept of 
cellular identity, reprogramming remains a very inefficient process (Gurdon and 
Melton, 2008). In addition, cellular reprogramming is most efficient with embryonic 
cells, and becomes progressively less efficient as cells become more differentiated 
(Gurdon and Melton, 2008; Yang et al., 2007).  As cells differentiate, they not only 
establish coordinated changes in patterns of cellular gene expression, but maintain 
these patterns long after they are established (Hemberger et al., 2009). Despite 
recent progress, the mechanisms underlying the establishment, maintenance, and 
propagation of these epigenetic states remain major challenges in biology.  What 
accounts for this stability of cellular phenotype?  
Nearly fifty years ago, Jacob and Monod already recognized that this relative 
stability of gene expression in higher eukaryotes marked a clear difference with the 
gene regulatory systems that they were uncovering in prokaryotes.
Most of the actual systems [involved in gene regulation in microorganisms]… 
are entirely reversible, in the sense that the effects of inhibitors, inducers, 
or repressors do not survive for any length of time after elimination of the 
active agent, and the cells soon return to their initial state. Differentiation, 
on the other hand, is stable, and persists once it has been induced. (Monod 
and Jacob, 1961)
Some of this phenotypic stability in the differentiation of metazoan cells can be 
attributed to autoregulatory loops of specific master regulatory transcription factors 
that reinforce cellular gene expression programs (Jaenisch and Young, 2008; 
Odom et al., 2006). However, transcription factors are not the only determinants 
of cellular identity.  Even after somatic cell nuclei have undergone two rounds of 
transfer to the completely different cellular environment of the egg, these nuclei 
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will sometimes inappropriately ‘remember’ their original tissue of origin, expressing 
genes characteristic of their previous differentiated state (Ng and Gurdon, 2005, 
2008).  How do cell nuclei remember their tissue identity, even in the face of a 
completely different cellular environment, with a distinct repertoire of transcriptional 
regulatory proteins? What is the material actually being transferred during somatic 
cell nuclear transfer? Recently, genetic and biochemical evidence has converged 
to connect many of the mechanisms underlying cellular memory at the level of 
chromatin, the complex of DNA and intimately associated proteins at the center of 
a eukaryotic nucleus (Goldberg et al., 2007).
Epigenetics
As described above, the differentiation of cells in a multicellular organism involves 
changes in gene expression, but largely not in DNA content (Hemberger et al., 
2009).  Such a stable and heritable alteration in cellular phenotype in the absence 
of DNA changes can be referred to as an ‘epigenetic’ phenomenon (Goldberg et 
al., 2007).
Epigenetics has recently evolved from a collection of diverse phenomena 
into a defined and far-reaching field of study (Allis et al., 2007).  Historically, the 
word ‘epigenetics’ was used to describe events that could not be explained by 
genetic principles. Conrad Waddington (1905-1975), who is given credit for coining 
the term, defined epigenetics as “the branch of biology which studies the causal 
interactions between genes and their products, which bring the phenotype into 
being” (Waddington, 1942). Over the years, numerous biological phenomena, 
some considered bizarre and inexplicable, have been lumped into the category of 
epigenetics. These include seemingly unrelated processes, such as paramutation 
in maize (an interaction between two alleles in which one allele causes heritable 
changes in the other allele) (Cuzin et al., 2008); position effect variegation (PEV) 
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in the fruit fly Drosophila (in which the local chromatin environment of a gene 
determines its expression) (Girton and Johansen, 2008); and imprinting of specific 
paternal or maternal loci in mammals (Kacem and Feil, 2009; Weaver et al., 
2009). Although mysteries abound, the field is now beginning to uncover common 
molecular mechanisms underlying epigenetic phenomena. 
Epigenetics, in a broad sense, is a bridge between genotype and phenotype—a 
phenomenon that changes the final outcome of a locus or chromosome without 
changing the underlying DNA sequence.  As described above, even though the 
vast majority of cells in a multicellular organism share an identical genotype, 
organismal development generates a diversity of cell types with disparate, yet 
stable profiles of gene expression and distinct cellular functions. Thus, cellular 
differentiation may be considered an epigenetic phenomenon, largely governed 
by changes in what Waddington described as the “epigenetic landscape” rather 
than alterations in genetic inheritance (Waddington, 1957); Figure 1.5). More 
specifically, epigenetics may be defined as the study of any potentially stable, 
and ideally, heritable change in gene expression or cellular phenotype that occurs 
without changes in Watson-Crick base-pairing of DNA (Allis et al., 2007; Goldberg 
et al., 2007). Despite the field’s recent progress, significant and fundamental 
questions remain to be answered, many of which center on the propagation of 
epigenetic information through cellular division and differentiation. 
Chromatin biology and epigenetic mechanisms
Current epigenetic research has recently converged on the study of covalent and 
non-covalent modifications of DNA and histone proteins, and the mechanisms by 
which such modifications influence overall chromatin structure. Various overlapping 
mechanisms have been implicated in the epigenetic regulation of gene expression, 
including transcription factors (TFs), non-coding RNAs, covalent and non-covalent 
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modifications to histone proteins, and DNA methylation (Guttman et al., 2009; 
Henikoff, 2008; Klose and Bird, 2006; Rando and Chang, 2009; Takahashi and 
Yamanaka, 2006).  Chromatin, the complex of protein and nucleic acids within 
the nucleus of eukaryotic cells, provides an attractive candidate for shaping the 
features of a cell’s epigenetic landscape (Bernstein et al., 2007; Goldberg et al., 
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Figure 1.5: Early and contemporary views of epigenetics
In 1957, Conrad Waddington proposed the concept of an epigenetic landscape to represent the 
process of cellular decision-making during development. At various points in this dynamic visual 
metaphor, the cell (represented by a ball) can take specific permitted trajectories, leading to different 
outcomes or cell fates. Today, developmental biology would represent the ball at its highest point as 
an embryonic stem (ES) cell or induced pluripotent stem (iPS) cell.  Further differentiation can give 
rise to precursor cells of a committed lineage, such as neural precursor cells or hematopoietic stem 
cells, each of which can also give rise to further precursors or terminally differentiated cells within 
that lineage. Figure reprinted and modified from Waddington, 1957.
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2007).
Chromatin – the physiological form of the eukaryotic genome
The term ‘chromatin’ was originally coined by Walther Flemming around 1880 to 
refer to “that substance in the nucleus which is readily stained” (Flemming, 1882; 
Olins and Olins, 2003), and now generally refers to the complex of nuclear DNA, 
RNA, and closely associated proteins (Allis et al., 2007).  Chromatin packages 
the eukaryotic genome into a periodic nucleoprotein structure, and serves as the 
physiological substrate of all DNA-dependent processes, including gene regulation 
(Wolffe, 1992).  In each cell of higher eukaryotes, chromatin packs two meters worth 
of genomic DNA more than 10,000 fold in order to fit into a nuclear compartment 
only a few microns in diameter (Allis et al., 2007; Felsenfeld and Groudine, 2003; 
Jiang and Pugh, 2009) (Figure 1.6A). Highly basic histone proteins form the core 
of chromatin’s repeating nucleosome core particle (Kornberg, 1974; Kornberg and 
Thomas, 1974; Olins and Olins, 1974; Oudet et al., 1975). In a single nucleosome, 
two superhelical turns of approximately 146 base pairs of DNA wrap around an 
octamer of histone proteins H2A, H2B, H3, and H4 (Luger et al., 1997) (Figure 
1.6B).  Critically, these repeating octamers of histone proteins and DNA do not 
form a homogenous, uniform chromatin structure inside the cell’s nucleus.  Rather, 
the eukaryotic nucleus is compartmentalized, and the location of a gene within the 
nucleus can significantly affect its expression (Lieberman-Aiden et al., 2009; Zhao 
et al., 2009). In general, the interphase eukaryotic nucleus can be divided into 
areas of highly condensed chromatin, known as heterochromatin, and regions with 
less compacted chromatin, known as euchromatin (Allis et al., 2007) (Figure 1.6C). 
Actively transcribed genes are generally found in euchromatin, which replicates 
early in S-phase, while the more densely packed heterochromatin is gene poor, 
enriched in repetitive DNA, and replicates late in S-phase (Carmo-Fonseca, 2002; 
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Martens et al., 2005).
Eukaryotic cells have evolved multiple overlapping mechanisms for 
introducing biologically-relevant variation into chromatin.  Nucleosome positioning 
in eukaryotic genomes is non-random, with some aspects of nucleosome 
organization encoded by intrinsic nucleotide sequence (Segal et al., 2006; Segal 
Figure 1.6:  Chromatin structure and organization
A.  Chromatin is the physiological form of the eukaryotic genome. The fundamental unit of chromatin 
organization is the nucleosome, in which 146 bp of DNA are wound around an octamer of histone 
proteins.  Nucleosomes are connected to one another by short stretches of linker DNA.  At the 
next level of organization, the string of nucleosomes is folded into a 30nm fiber, and these fibers 
are further folded into higher order structures.  Figure and legend adapted from (Felsenfeld and 
Groudine, 2003). 
B.  The crystal structure of the nucleosome core particle was solved by Luger and colleagues 
(Luger et al., 1997).  Note the DNA double helix wrapped around an octamer of histone proteins H3, 
H4, H2A, and H2B.  One protruding histone H3 N-terminal tail is indicated in red, and such histone 
tails are sites of dense covalent modifications (Allis et al., 2007; Kouzarides, 2007).
C.  Electron micrograph of a plasma cell from bone marrow. The nucleus is divided into electron-
dense dark regions of heterochromatin (H) and lighter regions of euchromatin (E).
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and Widom, 2009).  In addition, the localization and stability of nucleosomes at 
specific genomic locations appears to be regulated by a combination of factors, 
including ATP-dependent chromatin remodeling enzymes, covalent modifications 
to histone proteins and DNA, the binding of chromatin-associated effector proteins, 
the localization and molecular interactions of specific non-coding RNAs, and 
the incorporation of primary sequence histone variants (Henikoff, 2008; Jiang 
and Pugh, 2009; Klose and Bird, 2006; Loyola and Almouzni, 2007; Rando and 
Chang, 2009; Schones et al., 2008; Wilusz et al., 2009).  (Figure 1.7) It is likely 
that the macromolecular processes described below all significantly contribute 
to the physiologically relevant organization of most eukaryotic genomes. These 
entities, and possibly others yet unknown, should be considered collectively when 
exploring epigenetic mechanisms.  Each of these mechanisms will be discussed 
briefly below, with a larger focus on histone variants.
Non-coding RNA
Recently, it has become evident that RNAs, particularly non-coding RNAs, play 
critical roles in multiple epigenetic phenomena (Bernstein and Allis, 2005; Rinn et 
al., 2007). Clear examples of RNA involvement range from dosage compensation 
mechanisms in Drosophila and mammals mediated by the rox and XIST RNAs, 
respectively, to the silencing of both genes and repetitive sequences by post-
transcriptional (PTGS) and transcriptional (TGS) RNA interference (RNAi)-related 
pathways, respectively, in almost all eukaryotes (Bernstein and Allis, 2005).  These 
RNAs often act in concert with various components of the cell’s chromatin modifying 
and DNA methylation machinery to maintain active or inactive states of gene 
expression (Wilusz et al., 2009).  Although we might not consider PTGS–inducing 
RNAs (e.g. microRNAs, siRNAs etc.) to be epigenetic in nature, TGS-evoking 
RNAs (e.g. repeat associated siRNAs, Xist RNA, and small RNAs in S. pombe) are 
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more clearly epigenetic, as they can induce long term silencing effects that can be 
inherited through cell division (Bernstein and Allis, 2005).  In the last year, more 
than ~1600 large intervening non-coding RNA (lincRNA) transcripts were identified 
in mammalian cells, many of which were tissue-specific (Guttman et al., 2009).  A 
number of these lincRNAs have been shown to associate with chromatin-related 
silencing proteins and affect gene expression (Khalil et al., 2009), and it seems 
likely that our appreciation for the role of RNA in epigenetic phenomena will grow 
Nucleosome
remodeling
Chromatin
modifications
Histone
variants
Figure 1.7:  Mechanisms for introducing variation into chromatin
Eukaryotic cells utilize three primary mechanisms for intruding variation into the chromatin fiber. 
Nucleosomes can be physically mobilized and remodeled by ATP-dependent chromatin remodeling 
enzymes (top) (Clapier and Cairns, 2009). In addition, histones and DNA can be marked by 
various types of covalent modifications (red and blue spheres, middle). These modifications can 
result in distinct biological outcomes through direct physical effects, or through the binding of 
modification-specific effectors (Kouzarides, 2007). Finally, variant histone proteins with distinct 
amino acid compositions can be substituted into chromatin (bottom). These histone variants can 
bring with them a unique repertoire of covalent modifications, or they can serve to replace existing 
modifications (Loyola and Almouzni, 2007). In addition, histone variants can also have direct effects 
on nucleosome stability and mobility (Henikoff, 2008; Jin and Felsenfeld, 2007).
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significantly in the near future.
DNA methylation
DNA methylation is perhaps the best-characterized and most clearly heritable 
chemical modification of chromatin.  In mammals, nearly all DNA methylation 
occurs on cytosine residues of CpG dinucleotides (Ng and Bird, 1999).  Regions of 
the genome that have a high density of CpGs are referred to as CpG islands, and 
DNA methylation of these islands correlates with transcriptional repression (Goll 
and Bestor, 2005).  Genomic patterns of cytosine methylation in mammals, whether 
donated by de novo or maintenance DNA methyltransferases (DNMTs), play a 
critical role in gene regulation and chromatin organization during embryogenesis 
and gametogenesis (Goll and Bestor, 2005).  Maintenance methyltransferases 
add methyl groups to hemi-methylated DNA during DNA replication, whereas de 
novo DNMTs act after replication (Groth et al., 2007b). Moreover, the formation of 
heterochromatin in many organisms is mediated in part by DNA methylation and its 
binding proteins, in combination with RNA and histone modifications characteristic 
of silent chromatin (Zaratiegui et al., 2007). Methylated DNA can be recognized 
by binding proteins such as MeCP2 (Jones et al., 1998), and mutations in MeCP2 
have been shown to cause the human neurodevelopmental disorder Rett syndrome 
(Chahrour and Zoghbi, 2007).  DNA methylation plays a role in many cellular 
processes including silencing of repetitive and centromeric sequences from fungi 
to mammals; X chromosome inactivation in female mammals; and mammalian 
imprinting, all of which can be stably maintained through cellular division (Yang 
and Kuroda, 2007). Taken together, DNA methylation provides a stable, heritable, 
and critical component of epigenetic regulation.  
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Covalent histone modifications and chromatin remodeling
For many years, chromatin was considered largely an inert scaffold and packing 
mechanism for nuclear DNA (Felsenfeld and Groudine, 2003). If anything, histone 
proteins were recognized as a simple impediment to gene transcription, as they 
were found to inhibit RNA synthesis (Allfrey et al., 1963), but they were not widely 
seen as playing any active or regulatory role. However, over the last four decades, 
significant genetic and biochemical evidence has accumulated to connect histone 
modifications with the regulation of gene expression.
Histone proteins were originally recognized to carry a high level of acetylation 
over 45 years ago (Phillips, 1963).  In 1964, Vincent Allfrey and colleagues here 
at the Rockefeller University proposed a possible function of post-translational 
histone acetylation in the positive regulation of gene expression (Allfrey et al., 
1964).  Allfrey and colleagues noted that histones were acetylated even in the 
presence of inhibitors of protein synthesis, indicating that histone acetylation could 
take place following protein translation (Allfrey et al., 1964).  Moreover, they found 
that unlike unacetylated histones, acetylated histones were relatively permissive 
for RNA synthesis in isolated nuclei (Allfrey et al., 1964).  Intriguingly, the timing 
of histone acetylation was also correlated with gene transcription, with histone 
acetylation preceding the increase in RNA synthesis (Pogo et al., 1966). In a 
prescient suggestion, Allfrey and colleagues wrote:
The findings introduce the possibility that histone effects on nuclear RNA 
metabolism may involve more than a simple inhibition of RNA synthesis, 
and that more subtle mechanisms may exist which permit both inhibition 
and reactivation of RNA production at different loci along the chromosome 
(Allfrey et al., 1964).  
The relationship between histone acetylation and gene transcription was further 
supported by later studies showing that hyperacetylated core histones preferentially 
associate with active areas of the genome that are more easily accessible to 
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nuclease digestion (Sealy and Chalkley, 1978; Vidali et al., 1978).  In addition, 
genetic studies by Michael Grunstein and colleagues demonstrated that histone 
acetylation sites are required to alleviate nucleosomal gene repression in yeast 
(Durrin et al., 1991; Kurdistani and Grunstein, 2003). Biochemical experiments 
also suggested that histone tail acetylation could directly facilitate transcription 
factor access to nucleosomal DNA (Lee et al., 1993). However, despite this wealth 
of correlative evidence linking histone acetylation and transcriptional regulation, 
the specific molecular mechanisms responsible for histone covalent modifications 
remained obscure for many decades.
In the mid 1990s, two discoveries led to a major paradigm shift in the field 
of eukaryotic gene regulation, and forever upended the view that histones act 
solely as passive “scaffolding” for packaging genomic DNA. Using a novel in-gel 
activity assay, James Brownell, David Allis, and colleagues identified and purified 
the first histone acetyltransferase (HAT) enzyme from the transcriptionally active 
macronucleus of the ciliated protozoan Tetrahymena thermophila (Brownell and 
Allis, 1995; Brownell et al., 1996). Critically, this first HAT was highly homologous 
to the yeast protein Gcn5p, a transcriptional adaptor protein that had already 
been implicated in transcriptional activation (Brownell et al., 1996). This finding 
was soon followed by the identification of the first histone deacetylase (HDAC) 
enzyme by Stuart Schreiber and colleagues, and this first HDAC was found to 
be homologous to a yeast protein (Rpd3p) previously implicated in transcriptional 
repression (Taunton et al., 1996). Together, these landmark discoveries immediately 
suggested molecular mechanisms to employ “both inhibition and reactivation of 
RNA production at different loci along the chromosome,” as originally suggested 
by Allfrey, providing a critical and previously missing mechanistic link between 
chromatin structure and transcriptional output (Allfrey et al., 1964; Struhl, 1998).
It is now clear that histones can be marked with a wide variety of chemical 
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and peptide modifications in addition to acetylation, including methylation, 
phosphorylation, ADP-ribosylation, ubiquitination, and sumoylation (Kouzarides, 
2007). These covalent modifications can also be dynamically removed by a variety 
of enzymes and mechanisms, including histone deacetylases, phosphatases, 
dequbiquitinases, arginine demethyliminases, lysine demethylases, and direct 
histone proteolysis (Duncan et al., 2008; Keogh et al., 2006; Litt et al., 2009; 
Minucci and Pelicci, 2006; Nottke et al., 2009; Weake and Workman, 2008). 
Genetic and biochemical evidence has recently converged to clearly connect 
covalent histone modifications with longstanding epigenetic phenomena.  Genetic 
screens for suppressors of PEV (Su(var)) in Drosophila, for example, revealed 
over 100 genes that encode vital constituents of heterochromatin. Many of these 
genes are conserved from flies to humans, including heterochromatin protein 1 
(HP1) and the histone H3K9 methyltransferase Su(var)3-9 (Schotta et al., 2003). 
Drosophila genetics also provides another link between epigenetics and histone 
modifications, in the form of two evolutionarily conserved families of proteins that 
regulate homeotic genes antagonistically during development: the Polycomb 
Group (PcG) and the Trithorax Group (TrxG). Further molecular characterization 
of PcG genes reveals that they contribute to two distinct protein complexes that 
are responsible for ‘writing’ (Polycomb Repressive Complex 2) and ‘reading’ 
(PRC1) methylation of H3K27 and facilitating chromatin condensation (Whitcomb 
et al., 2007). Meanwhile, TrxG proteins mediate methylation of H3K4 and promote 
transcriptionally active chromatin (Ringrose and Paro, 2004; Ruthenburg et al., 
2007a). 
How might covalent histone modifications modify chromatin structure to 
influence patterns of gene expression (Jenuwein and Allis, 2001)?  A longstanding 
literature suggests that charge-altering modifications such as acetylation and 
phosphorylation can directly alter the physical properties of the chromatin fiber, 
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leading to changes in higher-order structures (Hong et al., 1993; Struhl, 1998). 
More recently, effector-mediated functions have been well documented, whereby 
histone modifications recruit or stabilize the localization of specific binding partners 
to chromatin. In the first example of an emerging epigenetic paradigm, the catalytic 
enzyme Su(var)3-9 serves as a ‘writer’ of histone H3K9 methylation (Rea et al., 2000), 
whereas HP1 serves as a ‘reader’ or ‘effector’ recognizing  H3K9 methylation and 
directing biological processes (such as heterochromatin stabilization) to particular 
areas of the chromatin fiber (Lachner et al., 2001). In addition, effector-repulsive 
functions have been demonstrated in which histone modifications abrogate the 
binding of particular effectors (Fischle et al., 2005; Ooi et al., 2007).
Several investigators have noted that the combinatorial complexity of 
various covalent modifications could provide the physical structure of the genome 
with a powerful epigenetic marking system for conveying information outside of 
DNA sequence itself (Jenuwein and Allis, 2001; Strahl and Allis, 2000; Turner, 
2000). This “histone code” of post-translational modifications could be read 
both by direct physical effects and by the binding of effector proteins, and could 
potentially contribute to the heritability of transcriptional states through cell division 
(Jenuwein and Allis, 2001; Strahl and Allis, 2000).  Recent evidence suggests that 
multiple histone modifications may provide a multivalent platform for combinatorial 
interactions with several linked effector modules (Moriniere et al., 2009; Ruthenburg 
et al., 2007b). However, it remains to be seen whether histone modifications are 
truly ‘epigenetic,’ and much research is currently focused on determining if and 
how patterns of histone modifications are inherited through DNA replication (Groth 
et al., 2007b).
Non-covalent mechanisms such as chromatin remodeling provide the cell 
with additional tools for introducing variation into the chromatin template (Figure 
1.7). ATP-dependent chromatin remodeling complexes are thought to modify 
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chromatin accessibility by altering histone-DNA interactions, perhaps by sliding 
or ejecting nucleosomes (Smith and Peterson, 2005).  Specifically targeted 
remodeling complexes may open or close chromatin in a localized area of the 
genome, or globally remodel chromatin structure throughout the nucleus (Lusser 
and Kadonaga, 2003; Smith and Peterson, 2005). 
Chromatin remodelers are critical for a variety of nuclear processes, 
including the proper spacing of nucleosomes following replication, access to DNA 
during DNA repair processes, regulating the exposure of regulatory elements, and 
the replacement and proper positioning of nucleosomes following transcription 
(Clapier and Cairns, 2009). For precise control of gene expression, such modulation 
of nucleosome location and stability may be particularly important in regulating 
access of transcription factors to regulatory elements, as well regulating access of 
the transcriptional machinery to promoters (Henikoff, 2008).  Mutations in specific 
chromatin remodelers have been linked to several human developmental disorders, 
including alpha thalassemia and X-linked mental retardation (Gibbons et al., 2008), 
a subject that will be discussed in more detail in Chapters Three and Four.  
Mechanistic links between covalent and non-covalent mechanisms 
have also been uncovered, as modification ‘effectors’ can include subunits of 
nucleosome remodeling complexes (Wysocka et al., 2006). It is becoming clear 
that significant ‘crosstalk’ exists between different epigenetic pathways. In S. 
pombe, for example, biochemical purification of the RNAi machinery revealed 
an interaction between small RNAs and chromatin regulators such as the 
H3K9me-reading chromodomain-containing protein Chp1 (Grewal and Jia, 2007). 
Silencing of the inactive X chromosome is another prime example, where Xist 
RNA, DNA methylation, histone modifications, their ‘writers’ and ‘readers,’ all 
play a role (Heard, 2005).  Moreover, DNMTs act in part by interacting directly 
or indirectly with chromatin modifying enzymes such as histone deacetylases 
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(Dobosy and Selker, 2001).  Recent studies reveal that DNMT3L, an essential 
accessory protein to the de novo DNMTs in the germline, interprets patterns of 
histone modifications, adding weight to an emerging theme that DNA methylation 
and histone modifications functionally interact (Freitag and Selker, 2005; Ooi et 
al., 2007).  Covalent modification, nucleosome remodeling, and histone variants 
(discussed in detail below) work together to introduce meaningful variation into the 
chromatin fiber, and their collective contribution to epigenetics is only now being 
rigorously explored. 
Chromatin immunprecipitation, high-throughput sequencing, and genome-
wide approaches to chromatin state
The development of chromatin immunoprecipitation (ChIP) has provided a powerful 
tool to assess the precise localization of specific proteins or covalent modifications 
in the genome (Kuo and Allis, 1999; O’Neill and Turner, 2003). For many years, 
histone acetylation was indirectly associated with transcriptionally active areas of 
the genome.  For example, acetylated histones and active genes were both found 
enriched in more open, accessible regions of the genome that were preferentially 
released following nuclease digestion (Sealy and Chalkley, 1978; Vidali et al., 
1978; Weintraub and Groudine, 1976).  However, one possibility was that the 
use of nucleases released multiple populations of chromatin, one of which was 
enriched in acetylated histones, and one of which was enriched in active genes 
(Hebbes et al., 1988). How could one determine if the population of chromatin 
with acetylated histones actually carried the sequences of active genes?  The 
direct association between histone modifications and active or repressed genes 
therefore required the development of a new technique.  In 1988, Crane-Robinson 
and colleagues published the first example of ChIP, demonstrating that acetylated 
histones were directly associated with active genes, and establishing a robust 
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method that separates chromatin on the basis of the histone modification itself 
(Hebbes et al., 1988).
 ChIP allows one to determine whether a specific histone modification or 
protein of interest is directly associated with a specific region of the genome. ChIP 
is generally performed with either formaldehyde-mediated crosslinking of proteins 
and nucleic acids within living cells followed by sonication (crosslinking, x-link 
ChIP), or by micrococcal nuclease (MNase) digestion of harvested cell nuclei and 
isolation of solubilized mono or short oligonucleosomes (native ChIP) (Figure 1.8). 
Crosslinking ChIP ‘freezes’ protein and nucleic acid interactions and enables the 
analysis of nucleosomal as well as non-nucleosomal proteins such as TFs and RNA 
polymerase, while native ChIP is more suitable for the analysis of core chromatin 
and nucleosomal components such as histones and histone modifications (Kuo 
and Allis, 1999; O’Neill and Turner, 2003).  After sonication or nuclease digestion 
to separate chromatin into oligonucleosomal fragments, an antibody to a specific 
protein or modification of interest is used to immunoprecipitate nucleosomes 
or oligonucleosomal fragments that contain the specific protein or modification. 
Unbound areas of the genome that do not contain the specific protein or modification 
are washed away.   Bound DNA can then be isolated and a variety of techniques 
can be used to probe for the presence of specific sequences, including blotting 
with radioactively labeled DNA probes, PCR, or semi-quantitative real-time PCR 
(Figure 1.8).
 Recently, the development of microarrays and high-throughput sequencing 
has allowed ChIP to provide global, genome-wide views of chromatin state in various 
cell types (Barski et al., 2007; Mendenhall and Bernstein, 2008; Mikkelsen et al., 
2007).  The hybridization of ChIP DNA to microarrays that tile across a portion of the 
genome (ChIP-chip) was one early iteration of genome-scale location analysis, and 
this technology yielded important insights, particularly in model organisms such as 
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Figure 1.8:  Chromatin immunoprecipitation and methods of analysis
For crosslinking chromatin immmunoprecipitation (x-link ChIP), proteins and nucleic acids in living 
cells are first crosslinked with a crosslinker (x-linker) such as paraformaldehyde.  For native ChIP, 
no crosslinker is used.  Cells are lysed, and nuclei are sonicated (x-link ChIP) or digested with a 
nuclease (native ChIP) to break up chromatin into smaller oligonucleosome or mononucleosome 
fragments. Highly selective antibodies are used to immunoprecipitate specific proteins or 
modifications of interest. In this case, the antibodies are depicted as previously bound or conjugated 
to a magnetic bead (left), and the antibodies bind to a specific histone tail modification (small green 
spheres on histone tails). Chromatin that is not bound by the antibody (right) is washed away. 
Chromatin fragments containing the protein or modification of interest are kept, and DNA from this 
chromatin is isolated.  This immunoprecipitated DNA can be analyzed in a variety of ways, including 
dot blots with radiolabeled probes for specific genomic regions (left), PCR with specific primers 
for genomic DNA (lower left), real-time PCR for relative quantitation (lower center), and massively 
parallel sequencing (ChIP-seq, right). ChIP-seq DNA reads can then be aligned and mapped to a 
reference genome of interest, enabling nucleosome level resolution (lower right).  Each blue or red 
dot indicates a read that has been specifically aligned to the  + or – strand.
For review of crosslinking and native ChIP, see (Kuo and Allis, 1999; O’Neill and Turner, 2003).
For review of ChIP-seq, see (Barski and Zhao, 2009; Mendenhall and Bernstein, 2008).
Please see Appendix for detailed discussion of ChIP and ChIP-seq, and for specific ChIP-seq 
protocols.
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yeast where small genome size allowed for interrogation of the entire genome (Lee 
et al., 2002b; Pokholok et al., 2005; Ren et al., 2000; Yuan et al., 2005). However, 
for genome-wide analysis of larger, more complex eukaryotic genomes, ChIP-chip 
has largely been rendered obsolete by the advent of relatively low cost, ultra high-
throughput sequencing.  Following ChIP and DNA isolation, bound DNA can be 
directly sequenced using massively parallel sequencing technologies such as those 
developed by Illumina/Solexa, and this technique is known as ChIP-seq (Barski 
et al., 2007; Barski and Zhao, 2009; Mikkelsen et al., 2007). Cluster generation 
and single-molecule-based sequencing produces millions of short (usually 36 bp) 
sequence tags in a single experiment, and these short sequences can be aligned 
to a reference genome to generate a genome-wide map (Figure 1.8) (Barski and 
Zhao, 2009).  There are multiple advantages of ChIP-seq, including a relatively 
unbiased approach to genomic location, higher resolution, the analysis of repetitive 
areas of the genome, and the potential use of sequence polymorphisms to analyze 
allele-specific incorporation (Barski et al., 2007; Barski and Zhao, 2009; Mikkelsen 
et al., 2007).  
As with any technique, there are limitations to ChIP-seq, particularly in 
the inherent bias of both crosslinking and native ChIP for the representation of 
specific, more accessible regions of the genome.  This bias makes it advisable 
to compare the genome-wide pattern of a specific modification or protein to the 
genome-wide pattern of input chromatin prior to IP, or to the genome-wide pattern 
of an IgG control (Barski and Zhao, 2009).  In addition, crosslinking ChIP can 
preserve multimeric complexes across large looped regions of DNA, and ChIP-
seq data from crosslinking ChIP therefore has the caveat that enrichment might 
be due to an artifact of looping and protein-protein interactions rather than direct 
DNA binding (Barski and Zhao, 2009).  Finally, like any ChIP experiment from 
multiple cells, genome-wide patterns from ChIP-seq represent an aggregate of the 
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chromatin state of all cell types in the examined population. Cell type heterogeneity 
can therefore produce conflated results from multiple chromatin states, and 
even the population of a single cell type can represent cells with specific genes 
at various stages of transcription.  For example, populations of undifferentiated 
mouse embryonic stem cells display heterogenous expression of multiple genes 
such as Dppa3, Nanog, Rex1, Pecam1, Brachyury, and Twist 2 (Tanaka, 2009). 
However, despite these limitations, ChIP-seq has emerged as a powerful high-
resolution technique for examining genome-wide localization (Barski and Zhao, 
2009; Mendenhall and Bernstein, 2008).
Genome-wide localization of nucleosomes
The majority of histone modifications are found in the context of nucleosomal 
histones that are incorporated into chromatin (Loyola et al., 2006).  Various studies 
have examined the localization of nucleosomes in multiple organisms (Jiang and 
Pugh, 2009; Schones et al., 2008; Yuan et al., 2005).  Most nucleosome positioning 
studies use MNase digestion followed by DNA hybridization to tiling microarrays or 
sequencing in order to profile nucleosome locations, or perform ChIP-chip or ChIP-
seq with an antibody to a core histone (Schones et al., 2008; Yuan et al., 2005). 
Nucleosome positioning is non-random, and many aspects of nucleosome position 
are dictated by the underyling DNA sequence, while nucleosome positioning at 
specific loci can also be modulated by chromatin modifications, histone variants, 
and a variety of chromatin remodeling machinery (Field et al., 2009; Henikoff, 
2008; Segal et al., 2006; Segal and Widom, 2009).  Each nucleosome wraps 
approximately 146 bp of DNA, and positioned nucleosomes have a characteristic 
length of short linker DNA between them, which averages ~38bp in humans (Jiang 
and Pugh, 2009; Luger et al., 1997; Schones et al., 2008).
At most loci, nucleosome position can be represented by a continuous 
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distribution, while at other loci, highly phased nucleosomes are more precisely 
positioned (Jiang and Pugh, 2009). The first nucleosome (+1) after the transcription 
start site (TSS) of both active and inactive genes is well-positioned, although 
the exact location differs slightly between active and inactive genes (Schones 
et al., 2008).  At active genes in human cells, the 5’ end of the +1 nucleosome 
peaks at +40bp, while the +1 nucleosome peaks at +10bp in inactive genes, a 
phenomenon that can perhaps be attributed to positional constraints placed by 
binding of the transcriptional machinery at the TSS of active genes (Schones et 
al., 2008).  Multiple studies have also established that a nucleosome free, or at 
least nucleosome-depleted region, exists at the TSS of both active and inactive 
genes, a phenomenon that causes a dip in general histone profiles at the TSS 
(Jiang and Pugh, 2009; Jin et al., 2009; Schones et al., 2008) (Figure 1.9).  The 
level of nucleosome depletion at the TSS is dependent on gene expression, 
with increased depletion at the TSS of active genes  (Schones et al., 2008). 
Nucleosome depletion at the TSS has recently been attributed to the instability 
of nucleosome core particles at this region, as well as the presence of specific 
nucleosome destabilizing DNA sequences at high CpG content promoters (Jin et 
al., 2009; Ramirez-Carrozzi et al., 2009). Unlike inactive genes, where only the 
+1 nucleosome is precisely positioned, multiple nucleosomes surrounding the 
TSS of actively transcribed genes are highly phased, with specific positioning and 
regular spacing of at least three nucleosomes upstream and five nucleosomes 
downstream of the TSS (Schones et al., 2008) (Figure 1.9).  Recent studies have 
established that nucleosomes are also highly phased at TFBS with bound TFs, 
suggesting that TF binding may promote regulated nucleosome positioning by 
chromatin remodeling complexes, potentially modulating TF access to regulatory 
elements (Henikoff, 2008; Zheng et al., 2009).
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Genome-wide patterns and functions of histone modifications at genes and 
regulatory elements
The genome-wide localization of histone modifications is intimately related to 
their function. Using ChIP-chip and ChIP-seq, landmark studies have recently 
established genome-wide maps of covalent histone modifications in multiple cell 
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Figure 1.9:  Nucleosomes are phased around active transcription start sites
A. Top profile represents the average pattern of general H3 around the TSS of transcriptionally active 
genes. Note the slight dip of H3 at the TSS itself, corresponding to a localized region of nucleosome 
depletion. The bottom data represent nucleosome profiles taken from genome-wide sequencing 
of micrococcal nuclease digested chromatin.  Data in this bottom profile and its description are 
adapted from (Schones et al., 2008). Nucleosomes near the TSS of expressed genes are phased 
with respect to the TSS.  The y axis shows the normalized number of sequence tags from the sense 
strand (red) and antisense strand (green) of DNA at each position.  The inferred nucleosomes are 
shown by filled ovals that are numbered. The -1 nucleosome (light gray) is lower than the -2 or +1 
nucleosome level in both active and inactive genes. This nucleosome depletion has been quantified 
by (Schones et al., 2008), though a recent study has suggested that this apparent depletion may 
stem from the fragility of H3.3/H2A.Z nucleosomes near the TSS (Jin et al., 2009).
B.  Top profile represents the average pattern of general H3 around the TSS of unexpressed genes. 
Bottom data represents nucleosome profiles around unexpressed genes, with data represented in 
similar manner to A.  The bottom data and legend is also adapted from (Schones et al., 2008). Only 
one well-positioned nucleosome exists near the TSS of unexpressed genes.
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types, including pluripotent ES cells, differentiated NPCs, CD4+ T cells, and various 
immortalized cancer cell lines (Barski et al., 2007; Heintzman et al., 2009; Meissner 
et al., 2008; Mikkelsen et al., 2007; Wang et al., 2008). Focusing predominantly on 
covalent modifications of histone H3 and H4 to which highly selective antibodies 
are available, these genome-wide studies demonstrate that specific histone 
modifications are highly correlated with gene expression (Barski et al., 2007; 
Mikkelsen et al., 2007).  Transcriptionally active and repressed genes maintain 
distinct modification-specific patterns across their transcription start site (TSS), 
gene body, and transcription end site (TES) (Figure 1.10, 1.11).  Although ChIP-
chip and ChIP-seq data typically depict the patterns for individual proteins or histone 
modifications, it is important to recall that that individual histones, nucleosomes, 
and chromatin domains are highly modified in vivo, and the combinatorial nature of 
multiple weak multivalent interactions are likely to be critical to chromatin biology 
(Ruthenburg et al., 2007b; Wang et al., 2008).  As described, histones are highly 
covalently modified (Kouzarides, 2007), but only a subset of these modifications 
have been rigorously studied at the genome-wide level. Therefore, the following 
section will focus only on the specific genome-wide patterns of histone methyl and 
acetyl marks that have been well characterized in mammalian cells.
H3K4 methylation
Histone H3 lysine 4 trimethylation (H3K4me3) is strongly associated with transcription 
initiation, and represents one of the best studied histone modifications to date 
(Guenther et al., 2007; Ruthenburg et al., 2007a). H3K4me3 is thought to serve 
as a genomic landmark for the transcription start site (TSS) in various biological 
processes (Guenther et al., 2007).  In yeast, H3K4me3 is found at the 5’ end of 
active but not inactive genes (Santos-Rosa et al., 2002). However, the correlation 
of H3K4me3 with gene expression in higher eukaryotes is more complex. High CpG 
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content promoter (HCP) genes in both ES cells and differentiated cells are marked 
by a peak of histone H3K4me3 and the presence of RNAPII, regardless of 
whether the gene is active or repressed (Barski et al., 2007; Guenther et al., 2007; 
Mikkelsen et al., 2007). Notably, the magnitude of the H3K4me3 signal at active 
and repressed HCP genes still correlates with transcriptional activity, with greater 
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Figure 1.10:  Patterns of specific histone H3 methylation marks at active genes
Representative patterns of histone methylation marks and general histone H3 are shown at active 
genes and regulatory elements.  Note that H3K4me1 is uniquely enriched at enhancer elements as 
well as across active genes.  H3K4me3 is more restricted to a few nucleosomes surrounding the 
TSS, and is relatively unenriched at enhancer elements.  In contrast, H3K36me3 marks a broad 
domain across an actively transcribed gene, which in mammalian cells can span many kilobases. 
Nucleosomes containing histone H3 are widespread throughout the genome, with specific patterns 
around TSS, and nucleosome depletion at the TSS itself.
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H3K3me3 signal at active TSS, and lower, but still distinctive peaks of H3K4me3 
at repressed HCP gene TSS (Barski et al., 2007; Mikkelsen et al., 2007) (Figure 
1.11).  Although the pattern of H3K4me3 is generally represented by a tight peak at 
a few nucleosomes following a gene TSS (with specific nucleosome peaks at +50, 
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Figure 1.11:  Patterns of specific histone H3 methylation marks at repressed genes
Representative patterns of histone methylation marks and general histone H3 are shown at 
repressed genes.  The TSS of repressed genes can be marked with lower levels of H3K4me1 and 
H3K4me3, and maintenance of H3K4me3 at the TSS may help to poise repressed genes for future 
activation (Guenther et al., 2007; Wang et al., 2009). Some repressed genes have no detectable 
H3K4 or H3K27 methylation (not shown) (Mikkelsen et al., 2007), and these genes may be less 
amenable to future activation. Repressed genes in mammalian cells are also frequently marked 
with H3K27me3, and this modification is deposited and read by polycomb group proteins (Whitcomb 
et al., 2007). Note also that repressed genes do not show any enrichment of H3K36me3 depicted 
in the previous figure.  Nucleosomes containing histone H3 are widely distributed throughout 
repressed genes, with a slight depletion at the TSS.  
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+210, and +360 bp), certain regions of the genome such as the Hox loci can show 
a broader pattern of H3K4me3 in specific developmental contexts, a pattern that 
may be related to large-scale transcription of intergenic non-coding RNA (Barski 
et al., 2007; Bernstein et al., 2005; Guenther et al., 2005; Guenther et al., 2007; 
Guttman et al., 2009; Rinn et al., 2007; Shilatifard, 2008).
H3K4me3 can be recognized by various specific effector proteins to 
mediate multiple different biological outputs (Guenther et al., 2007; Ruthenburg 
et al., 2007a; Shilatifard, 2008). For example, in the facilitation of transcription 
initiation, H3K4me3 can be recognized by PHD finger domains of a component 
of the NURF chromatin remodeling complex, as well as a PHD domain of the 
well studied protein TFIID, a component of the basal transcription machinery 
(Shilatifard, 2008; Vermeulen et al., 2007; Wysocka et al., 2006). In contrast, 
recognition of H3K4me3 by ING proteins is also important for the repression of 
proliferation genes following DNA damage, while recognition of H3K4me3 by 
RAG2 is required for efficient V(D)J recombination (Matthews et al., 2007; Shi et 
al., 2006). Intriguingly, the H3K4 methyltransferase Set1 is required for ribosomal 
DNA silencing and telomere length maintenance in yeast, as well as for normal 
rates of cell growth, but not for yeast viability (Briggs et al., 2001; Dehe and Geli, 
2006).  In higher eukaryotes, proteins responsible for ‘writing’ and ‘reading’ H3K4 
methylation are encoded by trithorax group proteins, and H3K4 methylation may 
play a more important role in fine-tuning and maintaining the positive regulation 
of gene expression in metazoans (Schuettengruber et al., 2007).  Recognition of 
H3K4me3 by NURF has been functionally linked to the maintenance of Hox gene 
expression during vertebrate development (Wysocka et al., 2006). In addition, a 
recent genetic study demonstrated that deletion of the enzymatic SET domain of 
the H3K4 methyltransferase mixed lineage leukemia (MLL) protein recapitulates 
the homeotic phenotype in mice, further suggesting a role for H3K4 methylation in 
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the regulation of epigenetic memory in mammals, though other non-histone targets 
of MLL could also be functionally important (Terranova et al., 2006).
Different methylation states on the same histone amino acid can show 
distinct genome-wide patterns of localization and distinct functions. For example, 
in contrast to H3K4me3, H3K4me1 shows a distinct pattern, with enrichment 
surrounding the TSS of active genes, a dip at the peak of H3K4me3 nucleosomes, 
and a broader distribution across the gene body of active genes (Figure 1.10) 
(Barski et al., 2007; Meissner et al., 2008).  Unlike H3K4me3, H3K4me1has 
recently been shown to have a strong genome-wide co-localization with TFBS, 
enhancers, and regulatory elements (Heintzman et al., 2007; Robertson et al., 
2008; Wang et al., 2008) (Figure 1.10).  H3K4me2 also shows a pattern that is 
similar to H3K4me1, with enrichment surrounding the TSS, depletion at the peak 
of H3K4me3, and broader enrichment into the gene body of active genes, as well 
as enrichment at regulatory elements (Barski et al., 2007).  Specific functions 
for H3K4me1 and H3K4me2 at regulatory elements have not been determined, 
although H3K4me2 was recently shown to play a role in the recruitment of HDACs 
and the suppression of nucleosome acetylation at the 5’ end of transcribed genes 
in yeast, just downstream of the high levels of nucleosome acetylation at H3K4me3 
near the TSS (Kim and Buratowski, 2009).
H3K36 methylation
H3K36me3 is a robust marker of actively transcribed gene bodies (Barski et al., 
2007; Mikkelsen et al., 2007).  In contrast to the tight peaks of a few nucleosomes 
marked by H3K4me3, H3K36me3 is often found over wide transcribed domains, 
particularly in larger eukaryotic genomes where smaller exons can be separated 
by long introns of many kilobases (Barski et al., 2007; Mikkelsen et al., 2007) 
(Figure 1.10).  H3K36me3 is a highly conserved histone modification, and it has 
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been associated with transcriptional elongation in a variety of eukaryotes, from 
yeast to mice and humans (Bannister et al., 2005; Barski et al., 2007; Mikkelsen 
et al., 2007).  Intriguingly, despite its association with actively transcribed genes, 
H3K36me3 has been functionally linked to transcriptional repression, and has 
specifically been shown to function in the repression of spurious intragenic 
transcripts (Carrozza et al., 2005; Keogh et al., 2005).  Set2-mediated H3K36me3 
is required for the recruitment of the HDAC Rpd3S complex to gene bodies in 
yeast, leading to the model that H3K36me3 prevents aberrant transcriptional 
initiation at sites other than the appropriate TSS, particularly at long or infrequently 
transcribed genes (Carrozza et al., 2005; Li et al., 2007a; Li et al., 2007c).  The 
presence of unannotated H3K4me3 peaks followed by regions of H3K36me3 have 
been recently used to identify novel transcripts and alternative TSS, as well as 
thousands of large intergenic regions that give rise to non-coding RNA transcripts 
(Guttman et al., 2009; Mikkelsen et al., 2007).
Histone lysine acetylation
For decades, histone acetylation has been associated with gene activation, 
while histone deacetylation has been associated with gene repression (Struhl, 
1998).  Histone acetylation can have both direct and indirect effects on chromatin 
(Shahbazian and Grunstein, 2007). Histone acetylation can be recognized by 
bromodomains within specific effector proteins and chromatin regulatory complexes, 
but can also directly regulate the degree of chromatin compaction, and is thought 
to help overcome the inhibitory effects of nucleosomes on transcription (Dhalluin et 
al., 1999; Shahbazian and Grunstein, 2007). Like histone methyl marks, different 
histone acetyl marks are localized to distinct regions of active genes (Wang et 
al., 2008).  Histone acetyl marks such asH3K9ac and H3K18ac are enriched in 
regions surrounding the TSS of active genes, while acetyl marks such as H4K12ac 
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and H4K16ac are enriched in promoter and transcribed regions of active genes 
(Wang et al., 2009b; Wang et al., 2008).  Certain histone acetyl marks, such as 
H3K18ac but not H3K14ac, are also enriched in a significant fraction of enhancers 
(Wang et al., 2008). Genome-wide maps of histone acetylation, HATs, and HDACs 
have recently been established, and these data reveal an unexpected association 
of both HATs and HDACs with active genes  (Wang et al., 2009b).  Surprisingly, the 
majority of HDACs are associated with active and poised genes, although some 
HDACs are also associated with intergenic enhancers, and no HDACs were found 
enriched at silent genes (Wang et al., 2009b). Current models suggest that most 
HDACs function to remove acetylation from active genes, ‘resetting chromatin’ from 
acetyl marks laid down by HATs associated with elongating polymerase in order 
to maintain a level and localization of acetylation ideal for accurate transcription 
(Wang et al., 2002; Wang et al., 2009b).
Histone H3K27 methylation marks repressed genes
In contrast to active genes, repressed genes are often marked by H3K27me3 
(Schuettengruber et al., 2007).  Genome-scale studies have established that 
H3K27me3 can be found at repressed genes either in broad domains, such as 
at key developmental loci including the Hox genes, or in a more narrow domain 
surrounding repressed TSS (Mikkelsen et al., 2007) (Figure 1.12).  As mentioned 
above, the ‘writing’ and ‘reading’ of H3K27 methylation is mediated by components 
of the evolutionarily conserved polycomb group (PcG) proteins that are associated 
with Hox gene repression (Whitcomb et al., 2007).  Mammalian homologs of the 
polycomb protein that recognizes  H3K27 methylation in Drosophila are encoded 
by the Cbx proteins, and these proteins have been found to play diverse roles in 
the regulation of cell cycle, homeotic, and developmental genes (Bernstein et al., 
2006b; Whitcomb et al., 2007).   H3K27me3 and polycomb proteins are enriched 
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at key developmental genes in ES cells, and polycomb proteins play critical roles 
in gene repression and the maintenance of cellular state (Boyer et al., 2006; Lee 
et al., 2006a). The PcG protein and H3K27 methyltransferase Ezh2 is required for 
mammalian development, and Ezh2 and its homolog Ezh1 play complementary 
roles in mediating H3K27me3 and transcriptional repression at key developmental 
genes (Ho and Crabtree, 2008; O’Carroll et al., 2001; Shen et al., 2008).  The 
PcG protein Eed is required for global H3K27me2 and H3K27me3, and loss of 
Eed leads to depression of multiple differentiation-specific PcG target genes in 
undifferentiated ES cells (Boyer et al., 2006; Montgomery et al., 2005).  More 
recently, Ezh2 has been shown to play an important role in tissue-specific stem 
cells, repressing specific proliferative and structural genes to fine-tune epidermal 
differentiation (Ezhkova et al., 2009).
Cell type specific differences in chromatin state
Chromatin state has been shown to vary with cellular differentiation state.  As 
described previously (Figure 1.1), pluripotent embryonic stem (ES) cells have the 
Figure 1.12:  Different genomic patterns of H3K27me3
Two general patterns of H3K27me3 are found at repressed genes in mammalian cells.  H3K27me3 
can be found in relatively tight regions surrounding the TSS, as in the case of the repressed gene 
Gata6 in ES cells (left). In contrast, larger regions such as the repressed Hox loci in ES cells can 
be marked by broader domains of H3K27me3 (right).
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capacity to give rise to all differentiated cell types of the vertebrate embryo, and 
they manifest a unique genome-wide chromatin state (Bernstein et al., 2007; Niwa, 
2007). In particular, pluripotent ES cells have large and open nuclei with smaller 
regions of heterochromatin, display hyperdynamic binding of structural chromatin 
proteins, and exhibit global transcriptional hyperactivity (Efroni et al., 2008; Gaspar-
Maia et al., 2009; Meshorer et al., 2006) (Figure 1.13).  ES cells also utilize unique 
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Figure 1.13:  Embryonic stem cells and differentiated cells display distinct chromatin 
states
A.  Electron micrographs of undifferentiated ES cells (left) and differentiated ES cells (right).  Note 
the large proportion of open euchromatin in the ES nucleus. Following differentiation into primitive 
endoderm, the nucleus shrinks, and the distribution of electron-dense heterochromatin changes 
dramatically.
B.  Characteristic features of ES and differentiated cell chromatin.  A variety of evidence suggests 
that undifferentiated ES and iPS cells maintain a uniquely open and plastic epigenome (Bernstein 
et al., 2007; Efroni et al., 2008; Gaspar-Maia et al., 2009; Meshorer et al., 2006; Niwa, 2007).
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chromatin remodeling complexes to maintain the pluripotent state. For example, the 
esBAF chromatin remodeling complex is required for self-renewal and pluripotency 
of mouse ES cells, but not for proliferation of differentiated fibroblasts (Ho et al., 
2009a; Ho et al., 2009b). In addition, the chromatin remodeling factor Chd1 is 
required to maintain open, hyperdynamic chromatin and ES cell pluripotency 
(Gaspar-Maia et al., 2009).
H3K4me3 and H3K27me3 bivalent domains mark specific repressed genes
As they have not yet committed to a particular lineage, ES cells must repress key 
developmental lineage-specific genes in order to maintain the pluripotent state 
(Chi and Bernstein, 2009; Jaenisch and Young, 2008).  Some of the repression of 
key developmental genes and upregulation of pluripotency genes can attributed to 
reinforcing gene expression programs driven by specific TFs such as Oct4, Sox2, 
and Nanog, as well as the expression of particular  microRNA genes (Chen et al., 
2008b; Jaenisch and Young, 2008; Marson et al., 2008; Niwa, 2007).  In addition, 
recent studies have established that ES cells maintain unique global patterns of 
specific covalent histone modifications at key lineage-specific genes (Barski et 
al., 2007; Bernstein et al., 2006a; Meissner et al., 2008; Mikkelsen et al., 2007). 
More than one-fifth of HCP genes in ES cells carry both H3K4me3 and H3K27me3 
in their promoters (Bernstein et al., 2006a; Mikkelsen et al., 2007) (Figure 1.14). 
These ‘bivalent’ genes are transcriptionally repressed in ES cells, and are enriched 
in genes encoding key developmental TFs and cell surface proteins, leading to the 
model that they represent repressed genes that are poised for activation following 
cell differentiation (Bernstein et al., 2006a; Mikkelsen et al., 2007).  
Upon cell differentiation, most H3K4me3 / H3K27me3 bivalent genes resolve 
either to H3K4me3, H3K27me3, or neither mark, though a minority of these genes 
remain bivalent (Figure 1.14) (Bernstein et al., 2006a; Mikkelsen et al., 2007). 
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Although most bivalent domains are located in punctuate regions around specific 
TSS, certain regions of the genome such as the Hox loci are enriched in large-scale 
bivalent domains (Figure 1.15) (Mikkelsen et al., 2007).  As bivalent gene promoters 
are transcriptionally repressed, but enriched in both H3K4me3 and H3K27me3, 
these data suggest that repressive PcG activity is dominant over activating TrxG 
activity (Bernstein et al., 2006a; Mikkelsen et al., 2007).  Bivalent domains can 
be divided into two classes based on their occupancy by PcG proteins (Ku et al., 
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Figure 1.14:  Transcriptionally repressed 
H3K4me3 / H3K27me3 bivalent domains 
resolve to various chromatin states
More than 20% of genes in ES cells 
are marked with both H3K4me3 and 
H3K27me3, and these bivalent genes 
are transcriptionally repressed.  Upon 
differentiation, bivalent genes can resolve 
to the various chromatin states depicted 
here. Note that while repressed genes 
manifest a variety of chromatin states, 
active genes are relatively typical, with 
high levels of H3K4me3 immediately 
downstream of the TSS, and H3K36me3 
throughout the transcribed gene body.
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2008).  Bivalent domains occupied by the polycomb repressive complex 1 (PRC1) 
protein Ring1b are particularly enriched in developmental regulator proteins, and 
these PRC1 positive bivalent domains are more likely to maintain H3K27me3 upon 
differentiation (Ku et al., 2008).  Although bivalent domains are not exclusive to 
pluripotent cells and have been observed at lower frequency in differentiated cells, 
ES cells are significantly enriched in bivalent domains relative to all other cell types 
examined (Barski et al., 2007; Mikkelsen et al., 2007).  Moreover, generation of 
iPS cells also re-establishes bivalent domains at key developmental genes, further 
suggesting that bivalent domains can reflect developmental potential (Mikkelsen 
et al., 2008).
Although differentiated cells have a small number of repressed genes 
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Figure 1.15:  Large-scale resolution of bivalent domains at the HoxA locus
In undifferentiated ES cells (left), the HoxA locus is bivalent and marked by widespread H3K4me3 
and H3K27me3.  Following differentiation into NPCs (right), the large bivalent domains at the 
HoxA locus resolve into a region of active HoxA genes marked by H3K4me3 (left), and a region of 
repressed HoxA genes marked by H3K27me3 (right). H3K4me3 and H3K27me3 ChIP-seq profiles 
in ES cells were generated by Bernstein and colleagues (Mikkelsen et al., 2007), and are publicly 
available from http://www.ncbi.nlm.nih.gov/geo/.
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marked by both H3K4me3 and H3K27me3, a subset of genes in differentiated cells 
marked only by H3K4me3 also remain surprisingly repressed (Guenther et al., 2007; 
Wang et al., 2009b).  These poised genes or ‘primed’ genes are transcriptionally 
repressed, but still marked by the presence of H3K4me3, H2A.Z, and low levels 
of histone acetylation near their TSS (Wang et al., 2009b). Poised genes rapidly 
gain histone acetylation and increased RNAPII binding following treatment of cells 
with HDAC inhibitors, suggesting that transient binding and cycling of HAT and 
HDAC activity helps to keep these genes repressed but primed for future activation 
(Wang et al., 2009b). The emerging picture of gene expression in mammalian cells 
is therefore one in which there is a characteristic pattern of histone modifications 
at active genes, and various patterns at poised, bivalent, or silent genes (Figure 
1.14).  Evidence suggests that multiple genes in undifferentiated and differentiated 
cells are repressed, but poised for expression (Guenther et al., 2007; Mikkelsen 
et al., 2007; Wang et al., 2009b).  In ES cells, bivalent domains may enable large 
numbers of genes to be poised with trithorax H3K4me3 activity and H2A.Z, but 
the use of polycomb and H3K27me3 ensures an additional level of transcriptional 
repression prior to differentiation.
 Patterns of histone modifications at regulatory elements can also be 
highly predictive of cellular state, and often vary more significantly than histone 
modifications at promoters.  A recent study has established that although histone 
modifications at many promoters are largely invariant across cell types with different 
patterns of gene expression, patterns of histone modifications at enhancers are 
highly cell-type specific, and correlate strongly with global cell-type specific gene 
expression programs (Heintzman et al., 2009).  Taken together, recent genome-
wide studies demonstrate that different cell types use TFs, chromatin remodeling 
machinery, DNA methylation, and histone modifications to reinforce cellular 
gene expression programs, patterns of specific histone modifications are highly 
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correlated with gene expression at promoters and enhancers, and genome-wide 
maps of histone modifications and DNA methylation reflect lineage commitment 
and cell state (Barski et al., 2007; Bernstein et al., 2006a; Boyer et al., 2006; 
Heintzman et al., 2009; Meissner et al., 2008; Mikkelsen et al., 2007).  However, 
chromatin modifications and remodeling processes are not the only methods used 
by cells to establish variation in the chromatin fiber.
Histone variants
In addition to chromatin modifications and nucleosome remodeling, eukaryotic 
cells also generate variation in chromatin by the introduction of variant histone 
proteins (Figure 1.7). Primary sequence variants of histones have been known for 
some time (Allis et al., 1980; Allis et al., 1982; Bustin and Cole, 1968; Franklin and 
Zweidler, 1977; Kinkade and Cole, 1966). Excluding histone H4, all core histone 
proteins in mammals (H1, H2A, H2B, and H3) have several primary sequence 
variants (Hake and Allis, 2006; Pusarla and Bhargava, 2005).  These variants 
can be classified into three general subtypes: replication-dependent, replication-
independent, and tissue-specific, based on their expression during the cell cycle, 
tissue-specific expression, and their genomic organization (Albig and Doenecke, 
1997; Frank et al., 2003; Hake and Allis, 2006).
During S-phase of the cell cycle, a eukaryotic cell must rapidly synthesize 
histones in stoichiometric amounts (~108 molecules of each histone protein in a 
mammalian cell) for the formation of chromatin with newly replicated DNA (Albig 
and Doenecke, 1997; Marzluff et al., 2002). These cell-cycle regulated histones are 
known as replication-dependent (RD) histones, and they account for the bulk of 
histone synthesis in dividing cells (Albig and Doenecke, 1997).  RD histone genes 
are found in large, multigene, intronless clusters in the genomes of all metazoans, 
and their transcripts lack a poly-A tail, ending instead in a highly conserved stem-
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loop sequence (Heintz et al., 1981; Marzluff et al., 2002).
In contrast, replication-independent (RI) or so-called replacement histones 
are synthesized throughout the cell cycle, independently from the replication of 
DNA, and they are also synthesized in terminally differentiated or quiescent cells 
(Frank et al., 2003).  RI histone genes are solitary, typically intron-containing genes 
located outside of the major histone gene clusters (Albig and Doenecke, 1997; 
Carozzi et al., 1984; Heintz et al., 1981; Marzluff et al., 2002). RI histone gene 
transcripts generally have long 5’ and 3’ UTRs, and are frequently polyadenylated 
(Frank et al., 2003).  In addition to RD and RI histones, metazoans also express a 
number of tissue-specific (TS) histones.  Some of the most highly studied examples 
of TS histones are expressed during specific stages of gametogenesis, such as 
the oocyte specific H1 variant H1oo (Tanaka et al., 2001), and the testis specific 
H1 variants H1t and HILS1 (Drabent et al., 1996; Iguchi et al., 2003; Yan et al., 
2003).  
Specific histone variants have been associated with particular biological 
processes. For example, histone H2A.Z was first found specifically enriched in 
transcriptionally active chromatin in Tetrahymena (Allis et al., 1986).  More recently, 
H2A.Z has been observed to be enriched at the transcriptional start sites of both 
active and repressed genes and regulatory regions in specific organismal and 
developmental contexts, and has been shown to play a variety of diverse roles 
including the silencing of developmental genes in mouse ES cells, the suppression 
of antisense RNA transcripts in S. pombe, and the protection of euchromatin 
from the ectopic spread of heterochromatin in S. cerevisiae (Creyghton et al., 
2008; Jin et al., 2009; Meneghini et al., 2003; Raisner et al., 2005; Zofall et al., 
2009).  Histone macroH2A has recently been shown to co-localize with Polycomb 
complex members, and to facilitate the fine-tuning of Hox gene expression during 
embryonic development (Buschbeck et al., 2009).  In contrast, histone H2A.X is 
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specifically phosphorylated in response to DNA damage, and this “guardian of the 
genome” helps to facilitate the assembly of DNA repair complexes and maintain 
genomic integrity (Celeste et al., 2002; Fernandez-Capetillo et al., 2004; Rogakou 
et al., 1998).  Variants of histone H1 are required for DNA methylation at specific 
imprinted genes, and for the maintenance of global chromatin structure (Fan et al., 
2003; Fan et al., 2005; Happel and Doenecke, 2009).
H3.3 and the Histone H3 Variant Family
Recently, attention has focused on variants of histone H3, a highly evolutionarily 
conserved family of histones whose members appear to be intimately associated 
with a variety of critical biological processes, ranging from gene regulation and 
centromeric function, to gametogenesis and early development (Govin et al., 2004; 
Hake and Allis, 2006; Hodl and Basler, 2009; Howman et al., 2000; Loppin et al., 
2005).
Evolution of H3 variants
Mammals express at least five different types of H3 variants:  a centromere-
specific H3 variant CENP-A, replication-dependent H3.1 and H3.2, replication-
independent H3.3, and a testis-specific variant H3.1t (Hake and Allis, 2006). The 
evolutionary conservation of non-centromeric H3 variants, and particularly of H3.3, 
is remarkable (Malik and Henikoff, 2003).  Outside of a centromeric H3 variant, the 
budding yeast S. cerevisiae possesses only one H3 protein, and this H3 variant 
is most closely related (>91% identity) to H3.3 in mammals (Malik and Henikoff, 
2003). In yeast, the so-called H3.3 variant therefore serves all functions of histone 
H3.  Indeed, there is no known eukaryote which expresses H3.2 or H3.1 without 
also expressing H3.3 (Malik and Henikoff, 2003). Over evolutionary time, various 
branches of the eukaryotic tree have independently evolved distinct replication-
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independent H3.3 and replication-dependent H3 variants on multiple occasions, 
with replication-dependent H3 variants likely expanding in number to package larger 
eukaryotic genomes, and H3.3 perhaps serving a more specialized function (Malik 
and Henikoff, 2003; Thatcher et al., 1994; Waterborg and Robertson, 1996).
H3.3 differs from H3.2 and H3.1 at a small number of amino acids
Histone H3.3 differs from H3.2 and H3.1 at only 4 or 5 amino acids (Figure 1.16A). 
Intriguingly, the location of these differences suggests that only one of these amino 
acids (H3.3 serine 31) is accessible in the context of nucleosomal H3.3 (Davey 
et al., 2002; Henikoff and Ahmad, 2005; Luger et al., 1997) (Figure 1.16B).  The 
H3 variant used in published structures of the nucleosome core particle was H3.2 
(Davey et al., 2002; Luger et al., 1997). Examination of the nucleosome structure 
indicates that the remainder of the differences between H3 variants (at positions 
87, 89, 90, and 96) are buried within the H3 α-helix 2 beneath the DNA double 
helices, and therefore inaccessible in an intact nucleosome (Henikoff and Ahmad, 
2005). However, prior to nucleosome formation, pre-deposition machinery would 
still be able to access and distinguish these amino acids in free H3.3 (Henikoff and 
Ahmad, 2005).
H3.3 nucleosomes are less stable than H3.1 nucleosomes 
Recent studies by Jin and Felsenfeld indicate that H3.3 nucleosomes may be 
intrisinically less stable than nucleosomes containing H3.2 (Jin and Felsenfeld, 
2007) (Figure 1.17).  Nucleosomes containing H3.3 are unusually sensitive to 
salt concentration (Jin and Felsenfeld, 2007). Following exposure to moderate 
salt concentrations of 80mM, H3.3 nucleosomes isolated from chicken cells 
preferentially lost H2A/H2B and H2A.Z/H2B, and H2A.Z in particular was not even 
detectable.  However, following nucleosome isolation under conditions of lower salt 
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Figure 1.16:  Sequence of H3 variants: most distinguishing H3 variant amino acids are not 
accessible in the context of the nucleosome
A.  Sequence alignment of mammalian H3.3, H3.2, and H3.1 histone variants.  Histone H3 structural 
elements such as the H3 tail and alpha helices are indicated above the sequences (Luger et al., 
1997).  H3.3 differs from the replication-dependent (RD) variant H3.1 at two locations:  position 31 
in the H3 tail (red arrow), and at positions 87, 89, 90, and 96, a region towards the beginning of the 
second alpha helix (red bracket). The RD variants H3.2 and H3.1 are identical, with the exception 
of position 96.
B.  Location of H3 variant amino acid differences in the context of the nucleosome.  The nucleosome 
core particle as crystallized by Luger and colleagues is shown here (Davey et al., 2002; Luger et al., 
1997). Core histone helices are shaded green. Histone protein backbones, including histone tails, 
are shaded light blue.  The nucleotide backbone of the surrounding DNA double helix is shaded 
gray.  The two views on the left represent the complete nucleosome core particle.  Accessible 
histone H3 tails are indicated by black brackets (left).  In the two views on the right, all other 
histones except H3 have been removed for purposes of visualization.   The location of positions 
31 (red arrows), as well as positions 87, 89, 90, and 96 (red brackets) are indicated.  Note that 
only position 31 in the H3 tail is accessible in the context of the nucleosome.  The remainder of the 
distinguishing H3 variant amino acids are buried and inaccessible in an intact nucleosome, though 
they may impact nucleosome stability (Jin and Felsenfeld, 2007).
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(10mM), some H2A.Z was detectable with H3.3 nucleosomes, and H2A was not 
preferentially depleted relative to H3.1 nucleosomes (Jin and Felsenfeld, 2007). 
Relative quantitation of these stabilities  revealed that H3.3/H2A.Z nucleosomes 
were even more unstable than H3.3/H2A nucleosomes (Jin and Felsenfeld, 2007) 
(Figure 1.17). This instability of H3.3 does not appear to depend on histone 
acetylation, as identical results were observed in the presence and absence of 
the HDAC inhibitor sodium butyrate (Jin and Felsenfeld, 2007).  Intriguingly, H3.3/
H2A.Z nucleosomes exist in vivo, and are enriched in differentiated vertebrate 
cells in specific areas of active chromatin, including active promoters and enhancer 
elements (Jin and Felsenfeld, 2006, 2007; Jin et al., 2009).  The relative instability 
of H3.3 nucleosomes, and particularly of H3.3/H2A.Z nucleosomes, has been 
suggested to reduce the energy required for nucleosome mobilization at dynamic 
regions of the genome (Jin and Felsenfeld, 2007).  Notably, this hypothesis has 
yet to be rigorously demonstrated biochemically, as studies of nucleosome stability 
have not yet been carried out with recombinant histone variants and remodeling 
machinery.  Overall, however, the results of Jin and Felsenfeld suggest that H3.3 
may not simply function as an identical replacement variant, but may play a unique 
role in active chromatin.
Adapted from Jin and Felsenfeld, 2007.
Least stable Most stable
RELATIVE STABILITY OF NUCLEOSOMES
H3.3 H2A.Z H3.3 H2A H2AH3.1 H2A.ZH3.1
?
Figure 1.17:  Relative stability of H3 variant nucleosomes
Schematic representation of relative stability of nucleosomes containing different histone variants, 
as assessed by Felsenfeld and colleagues (Jin and Felsenfeld, 2007).
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Histone H3 genetics in mammals
In mice, the histone H3 variants H3.2 and H3.1 are encoded by 12 intron-less 
genes located in two clusters (Marzluff et al., 2002).  These multiple H3.2 and 
H3.1 genes are expressed in all cycling cells, and their transcripts end in the highly 
conserved stem-loop sequence characteristic of replication-dependent histone 
genes (Marzluff et al., 2002; Plumb et al., 1983) (Figure 1.18). In contrast, H3.3 
is encoded by two different genes (H3.3A and H3.3B) that code for the same 
1 kb
H3.3A
H3.3B
H3f3a
:chr11
H3f3b
2 genes code for H3.3
0.5kb
12 genes in 2 clusters code for H3.2 and H3.1
:chr1
:chr13
Hist1h3e
Hist1h3a 0.5kb
Hist1h3h Hist1h3i Hist1h3g Hist1h3f
Hist1h3d Hist1h3c Hist1h3b
Hist2h3c2 Hist2h3c1 Hist2h3b
:chr30.5kb
Figure 1.18:  Genomic organization of mouse H3 variant genes
Genomic organization of mouse replication-independent H3.3 genes (top) and replication-
dependent (RD) H3 genes (bottom) is depicted.  Gene names are indicated in blue above the 
gene, and chromosomal locations are shown on the right.  Coding exons are depicted by thick blue 
rectangles, non-coding exon sequence by thin blue rectangles.  Note the presence of introns (thin 
hashed lines) in H3.3A and H3.3B.  The RD histone genes do not contain introns. RD histone H3 
genes are found in two clusters on mouse chromosomes 13 and 3, along with other RD histone 
H2B, H2A, and H4 genes (not shown).  For more information on histone genomic organization in 
mammals, see (Marzluff et al., 2002)
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amino acid sequence, but differ in their 5’ and 3’ UTRs, and also in their patterns 
of developmental expression (Figure 1.18) (Albig et al., 1995; Bramlage et al., 
1997; Lopez-Fernandez et al., 1997; Wells et al., 1987).  Unlike H3.2 and H3.1, 
the expression of H3.3 genes is replication-independent, and H3.3 has long been 
established as the only H3 variant synthesized in at high levels in quiescent, G1, 
and G2 cells (Wu et al., 1982).
Genomic localization of H3.3 at genes and regulatory elements
Despite the very small number of amino acid differences between non-centromeric 
H3 variants, groundbreaking work demonstrates that at least three of these amino 
acids (A87, I89, G90 in H3.3) are critically important for regulating the genomic 
localization of H3 variants in non-mammalian systems (Ahmad and Henikoff, 
2002; Mito et al., 2005, 2007; Schwartz and Ahmad, 2005).  Multiple lines of 
experimental evidence suggest that H3.3 plays a role in transcriptionally active 
chromatin in multicellular organisms.  Using GFP-tagged histones H3.2 and H3.3 
in Drosophila, Kami Ahmad and Steve Henikoff demonstrated in 2002 that a pulse 
of H3.3 and not H3.2 is deposited at transcriptionally active ribosomal DNA arrays 
in a replication-independent manner.  In addition, they showed that three of the 
four amino acid changes that distinguish H3.3 from H3.2 (A87, I89, G90 in H3.3, 
see Figure 1.16A) allow H3.3-GFP to engage in replication-independent as well 
as replication-dependent assembly into chromatin (Ahmad and Henikoff, 2002). 
GFP-tagged H3.3 was also shown by David Spector’s group to be deposited 
upon transcriptional induction of a transgene array in real-time analysis of single 
mammalian cells (Janicki et al., 2004).  In complementary studies, Schwartz and 
Ahmad demonstrated that H3.3 deposition is temporally coupled to transcription 
on Drosophila heat-shock genes (Schwartz and Ahmad, 2005). Strikingly, they 
found H3.3 to be deposited and rapidly turned over at continually active genes, 
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while incorporated H3.3 became stable at genes after transcription has ceased, 
leaving behind an enduring marker of past transcriptional activity (Schwartz and 
Ahmad, 2005, 2006).  Mass spectrometry studies from our laboratory and others 
have also revealed that specific post-translational histone modifications on histone 
H3 associated with gene activation (H3K4 methylation, H3K36 methylation) are 
significantly enriched on H3.3 in both Drosophila and mammalian cells  (Hake et 
al., 2006; Loyola et al., 2006; McKittrick et al., 2004). 
Genome-scale profiling of tagged H3.3 provides strong evidence of H3.3 
enrichment at transcriptionally active genes and cis-regulatory elements in 
Drosophila S2 cells (Mito et al., 2005, 2007).  Using chromatin immunoprecipitation 
(ChIP) and tiling microarrays, Henikoff and colleagues found that H3.3 replacement 
was significantly co-localized with sites of RNAPII and H3K4me2. They observed 
that H3.3 was particularly prominent in the gene bodies of highly active genes, 
which they suggest represent sites of ongoing transcription-coupled nucleosome 
replacement (Mito et al., 2005).  In 2007, Henikoff and colleagues found that H3.3 
was also enriched in Drosophila at cis-regulatory domain boundaries and sites of 
nuclease hypersensitivity, even outside of active or repressed genes (Mito et al., 
2007).  This enrichment of H3.3 at Drosophila regulatory elements represented 
an important demonstration that that specifically targeted H3.3 deposition was not 
limited to sites of transcriptional activation, and showed that regulatory elements 
are also sites of dynamic histone replacement (Mito et al., 2007).
Although genome-scale data regarding H3.3 localization in Drosophila has 
been consistent, more limited experiments suggested alternative and sometimes 
conflicting possibilities in vertebrates (Chow et al., 2005; Daury et al., 2006; Jin 
and Felsenfeld, 2006; Sutcliffe et al., 2009; Tamura et al., 2009; van der Heijden 
et al., 2007; Wirbelauer et al., 2005). One study found that H3.3 incorporation was 
confined primarily to active promoters, while another reported that H3.3 is enriched 
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throughout transcribed regions (Chow et al., 2005; Wirbelauer et al., 2005). 
Felsenfeld and colleagues found no clear correlation between H3.3 incorporation 
and levels of active transcription or histone modifications in chicken erythroid cells, 
with enrichment of H3.3 found in upstream regulatory regions, coding regions, or 
neither (Jin and Felsenfeld, 2006).  H3.3 was shown to be constitutively unenriched 
around the transcription start sites (TSSs) of two inducible genes in T-cells, but 
enriched in the coding region upon gene induction (Sutcliffe et al., 2009).  A recent 
genome-wide study of H3.3 in HeLa cells found that H3.3 was enriched at the 
TSSs of active genes, and also within the body of active genes in proportion 
to transcriptional activity, but significant levels of H3.3 were not detected at the 
TSSs of inactive genes in this differentiated human cancer cell line (Jin et al., 
2009).  However, H3.3 was also recently shown to be constitutively enriched in the 
promoter region of repressed interferon-inducible genes in fibroblasts, with levels 
of enrichment increasing in the coding regions upon gene induction (Tamura et al., 
2009), and the precise pattern of H3.3 at active and inactive genes in vertebrates 
therefore has yet to be clearly established.
Roles for H3.3 in large-scale nucleosome replacement 
H3.3 has not been exclusively linked with transcriptional regulation at specific loci, but 
has also been implicated in a variety of developmental processes and larger-scale 
chromatin remodeling events that are likely to involve nucleosome replacement. 
H3.3 appears to play particularly important roles in multiple phenomena related 
to reproduction, including meiotic sex chromosome inactivation, sperm chromatin 
remodeling, and paternal pronuclear decondensation (Orsi et al., 2009; Santenard 
and Torres-Padilla, 2009).
H3.3 has been associated with chromosome-wide formation of 
heterochromatin at the X and Y chromosomes during mouse male meiosis (van 
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der Heijden et al., 2007).  During male meiotic prophase I, mammalian sex 
chromosomes form a separate repressive chromatin domain known as the XY 
body (Handel, 2004).  The XY body is transcriptionally silenced, associated with a 
variety of heterochromatic proteins and histone modifications, and restricted from 
homologous recombination (Handel, 2004). Some of the heterochromatic proteins 
and modifications enriched in the XY body include the histone variants macroH2A 
and gammaH2A.X, H3K9 methylation, CBX1 (HP1beta), CBX3 (HP1gamma), as 
well as the small ubiquitin modifier protein SUMO and the SUMO substrates PML 
and Daxx  (Handel, 2004; Metzler-Guillemain et al., 2003; Rogers et al., 2004).  
Patterns of H3.3 gene expression coincide with the reported incorporation of 
H3.3 protein at the XY body during meiotic sex chromosome inactivation (Bramlage 
et al., 1997; van der Heijden et al., 2007).  During mammalian spermatogenesis, 
H3.3A mRNA can be detected throughout pre- and post-meiotic cells, while 
expression of H3.3B appears to be more restricted but highly expressed during 
meiotic prophase (Bramlage et al., 1997). Using an antibody specific to H3.1/H3.2, 
van der Heijden and colleagues demonstrated that H3.1 and H3.2 are gradually 
removed from the XY body during male meiotic prophase I (van der Heijden et al., 
2007).  Moreover, using transgenic mice with tagged H3.3, they demonstrated that 
H3.3 is simultaneously incorporated throughout the transcriptionally silenced X 
and Y chromosomes during pachytene stages of spermatogenesis, coincident with 
loss of most histone post-translational modifications and meiotic sex chromosome 
inactivation (van der Heijden et al., 2007).  This report marks the first demonstration 
that H3.3 can also be associated with the large scale formation of repressive 
heterochromatin.
H3.3 also plays a role in paternal pronuclear decondensation in a variety 
of species (Orsi et al., 2009). The early stages of post-fertilization mammalian 
development provide a remarkable example of genome-wide epigenetic 
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reprogramming, as gametic epigenetic marks are erased and replaced with 
embryonic marks important for early embryonic development and toti/pluripotency 
(Feil, 2009; Morgan et al., 2005). Soon after fertilization in mammals, paternal 
genomic DNA is actively demethylated, the sperm pronucleus is decondensed, 
and its protamines replaced by histones  (Morgan et al., 2005).  In Drosophila, 
nucleosomes containing H3.3 and not H3.2 were shown to be specifically assembled 
in the sperm pronucleus following fertilization, and the H3.3 chaperone HIRA and 
the chromatin remodeling protein CHD1 are also required for male pronuclear H3.3 
deposition (Bonnefoy et al., 2007; Konev et al., 2007; Loppin et al., 2005).  There 
is some evidence that H3.3 plays a similar role in mammals.  The male pronucleus 
in the pre-S-phase mouse zygote has been shown to be virtually devoid of H3.1/
H3.2, while H3.1/H3.2 is enriched in the female pronucleus (van der Heijden et 
al., 2005).  In addition, an antibody ostensibly specific to histone H3.3 has also 
been used to demonstrate that H3.3 is present in the mouse oocyte as a maternal 
factor, and incorporated preferentially into the male pronucleus prior to genome 
activation, although this antibody is no longer available (Torres-Padilla et al., 
2006).  Intriguingly, although most DNA in human sperm is packaged in protamines, 
approximately 15% remains associated with histones, and both H3.3 and H3.1 
have been shown to be present in core histones isolated from human sperm 
(Gatewood et al., 1990). Therefore, it is also possible that incorporation of H3.3 
might play a role in the recently demonstrated epigenetic marking that packages 
key developmental loci in human sperm (Hammoud et al., 2009). However, despite 
the association between H3.3 and various developmental processes, the precise 
role of endogenous H3.3 in mammalian reproduction remains difficult to study due 
to the lack of available antibody or genetic tools.
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H3.3 serine 31 phosphorylation is a mitosis specific mark
As mentioned above, the only residue unique to H3.3 that is accessible in the 
context of the nucleosome is H3.3 serine 31 (H3.3S31) (Figure 1.16).   H3.3S31 
was recently established as a target for phosphorylation (H3.3S31p), and the 
genomic localization of this phosphorylation appears to be developmentally 
regulated (Hake et al., 2005; Wong et al., 2009). In human cervical cancer cells 
(HeLa) and immortalized human embryonic kidney cells (HEK293), H3.3S31p is 
specific to mitosis, and a timecourse of immunofluorescence (IF) studies revealed 
that H3.3S31p is restricted to late prometaphase and metaphase (Hake et al., 
2005).  Chromosome spreads in HeLa and HEK293 show that H3.3S31p is 
localized to regions surrounding centromeres on metaphase chromosomes (Hake 
et al., 2005).  Unlike in HeLa and HEK293 cells, H3.3S31p is localized to telomeres 
in mouse ES cells (Wong et al., 2009) (Figure 1.19).
Telomeres and telomeric chromatin
Telomeres are specialized nucleoprotein structures that protect the ends of eukaryotic 
chromosomes from DNA degradation and inappropriate DNA repair (Palm and 
de Lange, 2008). Telomeres consist of tandem arrays of short DNA repeats, and 
these sequences are maintained by the reverse transcriptase enzyme telomerase 
(Blackburn et al., 2006; Luke and Lingner, 2009; Meyne et al., 1989; Palm and de 
Lange, 2008). Telomere length and telomerase expression play important roles 
in cellular lifespan and replicative capacity, and telomerase protects cells from 
the cellular senescence and genomic instability that would otherwise result from 
telomere shortening after excessive cell division (Allsopp et al., 1992; Bodnar et 
al., 1998; Harley et al., 1990; Levy et al., 1992; Luke and Lingner, 2009).  The ends 
of linear eukaryotic chromosomes have the potential to be recognized as sites of 
DNA damage, and a multi-protein complex known as shelterin therefore protects 
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telomeres from recognition and repair by the non-homologous end joining and 
homology directed DNA repair pathways (Palm and de Lange, 2008). Telomeres 
are bordered by subtelomeric regions that are enriched in repetitive DNA and 
contain a low density of genes (Blasco, 2007). 
Like the rest of the eukaryotic genome, vertebrate telomeres are not made up 
simply of naked DNA, but are packaged into nucleosomes containing core histones 
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Figure 1.19:  Developmentally regulated localization of H3.3S31 phosphorylation
A.  Organization of mitotic mouse chromosomes.  Unlike metacentric human chromosomes, with 
their centromeres in the center of the chromosome, mouse chromosomes are acrocentric, with 
their centromeres located extremely near one end of the chromosome.  The distribution of major 
(pericentric) and minor (centromeric) satellite repeats and of the various interspersed repetitive 
elements are indicated.
B.  The chromosomal localization of H3.3S31p is developmentally regulated (Wong et al., 2009). 
In undifferentiated ES cells, H3.3S31p is localized to telomeres. However, upon retinoic acid 
differentiation, H3.3S31p is relocalized to pericentromeric regions.
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(Lejnine et al., 1995; Makarov et al., 1993; Tommerup et al., 1994). However, 
telomeric chromatin appears to have unique features, including a short nucleosomal 
repeat length, hypersensitivity to MNase, and higher intrinsic nucleosome mobility 
(Pisano et al., 2007; Tommerup et al., 1994).  Moreover, telomeric chromatin has 
features that are consistent with repressive heterochromatin, including H3K9me3, 
H4K20me3, hypoacetylation of H3 and H4, and DNA methylation of subtelomeric 
regions (Blasco, 2007) (Figure 1.20). In other organisms such as yeast and 
Drosophila, telomeric heterochromatin has been shown to silence neighboring 
genes in a phenomenon known as telomeric position effect (TPE), though clear 
evidence for TPE in mammalian cells is still lacking (Ottaviani et al., 2008). 
Although telomeres were long thought to be transcriptionally silent, recent studies 
demonstrate that telomeres are transcribed into telomeric repeat-containing RNA 
(TERRA), a large non-coding RNA that forms an integral component of telomeric 
heterochromatin (Azzalin et al., 2007; Luke and Lingner, 2009; Luke et al., 2008; 
Schoeftner and Blasco, 2008, 2009).  The function of TERRA remains unclear, but 
Adapted from Blasco Nat Rev Genet 2007.
Figure 1.20: Telomeric chromatin has characteristics of heterochromatin
Telomeric and subtelomeric chromatin is heavily enriched in H3K9me3, H4K20me3, and HP1. 
Subtelomeric DNA is heavily methylated by the DNA methyltransferases DNMT1, DNMT3A, and 
DNMT3B. DNA methylation has been shown to inhibit telomere recombination. H3K9me3 and DNA 
methylation act independently as negative regulators of telomere length.  For review, see: (Blasco, 
2007).
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it has been implicated in telomerase regulation, and has been suggested to play a 
role in the stabilization and maintenance of telomeric heterochromatin state (Luke 
and Lingner, 2009; Schoeftner and Blasco, 2009). Recent studies also indicate 
that telomere chromatin state is developmentally regulated (Marion et al., 2009; 
Schoeftner and Blasco, 2008).  ES and iPS cell telomeres have unique features, 
including telomerase activation during reprogramming, increased transcription 
of telomeric RNA, and reduced levels of heterochromatic histone modifications 
(Marion et al., 2009; Schoeftner and Blasco, 2008).
Developmentally regulated telomeric and pericentromeric localization of 
H3.3 and H3.3 serine 31 phosphorylation
A study published in the last year suggests that H3.3 and H3.3S31p may play 
a role in ES cell telomeric chromatin (Wong et al., 2009). Although H3.3S31p 
is localized to telomeres of metaphase chromosomes in ES cells, upon ES cell 
differentiation with retinoic acid H3.3S31p is re-localized to pericentromeric DNA 
of metaphase chromosomes, similar to its localization in differentiated human 
cancer cells (Hake et al., 2005; Wong et al., 2009) (Figure 1.19). H3.3S31p was 
also found at the telomeres of mouse embryonic germ cells, further suggesting 
that telomeric localization of H3.3S31p may be related to pluripotency (Wong et 
al., 2009).  Transfection of myc-tagged H3.3 and H3.2 revealed that H3.3 itself 
was also specifically associated with telomeres in both metaphase chromosomes 
and interphase nuclei, as demonstrated by colocalization with the telomeric 
protein TERF1  (Wong et al., 2009). The  telomeric localization of H3.3 increases 
during early to late S/G2, suggesting that H3.3 telomeric deposition is coupled to 
telomeric DNA replication, although the timing of H3.3 telomeric deposition has 
not been conclusively established  (Wong et al., 2009).  Knockdown of H3.3A 
and H3.B in ES cells induced a slight increase in telomere dysfunctional foci 
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(TIFs), as assessed by the presence of DNA damage factors on telomeres such 
as phosphorylation of gamma H2A.X (Wong et al., 2009).  The authors of this 
study also found that the putative H3.3 chaperone HIRA partially co-localized to 
telomeres, and based on this co-localization they suggest that HIRA may mediate 
H3.3 telomeric deposition (Wong et al., 2009). Notably, the precise function of H3.3 
at telomeres remains unclear.  Moreover, despite the co-localization of HIRA with 
telomeres, the evidence described above also suggests that H3.3 is deposited at 
telomeres during S-phase, while HIRA-mediated nucleosome assembly has been 
demonstrated to occur independent of replication (Ray-Gallet et al., 2002; Tagami 
et al., 2004; Wong et al., 2009). The authors do not remove HIRA and assess 
telomeric incorporation, and therefore it is not clear whether HIRA is required for 
H3.3 telomeric deposition in ES cells  (Wong et al., 2009).
Functional requirements for H3.3 in transcriptional regulation and 
development
Levels of H3 variants have been shown be important for regulating gene 
expression in somatic cells and for organismal fertility (Couldrey et al., 1999; 
Hodl and Basler, 2009; Sakai et al., 2009; Tamura et al., 2009). The expression 
of specific genes in chicken erythroid cells was altered by expression of ectopic 
H3.2 and H3.3, suggesting an active role for H3 variants, and raising concerns 
regarding other experiments that use overexpressed tagged proteins to track H3 
variants (Jin and Felsenfeld, 2006).  In a mouse fibroblast cell line, knockdown of 
H3.3 was also shown to inhibit the expression of interferon induced genes, again 
implicating H3.3 in gene activation (Tamura et al., 2009).  H3.3 may also play a 
role in epigenetic memory (Ng and Gurdon, 2008), although later experiments 
demonstrate that H3.3 is not absolutely required for development (Hodl and Basler, 
2009; Sakai et al., 2009).  Following nuclear transfer experiments, a number of 
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embryos sometimes ‘remember’ their tissue of origin by inappropriately expressing 
genes characteristic of their pre-transplantation lineage (Ng and Gurdon, 2005). 
Intriguingly, overexpression of H3.3 has been shown to enhance this expression 
of pre-transplantation lineage-specific genes following nuclear transplantation (Ng 
and Gurdon, 2008).  Although the role of H3.2 in this process was not directly 
compared with H3.3, these experiments suggest that H3.3 levels (or at least H3 
variant levels) may play a role in modulating epigenetic memory (Ng and Gurdon, 
2008).
H3.3 in neurobiology
Chromatin regulation plays important roles in neuronal physiology and development 
(Borrelli et al., 2008). Histone modifications and chromatin remodeling have been 
linked with synaptic plasticity as well as with behavioral memory (Borrelli et al., 
2008; Fagiolini et al., 2009; Levenson and Sweatt, 2005). Moreover, multiple 
neurological disorders involve mutations in genes that encode chromatin-binding 
or chromatin-modifying enzymes.  Intriguing examples include mutations in a 
chromatin remodeling protein that causes alpha-thalassaemia and X-linked 
mental retardation (ATRX) syndrome, in a histone H3K4me3 demethylase that 
causes epilepsy and X-linked mental retardation, in a DNA methylation binding 
protein that causes Rett syndrome, and in a HAT that causes Rubinstein-Taybi 
syndrome (Chahrour and Zoghbi, 2007; Gibbons et al., 2008; Murata et al., 2001; 
Tahiliani et al., 2007). A common theme of these disorders is that mutations in 
epigenetic regulators can alter chromatin structure and induce a broad spectrum 
of neurodevelopmental defects.
Multiple lines of evidence suggest that H3.3 is likely to play an important 
role in neuronal biology.  Most neurons in the mammalian central nervous system 
are post-mitotic, and H3.3 is the only H3 variant expressed at significant levels 
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outside of S phase (Wu et al., 1982). H3.3 RNA and protein levels were observed 
to increase during models of cell differentiation in non-neuronal systems (Krimer 
et al., 1993; Lord et al., 1990; Wunsch and Lough, 1987). High levels of H3.3 
protein have been found in differentiating rat neurons, and H3.3 has been shown 
to become the dominant histone H3 variant protein in rat brain cortical neurons 
(Pina and Suau, 1987; Scaturro et al., 1995). H3.3A and H3.3B mRNA are highly 
expressed in distinctive, yet partially overlapping patterns of expression in the 
mouse brain (Lein et al., 2007). Indeed, RNA in situ hybridization studies indicate 
that H3.3A expression is relatively ubiquitous throughout the mouse brain, while 
H3.3B is mostly expressed in the cerebellum and the hippocampus, particularly 
in the dentate gyrus (Lein et al., 2007) (Figure 1.21).  Gene trap mice with 
reduced expression of H3.3A also showed neuromuscular defects, with impaired 
performance on tasks involving grip strength and muscle tone, further suggesting 
a function for H3.3 in neuronal biology (Couldrey et al., 1999).  However, due to the 
hypomorphic nature of available studies and the lack of an available H3.3 antibody, 
the specific role of H3.3 in mammalian neuronal biology has yet to be elucidated.
Requirements for H3.3 in sexual reproduction
H3.3 plays a critical role in sexual reproduction in multiple organisms.  Given the 
association of H3.3 with specific processes in the reproduction of a variety of 
species, as described above (Cui et al., 2006; Loppin et al., 2005; Ooi et al., 2006; 
Torres-Padilla et al., 2006), it is not surprising that recent studies have shown 
that H3.3 is required for fertility in flies, ciliates, and mammals.  Although the 
functional requirements for H3.3 in transcriptional regulation are not absolute, the 
requirements for H3.3 in fertility are clear (Couldrey et al., 1999; Hodl and Basler, 
2009; Sakai et al., 2009).  
In 1999, Couldrey and colleagues reported a retroviral gene trap insertion 
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Figure 1.21: Patterns of H3.3A and H3.3B expression in the adult mouse brain
A. In situ hybridization of H3.3A and H3.3B RNA in the adult mouse brain reveals distinct, but 
partially overlapping patterns of expression.  Three-dimensional oblique views of the mouse brain 
are shown, with structures depicted on the sagittal and coronal planes.  H3.3A RNA expression 
is shown in yellow (top), and H3.3B RNA expression is shown in orange (bottom).  While H3.3A 
expression is relatively ubiquitous, H3.3B expression is limited to the cerebellum (CB), hippocampus 
(HIP), and olfactory bulb (OLF). Data was downloaded from the Allen Brain Atlas and represented 
within the Allen Brain Atlas Brain Explorer.
B.  Relative quantification of H3.3A and H3.3B expression level and expression density in specific 
brain structures, as reported by the Allen Brain Atlas (Lein et al., 2007).  
 CB  Cerebellum 
 CTX  Cerebral cortex 
 HIP  Hippocampal region 
 HPF  Hippocampal formation
 HY  Hypothalamus
 LSX  Lateral septal complex 
 MB  Midbrain
 MY  Medulla
 OLF  Olfactory bulb
 P  Pons
 PAL  Pallidum
 RHP Retrohippocampal region
 sAMY  Striatum-like amygdalar nuclei
 STR  Striatum
 STRd  Striatum dorsal region
 STRv  Striatum ventral region
 TH  Thalamus
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into the first intron of murine H3.3A that created a hypomorphic mutation, resulting 
in partial neonatal lethality, stunted growth, neuromuscular deficits, and male sub-
fertility (Couldrey et al., 1999).  H3.3A gene trap hypmorphic mice had significantly 
fewer matings, and of these matings, only 6% of matings (1/16) of H3.3A 
hypomorphic mice resulted in pregnancy, while 74% (48/65) of matings in wild-type 
mice resulted in pregnancy (Couldrey et al., 1999). However, hypomorphic H3.3A 
homozygotes still retained expression of H3.3A detectable by RT-PCR (Couldrey et 
al., 1999), and the phenotype is also likely to have been rescued by the presence 
of H3.3B, which codes for an identical protein. Therefore, the precise function of 
H3.3 in mammalian development and physiology has yet to be established.  More 
recently, full knockouts of both copies of H3.3 have been reported in Drosophila 
and Tetrahymena, and they show an absolute requirement of H3.3 for sexual 
reproduction (Cui et al., 2006; Hodl and Basler, 2009; Sakai et al., 2009).
In both Drosophila and Tetrahymena, replication-independent H3.3 or H3.3-
like genes are not essential for growth, but are required for sexual reproduction 
(Cui et al., 2006; Hodl and Basler, 2009; Sakai et al., 2009). In Tetrahymena, cells 
can grow with expression of either replication-coupled or replication-independent 
H3 variants, but they show an absolute requirement for the minor H3 variants (H3.3 
and H3.4) in the production of viable sexual conjugation progeny (Cui et al., 2006). 
Two groups recently reported that H3.3 was also absolutely required for fertility, but 
only partially required for developmental viability of Drosophila (Hodl and Basler, 
2009; Sakai et al., 2009). In Drosophila, loss of both copies of H3.3 leads to partial 
but incomplete lethality (~42% viability), complete sterility, and transcriptional 
defects, particularly at highly expressed genes (Sakai et al., 2009). However, the 
survival of even less than half of H3.3 double null flies indicates that H3.3 is not 
absolutely required for transcription (Hodl and Basler, 2009; Sakai et al., 2009). 
Loss of both copies of H3.3 appears to be partially compensated by an increase 
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in the expression of the normally replication-dependent histone genes, and these 
upregulated histone gene transcripts were found to be polyadenylated (Sakai et 
al., 2009). In double null H3.3 flies, expression of the H3.3 rescue transgene (but 
not the H3.2 rescue transgene) suppresses overexpression of the endogenous H3 
genes, suggesting that Drosophila cells can distinguish H3.3 expression from bulk 
H3 (Sakai et al., 2009). These experiments also showed that maintaining wild-type 
levels of H3K4 methylation is likely still important for transcriptional regulation, but 
is still partially dispensable for normal fly development (Hodl and Basler, 2009), as 
~20% of H3.3K4R mutant flies remain viable (Sakai et al., 2009). 
The absolute requirement of H3.3 for fertility appears to be due to its role 
in chromosome segregation during spermiogenesis, and remodeling of germline 
chromatin (Sakai et al., 2009). H3.3 double null flies fail to properly  condense and 
segregate chromosomes during male meiosis, and they also show an abnormal 
arrangement of chromatin in posmeiotic nuclei, indicating that H3.3 is critical for 
remodeling of germline chromatin (Sakai et al., 2009).  Intriguingly, in H3.3 double 
null flies, H3.3S31A, H3.3K4R, and H3.3K9R rescue fly fertility, while expression of 
H3.2 does not. Therefore, although known H3.3 modification sites are not required 
for fertility, the H3.3 specific residues at 87, 89, and 90 (Figure 1.16) are absolutely 
required, suggesting that these amino acids play an essential role in the remodeling 
and packaging of germline chromatin (Sakai et al., 2009).
Histone H3 deposition machinery
Progress has also been made on the molecular machinery that deposit different 
histones into chromatin (De Koning et al., 2007; Loyola and Almouzni, 2007). 
Nucleosome deposition or nucleosome replacement occurs in a variety of 
contexts, including DNA replication, DNA repair, and transcription, and elucidating 
the mechanisms responsible for recruitment of histone deposition factors to these 
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distinct genomic regions remains an intense area of research  (De Koning et al., 
2007; Groth et al., 2007b; Polo and Almouzni, 2006).
Histone H3.3 has been shown to be deposited into Drosophila chromatin 
in both a replication-coupled (RC) and replication-independent (RI) manner, while 
H3.2 deposition is coupled to replication (Ahmad and Henikoff, 2002). Biochemical 
purification of tagged-H3.1 and H3.3 from human HeLa cells by Nakatani, Almouzni 
and colleagues yielded complexes with distinct histone chaperones (Tagami et 
al., 2004).  The chromatin assembly factor complex 1 (CAF-1) was associated 
with H3.1, while histone regulatory protein A (HIRA) was associated with H3.3 
(Tagami et al., 2004).  Intriguingly, CAF-1 has been shown to mediate DNA 
synthesis-dependent nucleosome assembly, while HIRA mediates DNA synthesis-
independent nucleosome assembly (Ray-Gallet et al., 2002; Tagami et al., 2004).
The H3.1 associated CAF-1 is composed of three subunits, p150, p60, and 
p48, and this complex has been shown to promote chromatin assembly in the 
context of DNA replication or DNA repair (Polo et al., 2006; Smith and Stillman, 
1989; Verreault et al., 1996).  Biochemical studies have established that CAF-
1 is required for DNA synthesis-dependent nucleosome assembly in Xenopus 
egg extracts, as well as for H3.1 deposition at sites of DNA damage (Polo and 
Almouzni, 2006; Polo et al., 2006; Tagami et al., 2004).  CAF-1 colocalizes with 
the proliferating cell nuclear antigen (PCNA) on newly replicating DNA, and is 
also required for heterochromatin organization in pluripotent ES cells and for early 
embryonic development (Shibahara and Stillman, 1999; Verreault et al., 1996).
In addition to CAF-1 and HIRA, which appear to be specific in their preferences 
for H3.1 or H3.3, Nakatani, Almouzni, and colleagues identified a variety of proteins 
were associated with both H3.1 and H3.3  (Tagami et al., 2004). Such common 
partners included the histone H3-H4 chaperones anti-silencing function 1 (ASF1) A 
and B, the H1 binding protein NASP, the histone acetyltransferase HAT1, and the 
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common CAF-1 subunit p48, also known as retinoblastoma binding protein p48 
(Tagami et al., 2004).
Deposition of H3-H4 as a heterodimer
H3 and H4 form a (H3-H4)2 tetramer in the context of the nucleosome, and 
this tetramer is stable even in the absence of DNA, leading to the longstanding 
suggestion that H3 and H4 are deposited into chromatin as a tetramer (Baxevanis 
et al., 1991; De Koning et al., 2007; Luger et al., 1997). However, H3-H4 bound to 
HIRA or CAF-1 was recently shown to exist as a H3-H4 heterodimer rather than a 
tetramer (Tagami et al., 2004). Moreover, recent biochemical and crystallographic 
studies have demonstrated that both yeast and human ASF1 bind to and stabilize 
H3-H4 heterodimers, physically blocking assembly of (H3-H4)2 tetramers (Bao and 
Shen, 2006; English et al., 2006; Natsume et al., 2007) (Figure 1.22).  Soluble 
H3-H4 heterodimers have also been shown to be heavily acetylated at H4K5 
and H4K12 (Groth et al., 2007b; Loyola et al., 2006). In vertebrate cells, H4K5ac/
H4K12ac is largely mediated by the two subunit enzyme HAT1-RbAp46, and these 
acetyl marks have been implicated in histone deposition in a variety of organisms 
(Barman et al., 2006; Sobel et al., 1994; Sobel et al., 1995; Verreault et al., 
1996, 1998).  HAT1 is surprisingly dispensable for replication-coupled chromatin 
assembly in vertebrate cells, though HAT1-/- cells are sensitive to DNA damage, 
and the precise function of H4K5/K12 diacetylation remains unclear (Barman et 
al., 2006; Groth et al., 2007b).
Current models suggest that ASF1 serves as a donor for deposition of 
H3.1-H4 or H3.3-H4 heterodimers by CAF-1 or HIRA (De Koning et al., 2007) 
(Figure 1.22).  CAF-1 and HIRA both bind to ASF1A, and ASF1A and ASF1B have 
recently both been shown to play a role in both RI and RC nucleosome assembly 
in human cells (Galvani et al., 2008; Tang et al., 2006).  Interestingly, although 
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Adapted from De Koning 2007.
Chd1?
H3K56ac
H3.1/H3.3-H4
H4K5ac/H4K12ac
Asf1a/b
Replication-independent
assembly
Replication-coupled
assembly
(H3-H4)   tetramer2 H3-H4 dimer
Figure 1.22: Current view of H3 variant deposition pathways
The current view of histone H3 variants in chromatin assembly pathways is depicted here.  Histone 
H3 and H4 can exist in vitro as tetramers or dimers, and it remains unclear (question mark) 
whether the H3-H4 dimer utilized in histone deposition comes from a split tetramer (upper left) 
or a dimeric source (upper right).  Asf1 (red) interacts with and stabilizes the H3-H4 dimer.  In 
replication-coupled chromatin assembly (right), Asf1a and Asf1a act as histone donors for CAF-1. 
In replication-independent chromatin assembly (left), Asf1a and Hira act together to deposit H3.3 
during transcription or specific developmental contexts.  Chd1 may also cooperate with Hira to 
deposit H3.3 into chromatin (Konev et al., 2007).  Notably, in current models, Hira is required for 
H3.3-specific deposition into chromatin (De Koning et al., 2007).
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HIRA is reported to physically interact with ASF1A but not ASF1B, depletion of 
both ASF1A and ASF1B were required to inhibit G1-phase deposition of H3.3 into 
chromatin, indicating that H3.3 deposition during G1 could still occur in the absence 
of a HIRA-ASF1A interaction (Galvani et al., 2008; Zhang et al., 2005).
ASF1 can participate in both nucleosome assembly and disassembly (Groth 
et al., 2007b). In human cells, ASF1 interacts with the putative replicative helicase 
(MCM1-7) through a H3-H4 bridge, and ASF1A is required for vertebrate cellular 
viability and chromatin assembly during replication (Groth et al., 2007a; Sanematsu 
et al., 2006).  In yeast and mammals, ASF1 is required for H3K56ac, a modification 
that has been associated with sites of newly deposited histones in replication-
coupled, replication-independent, and DNA damage deposition pathways (Chen 
et al., 2008a; Fillingham and Greenblatt, 2008; Li et al., 2008; Recht et al., 2006; 
Yuan et al., 2009).  Because of its common role in multiple H3 deposition pathways, 
H3K56ac has been suggested as a universal signature of newly assembled yeast 
chromatin (Fillingham and Greenblatt, 2008).    Interestingly, despite its association 
with chromatin assembly, H3K56ac has also been shown to be required for normal 
promoter activation and chromatin disassembly in yeast (Williams et al., 2008). 
Genome-scale profiles of H3K56ac have recently been established in human 
ES cells, and this modification localizes to both active and inactive promoters, 
significantly overlapping with binding sites for key regulators of pluripotency (Xie et 
al., 2009).  H3K56ac has been shown to increase the affinity of H3 for CAF-1 as well 
as the histone chaperone Rtt106 in yeast, although it remains unclear if H3K56ac 
can play a similar role in increasing affinity of H3.3 for HIRA in mammalian cells 
(Chen et al., 2008a; Fillingham and Greenblatt, 2008; Li et al., 2008).
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HIRA – histone regulatory protein A
The H3.3-associated protein HIRA is required for replication-independent 
nucleosome assembly in vitro, and for Drosophila male pronuclear decondensation 
in vivo (Bonnefoy et al., 2007; Loppin et al., 2005; Ray-Gallet et al., 2002; Tagami et 
al., 2004).  Although humans have a single HIRA protein, both budding and fission 
yeast have two homologs of HIRA that function together (Blackwell et al., 2004; 
Kanoh and Russell, 2000; Lamour et al., 1995; Spector et al., 1997). The yeast 
homologs of HIRA (Hir1 and Hir2 in S. cerevisiae) were initially identified as factors 
that repress the transcription of histone genes outside of S phase, and subsequent 
work has shown that these proteins are also required to maintain pericentromeric 
heterochromatin in the fission yeast S. pombe (Blackwell et al., 2004; Lamour et al., 
1995; Spector et al., 1997).  Consistent with its role in the promotion of repressive 
yeast chromatin, nucleosomes bound by the yeast HIR complex are resistant 
to chromatin remodeling by SWI/SNF (Prochasson et al., 2005).  Intriguingly, a 
recent study demonstrated that the S. pombe HIRA complex functions as a global 
transcriptional repressor, and is particularly important for promoter silencing and 
the suppression of cryptic antisense transcripts (Anderson et al., 2009). HIRA has 
also been show to play a role in human heterochromatin, as HIRA and ASF1A drive 
chromosome condensation during the formation of specialized heterochromatin 
domains known as senescence associated heterochromatin foci (SAHF) (Adams, 
2007; Ye et al., 2007; Zhang et al., 2007; Zhang et al., 2005). However, despite this 
conserved functional association with heterochromatin and gene repression, the 
human homolog of HIRA was specifically isolated with H3.3 from HeLa cells, and 
as we have seen, H3.3 is largely associated with active chromatin (Ahmad and 
Henikoff, 2002; Tagami et al., 2004).
Biochemical experiments clearly link HIRA to replication-independent 
nucleosome assembly (Ray-Gallet et al., 2002; Tagami et al., 2004).  HIRA is a 
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large WD repeat containing protein with seven WD repeats conserved between 
yeast and human HIR proteins, and both the mammalian and Xenopus homologs 
of HIRA interact with core histones (Lorain et al., 1996; Lorain et al., 1998; 
Magnaghi et al., 1998).  Following this observation, the role of HIRA in nucleosome 
assembly has largely been studied in Xenopus egg extracts, which provides a 
powerful system for studying chromatin assembly (Ray-Gallet et al., 2002; Tagami 
et al., 2004).  Proteins contained within egg extracts will assemble chromatin on 
plasmid DNA (Almouzni and Mechali, 1988; Gaillard et al., 1996; Gaillard et al., 
1999).   If the plasmid has been previously irradiated with UV, the Xenopus egg 
extract will perform chromatin assembly in the presence of DNA synthesis during 
the process of nucleotide excision repair (Gaillard et al., 1999).  In Xenopus egg 
extracts, immunodepletion of HIRA did not effect nucleosome assembly of UV-
irradiated plasmids coupled to nucleotide excision repair, but loss of HIRA severely 
impaired DNA synthesis independent nucleosome assembly (Ray-Gallet et al., 
2002; Tagami et al., 2004).  This defect in replication-independent nucleosome 
assembly could be rescued by addition of recombinant HIRA protein and (H3-H4)2 
tetramers, or HIRA enriched protein fractions from egg extract (Ray-Gallet et al., 
2002).  More interestingly, RI nucleosome assembly could also be rescued by 
purified H3.3 complexes from HeLa cells that contained HIRA, but not by purified 
H3.1 complexes that contained CAF-1, or by recombinant HIRA or CAF-1 (Ray-
Gallet et al., 2002; Tagami et al., 2004). Conversely, CAF-1 was required for DNA 
synthesis-dependent nucleosome assembly, and this defect could be rescued by 
purified H3.1 complexes containing CAF-1, but not by H3.3 complexes (Tagami 
et al., 2004).  In summary, these experiments demonstrated that H3.3 and H3.1 
associate with distinct complexes containing HIRA and CAF-1, and these complexes 
are critical for replication-independent (HIRA) or replication-dependent (CAF-1) 
chromatin assembly (Ray-Gallet et al., 2002; Tagami et al., 2004).
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Functional roles for HIRA and CHD1 in histone deposition, cellular 
differentiation, and development
In vivo studies in Drosophila show that Hira is required for chromatin assembly 
and H3.3 deposition in the male pronucleus (Loppin et al., 2005).  Maternal HIRA 
and FLAG-tagged H3.3 accumulate in the male pronucleus following fertilization 
(Loppin et al., 2005). A specific point mutation in Hira (known as ssm) impairs 
H3.3 deposition to the male pronucleus and prevents male pronucleus formation, 
providing the first direct link between H3.3 deposition and Hira in vivo (Loppin et al., 
2005).  Without male pronuclear formation, embryos from eggs laid by ssm females 
are haploid, develop only with maternal chromosomes, and die before hatching 
(Loppin et al., 2005; Loppin et al., 2000). Interestingly, this same mutation in Hira 
enhanced variegation of a reporter transgene located between heterochromatin 
and a site for H3.3 replacement, suggesting that Hira-directed H3.3 replacement 
can help to counteract heterochromatin spreading in somatic cells (Nakayama et al., 
2007).  Surprisingly, however, later studies demonstrated that paternal chromatin 
assembly after fertilization is the only developmental process in flies that absolutely 
required HIRA, as HIRA null flies were viable, but females were sterile (Bonnefoy et 
al., 2007). Strikingly, HIRA is not required for global H3.3 deposition in Drosophila 
embryos or adult cells, providing intriguing hints that alternate pathways exist to 
mediate H3.3 nucleosome assembly (Bonnefoy et al., 2007).  
 Loss of Hira in mammals leads to a far more severe phenotype than the loss 
of Hira in flies (Bonnefoy et al., 2007; Roberts et al., 2002).  Targeted mutagenesis 
of Hira in mice results in gastrulation defects and patterning abnormalities of 
mesendodermal derivatives prior to early embryonic lethality (Roberts et al., 
2002).  Hira -/- embryos displayed a range of defects, including a distorted 
primitive streak, delayed and abnormally displaced expression of the primitive 
streak marker Brachyury, severe axial and paraxial defects, abnormally patterned 
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neuroepithelium, abnormal placentation, and cardiovascular defects (Roberts et 
al., 2002). Inbred Hira -/- embryos died by E10, and even Hira -/- embryos from 
mice crossed to an outbred background all died by E11 (Roberts et al., 2002). 
Despite this severe early embryonic lethality of Hira -/- embryos, Hira -/- ES cells 
are surprisingly viable (Meshorer et al., 2006).  
 Hira -/- ES cells proliferate normally and express the pluripotency marker 
Oct4, but show elevated levels of unbound histones (Meshorer et al., 2006).  Hira 
-/- ES cells display significantly reduced incorporation of both H3.3-YFP and H3.2-
YFP as assessed by rapid fluorescence recovery after photobleaching (FRAP), 
and salt extraction also revealed an increased fraction of soluble H3 (Meshorer 
et al., 2006).  Intriguingly, Hira -/- ES cells underwent accelerated differentiation 
during the formation of embyoid bodies, despite normal regulation of differentiation 
specific genes in Hira -/- ES cells (Meshorer et al., 2006).  However, while they 
gave rise to early NPCs, Hira -/- cells failed to progress further into differentiated 
neurons (Meshorer et al., 2006).   Overall, these results indicate that Hira is 
dispensable for the survival of proliferating ES cells, but is required to maintain 
normal levels of histone incorporation, and is required for normal gene regulation 
and survival during cellular differentiation and early development (Meshorer et al., 
2006; Roberts et al., 2002).
HIRA has also been implicated in genome-wide DNA demethylation and 
chromatin remodeling during establishment of the mammalian germ line (Hajkova 
et al., 2008). Primordial germ cells (PGCs) are specified during early mammalian 
development (Hayashi and Surani, 2009; Kurimoto et al., 2008; Ohinata et al., 2005). 
In mice, this germline specification takes place at E7.25, followed by migration 
of PGCs into the developing gonad (Saga, 2008).  Between E11.5 and E12.5, 
PGCs show genome-wide DNA demethylation and erasure of genomic imprinting 
(Hajkova et al., 2002; Lee et al., 2002a), along with a concomitant genome-wide 
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transient or persistent loss of histone modifications such as H3K9me3, H3K9ac, 4/
H2AR3me2, H3K27me3, and histone variants such as H1 (Hajkova et al., 2008). 
This specific timepoint also exactly coincides with the nuclear localization of Hira 
and the nuclear exclusion and cytoplasmic localization of CAF-1 (Hajkova et al., 
2008).  These results implicate Hira-mediated histone replacement and potentially 
H3.3 as likely players in mammalian germline chromatin remodeling, though the 
lack of H3.3 antibodies has made further study of this question difficult.
More recently, the chromatin remodeling factor CHD1 was also shown to be 
important for H3.3 deposition in Drosophila (Konev et al., 2007).  Like Hira, maternal 
CHD1 is required for H3.3 deposition into the male Drosophila pronucleus, and for 
the participation of the male pronucleus in zygotic mitoses (Konev et al., 2007). 
Embryos from homozygous CHD1-null females develop with only maternally 
derived genomes, and die before hatching (Konev et al., 2007). CHD1 physically 
associates with Hira, and has been suggested to work together with Hira to mediate 
H3.3 incorporation into chromatin, with Hira proposed to be essential for histone 
delivery, and CHD1 thought to facilitate histone deposition (Konev et al., 2007).  
Recent studies have established that CHD1 plays an important role in the 
regulation of chromatin state in mammalian cells (Gaspar-Maia et al., 2009; Sims and 
Reinberg, 2009).  The chromodomain of human CHD1 recognizes H3K4me2 and 
H3K4me3, and CHD1 localizes to euchromatic promoter regions in mouse ES cells 
(Gaspar-Maia et al., 2009; Sims et al., 2005). CHD1 is critical for the maintenance 
of open chromatin in ES cells, as downregulation of CHD1 impaired the normally 
hyperdynamic chromatin state of ES cells and significantly increased the number 
of H3K9me3 nuclear foci (Gaspar-Maia et al., 2009). Surprisingly, CHD1 RNAi ES 
cells showed global maintenance of the ES cell transcriptome (Gaspar-Maia et al., 
2009).  However, CHD1 RNAi ES cells also have a high propensity for neuronal 
differentiation, and failed to give rise to primitive endoderm or beating cardiac 
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mesoderm, indicating that CHD1 is required for normal pluripotency (Gaspar-
Maia et al., 2009). After the recent finding that CHD1 is required for H3.3 male 
pronuclear deposition in Drosophila (Konev et al., 2007), it has been speculated 
that CHD1 may be mediating its role in pluripotency and open chromatin through 
the deposition of H3.3 (Gaspar-Maia et al., 2009).
Localization and function of H2A.Z in undifferentiated and differentiated 
cells
As described above, the histone H2A variant H2A.Z co-occupies nucleosomes with 
H3.3 at specific regions of the genome in differentiated cells, including promoters 
and regulatory elements, and H3.3/H2A.Z nucleosomes have been shown to be 
less stable in vitro (Jin and Felsenfeld, 2006, 2007; Jin et al., 2009).  
Recent ChIP-chip studies of H2A.Z have revealed that the genome-wide localization 
of this variant changes dramatically upon ES cell differentiation (Creyghton et al., 
2008).  Previous studies in differentiated cells have shown that H2A.Z is enriched 
at promoters in proportion to transcriptional activity, as well as at regulatory regions 
(Barski et al., 2007; Jin et al., 2009; Schones et al., 2008).  However, in pluripotent 
ES cells, H2A.Z localizes to the promoters of transcriptionally repressed polycomb 
target genes, but changes its localization to the promoters of actively transcribed 
genes upon ES cell differentiation to neural precursor cells (NPCs) (Creyghton 
et al., 2008). Knockdown studies demonstrated that H2A.Z is required for the 
repression of polycomb target genes, and that the localization of H2A.Z and the 
PcG protein Suz12 at target promoters is interdependent, with loss of appropriate 
localization of one upon depletion of the other (Creyghton et al., 2008).   Embryoid 
body differentiation and tetraploid complementation studies revealed that H2A.Z 
depleted ES cells were defective in differentiation and lineage commitment, failing 
to repress pluripotency genes and failing to express differentiation specific genes 
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in an appropriate spatiotemporal manner (Creyghton et al., 2008).   Overall, these 
studies indicate that H2A.Z plays an unexpected role in gene repression in ES 
cells, and is required for ES cell differentiation.  
Concluding remarks – setting the stage for the study of H3.3 in mammalian 
embryonic stem cells
As we have seen, the H3.3 Drosophila deposition factor Chd1 and the H3.3 
nucleosome destabilizing partner H2A.Z are both required for mouse ES cell 
pluripotency (Creyghton et al., 2008; Gaspar-Maia et al., 2009).  In addition, the 
Drosophila H3.3 chaperone HIRA is also required for normal ES cell differentiation 
(Meshorer et al., 2006; Roberts et al., 2002).  Given these findings, as well as the 
conserved association between H3.3 and active chromatin, H3.3 itself has therefore 
been speculated to play an important role in in establishing and maintaining the 
pluripotent chromatin state (Creyghton et al., 2008; Gaspar-Maia et al., 2009). 
However, as of yet, no genome-wide studies in pluripotent cells distinguish between 
H3 variants, nor do they examine the genome-wide role of Hira or other histone 
chaperones in specifying H3.3 deposition at specific genomic regions.  Although 
studies in non-mammalian systems point to a role for H3.3 in transcriptional 
regulation and an absolute requirement for H3.3 in sexual reproduction (Hodl and 
Basler, 2009; Sakai et al., 2009), the genomic localization and precise function of 
H3.3 in mammalian cells remains an open question.
 With this foundation, I set out to generate tools to examine the genome-
wide localization of histone H3.3 in mammalian cells. In Chapter Two, I will 
describe a zinc finger nuclease technology that enables rapid targeting and point 
mutagenesis of the endogenous histone H3.3B gene in mouse ES cells.  After 
differentiating these targeted ES cells into neural precursor cells (NPCs), I have 
generated the first genome-wide profiles of H3.3 localization in pluripotent and 
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differentiated cells.  In Chapter Three, I use wild-type and Hira -/- ES cells to 
determine the genome-wide dependence of H3.3 localization on the known H3.3 
chaperone Hira.  Surprisingly, my data show that while Hira is required for H3.3 
deposition at active and repressed genes, Hira is not essential for H3.3 deposition 
at telomeres, ribosomal DNA (rDNA), and specific TFBS.  This striking result 
opened up an entirely new area of investigation for my thesis, and for the field.  To 
identify H3.3 interacting proteins that might mediate Hira-independent deposition 
at these elements, I purified H3 variant associated proteins from wild-type and Hira 
-/- ES cells, and my collaborator Dr. Ileana Cristea performed mass spectrometry.  I 
found that the chromatin remodeling protein Atrx and the death domain associated 
protein Daxx specifically associate with H3.3 in the presence and absence of Hira. 
Finally, I show that Atrx is required for deposition of H3.3 at telomeres and rDNA, 
and for the repression of telomeric and ribosomal  transcription. In Chapter Four, 
I will describe some additional collaborative studies in progress, and discuss the 
implications of my work for the field.  Chapter Five provides the materials and 
methods used in my studies.  In addition, I have included an appendix with a more 
detailed discussion of ChIP and ChIP-seq, as well as the ChIP-seq protocols that 
I have used throughout my work.
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CHAPTER 2
GENOME-WIDE PATTERNS OF HISTONE H3.3 
IN MAMMALIAN CELLS ARE DEPENDENT ON 
ENDOGENOUS AMINO ACID SEqUENCE AND 
CELLULAR STATE
Summary
As described in Chapter One, recent landmark studies have established genome-
wide maps of covalent histone H3 modifications in undifferentiated mammalian 
embryonic stem (ES) cells and differentiated cells (Barski et al., 2007; Mikkelsen 
et al., 2007).  However, mammalian cells express multiple, distinct genetically 
encoded variants of histone H3 proteins (Ahmad and Henikoff, 2002).  When I 
began this project, there were no genome-wide or genome-scale profiles of histone 
H3 variants in any mammalian cell type.  Moreover, existing H3 antibodies used 
by prior studies did not distinguish between these variants.  As we have seen in 
Chapter One, histone H3 variants are extremely similar in sequence, and most 
of the amino acids that differ between them are inaccessible in the context of the 
nucleosome (see Figure 1.16). 
To distinguish histone H3 variants, I began a collaboration with Sangamo 
Biosciences with the goal of rapidly editing the genomic sequence of an endogenous 
mammalian histone H3.3 gene.  I used designed zinc finger nucleases (ZFN) and 
short, drug selection-less targeting constructs to rapidly knock-in epitope tags 
into the endogenous histone H3.3B gene of mouse embryonic stem (ES) cells. 
To establish the dependence of H3 variant localization on amino acid sequence, 
I created point mutations to mutate endogenous H3.3B towards H3.2 or H3.1. 
Using chromosome spreads and chromatin immunoprecipitation assays coupled to 
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high-throughput sequencing (ChIP-seq), I have established the first genome-wide 
profiles of histone H3 variants in mammalian ES cells.  To facilitate the analysis of 
this genome-wide ChIP-seq data, I began a collaboration with Assistant Professor 
Deyou Zheng at the Albert Einstein College of Medicine.  My collaborators and I found 
enrichment of H3.3 in specific genic and intergenic regions and in specific repeats, 
including telomeres.  Surprisingly, we determined that H3.3, like H3K4 methylation, 
is enriched around transcription start sites of high CpG content promoters in ES 
cells at both transcriptionally active and transcriptionally repressed genes, as well 
as the transcription start sites of H3K4me3/H3K27me3 bivalent genes.  We also 
found H3.3 enriched within the bodies of actively transcribed protein coding genes 
as well as large intervening non-coding RNAs (lincRNAs), correlated with H3K36 
methylation.  We observed that the transcription end sites of highly transcribed 
genes are marked by peaks of H3.3 and phosphorylated RNA polymerase II, a 
phenomenon that has not been previously described in mammalian cells.  We also 
found that H3.3, like H3K4me1, is enriched at all known classes of transcription 
factor binding sites (TFBS) in mouse ES cells, including intergenic sites. We 
established that all specific patterns of H3.3 enrichment in mammalian cells are 
dependent on H3.3-specific amino acid sequence.  Following differentiation of 
ES cells into neuronal precursor cells, we showed that the localization of H3.3 
changes with cellular differentiation at specific genic and intergenic sites.  The 
work described in this chapter provides a foundation for integrating histone H3 
variants into our understanding of the epigenetic regulation of gene expression in 
mammalian cells.
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Results
Designed zinc finger nucleases enable highly efficient gene targeting of 
histone H3.3B
In mammals, histone H3.3 is encoded by two different genes (H3.3A and H3.3B) 
that code for the same amino acid sequence, but 
differ in their 5’ and 3’ UTRs, and also in their 
patterns of tissue-specific expression (Bramlage et 
al., 1997).  Using RT-PCR, I found that the mRNA 
of H3.3A and H3.3B are both highly expressed in 
ES cells and neural precursor cells, with H3.3B 
slightly more highly expressed than H3.3A in ES 
cells (Figure 2.1).
To establish a rapid system for editing the 
endogenous H3.3B gene, I began a collaboration 
with Sangamo Biosciences, which has recently 
developed a technology for highly efficient 
targeting of mammalian genes (Urnov et al., 2005). 
Gene editing using conventional technology has 
been very successful (Hogan, 2007), but is generally inefficient (<~0.0025% of 
electroporated cells) due to the low frequency of homologous recombination, 
(Carroll, 2008; Hasty et al., 1991; te Riele et al., 1992). Despite the low efficiency 
of homologous recombination, the introduction of a selectable antibiotic resistance 
marker (neomycin phosphotransferase) and the use of antibiotics (neomycin, G418) 
has made conventional gene targeting a viable and successful technology (Hogan, 
2007; te Riele et al., 1992).  Zinc finger nuclease (ZFN) mediated gene targeting 
is based on the principle that a targeted DNA double-strand break can significantly 
enhance the efficiency of homologous recombination at a target site by engaging 
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Figure 2.1: Expression of H3.3A 
and H3.3B in embryonic stem (ES) 
cells and neural precursor cells 
(NPCs)
Real-time PCR indicates expression 
of H3.3A and H3.3B mRNAs in mouse 
ES cells and differentiated NPCs, as 
a percentage of Gapdh expression. 
The pluripotency gene Pou5f1 (Oct4) 
and the neural precursor marker 
Olig1 serve as controls for cellular 
differentiation state.
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the cell’s endogenous system of homologous recombination and homology-
directed repair (Carroll, 2008; Urnov et al., 2005).  The C2H2 zinc finger is the most 
common DNA binding motif in all metazoa (Tupler et al., 2001; Vaquerizas et al., 
2009), and recent work has enabled the engineered design of linked zinc fingers to 
recognize particular DNA sequences with high specificity (Klug, 2005; Moore et al., 
2001). Linked and engineered zinc fingers can be coupled to the nonspecific DNA 
restriction enzyme FokI to target a DNA double strand break to a desired location, 
producing homologous recombination with specific targeting rates as high as 20% 
for the introduction of simple point mutations, even in the absence of selection 
(Urnov et al., 2005). 
Taking advantage of the highly efficient technique of targeted gene editing 
mediated by ZFNs (Carroll, 2008), my collaborators and I used an archive of 
validated two-finger modules (Doyon et al., 2008; Urnov et al., 2005) to generate 
designed ZFNs specific to the last coding exon of the H3.3B gene (Figure 2.2A). 
I designed two general strategies to knock-in epitope tags fused to the C-terminus 
of H3.3B.  One strategy was designed to knock-in the open reading frame (ORF) of 
the enhanced yellow fluorescent protein (EYFP) (Figure 2.2B).  To address possible 
concerns regarding the large size of the EYFP tag (~25 kDa), I also designed a 
parallel strategy to knock-in a shorter C-terminal hemagglutinin (HA) tag (~1 kDa), 
along with an internal ribosomal entry site (IRES) and separately translated EYFP 
tag to provide a fluorescent reporter of H3.3B gene expression (Figure 2.2C). 
Promoter-less and selection-less donor constructs were designed and cloned out 
of mouse B6 genomic DNA to include approximately 0.6kb of genomic sequence 
at the 5’ end of H3.3B, an EYFP sequence with a short linker or a HA-IRES-EYFP 
sequence fused to the final H3.3B coding exon, and approximately 1.3kb of the 
H3.3B 3’UTR (Figure 2.2B-C).  Because of the high efficiency of ZFN mediated 
gene targeting (Carroll, 2008; Urnov et al., 2005), our donor constructs are far 
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Figure 2.2: Zinc finger nuclease targeting scheme
  
A. Schematic of zinc finger nucleases (ZFNs) recognizing endogenous H3.3B (h3f3b) sequence 
near the end of the last coding H3.3B exon on chromosome 11.
B-C. Designed zinc finger nucleases (ZFN) target the endogenous sequence of the final coding 
exon of the mouse histone H3.3B gene on chromosome 11. Exon coding sequences are thick 
rectangles, while non-coding untranslated sequences are thin rectangles. ZFN targets double-
strand break (DSB) formation at H3.3B, with H3.3B-EYFP or H3.3B-HA-IRES-EYFP donors 
generating a new H3.3B allele with a C-terminal EYFP tag (B), or a C-terminal HA tag (red) and an 
internal ribosomal entry site (IRES, blue) followed by an EYFP reporter (C). Location is indicated for 
genomic forward primer outside donor sequence and reverse primer within EYFP sequence used 
for PCR amplification and sequencing (2.6) of modified H3.3B alleles.
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shorter than traditional mouse targeting constructs (Deng and Capecchi, 1992; 
Hasty et al., 1991).
I found ZFN-mediated targeting to be highly efficient at driving homology-
directed addition of EYFP or HA epitope tags, as well as targeted editing of the 
endogenous H3.3B gene. To evaluate the efficiency of ZFN-mediated targeting, 
the donor construct was transfected in the presence and absence of ZFN.  5 days 
post-transfection with H3.3-EYFP donor construct in the absence of ZFN, less 
than 1/100,000 cells were EYFP+ (Figure 2.3A), while in the presence of ZFN, 
between 1-2% of cells were EYFP+ (Figure 2.3B), an over 1000 fold increase in 
the frequency of EYFP+ cells. 
To evaluate the dependence of H3.3 localization on amino acid sequence, 
we also modified our donor constructs to knock-in point mutations at H3.3 codons 
31, 87, 89, 90, and 96 and simultaneously mutate endogenous H3.3B towards H3.2 
or H3.1 via marker co-conversion (Figure 2.4).  While greater than 1% of ES cells 
were correctly targeted with H3.3-EYFP or H3.3-HA-IRES-EYFP at one H3.3B 
allele, we found that the introduction of point mutations decreased the efficiency 
of gene targeting (Figure 2.5). Less than 0.5% of cells became EYFP+ following 
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Figure 2.3: Zinc finger nucleases increase the efficiency of H3.3B gene targeting in mouse 
embryonic stem cells by over 1000 fold.
A-B. Mouse ES cells were transfected with H3.3-EYFP donor alone (A) or H3.3-EYFP donor + zinc 
finger nucleases (ZFN) (B) and analyzed by flow cytometry 3 days post-transfection. Percentage 
EYFP positive are indicated.
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transfection of H3.2-HA-IRES-EYFP or H3.1-HA-IRES-EYFP donor constructs, 
and less than 1/5 of these EYFP+ clones were fully corrected to H3.2 or H3.1 
codons at the modified allele (Figure 2.5, and data not shown). Notably, these 
percentages are still far higher than traditional gene targeting in the absence of 
ZFNs (te Riele et al., 1992).  
Fluorescent cells were manually picked or sorted using flow cytometry 
(Figure 2.3, 2.5), and screened by PCR (Figure 2.6A), sequencing of both H3.3B 
A ZFN target site
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Figure 2.4: Gene conversion of endogenous H3.3B to epitope-tagged H3.2 or H3.1
A-B.  Schematic of ZFN-mediated targeting of H3.3B EYFP tag and simultaneous co-conversion of 
H3.3B sequence to H3.2 (A) or H3.1 (B). A similar ZFN-mediated co-conversion strategy was used 
with H3.2-HA-IRES-EYFP and H3.1-HA-IRES-EYFP donor constructs.  Point mutations in H3.3 
sequence are indicated in green. F and R primers used for PCR (2.6) are indicated as in 2.2B-C.
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alleles (Figure 2.6B), and Southern blotting (Figure 2.6C).  Nearly all (>90%) of the 
EYFP+ ES lines targeted with H3.3B-EYFP were correctly targeted at the H3.3B 
allele, as confirmed by genomic PCR and sequencing.   Multiple heterozygous 
lines of ES cells were isolated with one targeted allele expressing H3.3-EYFP, 
H3.2-EYFP, H3.1-EYFP, H3.3-HA-IRES-EYFP, H3.2-HA-IRES-EYFP, or H3.1S31-
HA-IRES-EYFP (Figure 2.6B-C).  Initial screening was unable to isolate a line fully 
converted to H3.1-HA; hence, lines denoted H3.1S31-HA retain the H3.3 serine 
at position 31. All heterozygously tagged ES cells retain three “wild-type” copies 
of H3.3 genes, including one copy of unmodified H3.3B (Figure 2.6C), and two 
copies of H3.3A. Western blots demonstrate comparable protein expression in the 
wild-type and mutated epitope-tagged H3.3B ES lines (Figure 2.6D).  
Although ZFN-mediated gene targeting represents a far more efficient 
method of mutageneis than conventional methods (Carroll, 2008; te Riele et al., 
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Figure 2.5: Efficiency of H3.3B gene targeting is dependent on donor sequence homology.
Introduction of point mutations decreases efficiency of targeting for H3-EYFP donors (top row) and 
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Figure 2.6: Generation and validation of H3.3B targeted ES lines
A. Genomic DNA from wild-type and targeted ES lines were subject to PCR amplification, using 
primers indicated in 2.2 and 2.4.
B. Nucleotide sequence of wild-type and modified H3.3B alleles. PCR fragments shown in A were 
sequenced and aligned to sequence from endogenous wild-type H3.3B allele. These nucleotide 
sequences correspond to the amino acids shown in Figure 1.16.  Note that in cell lines targeted 
with H3.1-HA-IRES-EYFP, mutagenesis was incomplete, with H3.3B mutated to H3.1 sequences 
at positions 87, 89, 90, and 96, but retaining a serine at position 31.  These cell lines are hereafter 
referred to as H3.1S31. 
C. Genomic DNA from wild-type and targeted ES cells was digested with BsrBI and analyzed by 
Southern blot, using a 638bp AvaII fragment of the H3.3B donor as probe. 
D. Whole cell extracts from wild-type ES and targeted ES cell lines were immunoblotted with GFP, 
HA, and C-terminal (untagged) H3 antibodies as indicated.
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1992; Urnov et al., 2005), it is still necessary to carefully screen targeted cells 
to ensure desired genomic editing.  For example, upon Southern blotting, my 
collaborators and I found some clones (<20%) where the donor sequence had 
misintegrated elsewhere in the genome (Figure 2.7A, right).  In addition, I also 
found that both the ‘modified’ and ‘unmodified’ allele had occasional (~10% of 
sequenced clones) mutations and small deletions at the ZFN target site (Figure 
2.7B), a phenomenon likely to reflect incomplete DNA repair by non-homologous 
end joining (Carroll, 2008).  It is important to note that the only ‘selection’ in this case 
is EYFP fluorescence.  Although the frequency of undesired mutations (~10-20%) 
following ZFN-mediated gene targeting point to the necessity of careful screening, 
the frequency of desired clones remains far higher than conventional targeting, 
where several hundred clones are often screened even following antibiotic selection 
(te Riele et al., 1992).
Specific enrichment of H3.3 in gene-rich euchromatic chromosome arms and 
telomeres is dependent on amino acid sequence
To assess the incorporation and chromosomal distribution of H3 variants in mouse 
ES cells, I initially examined chromosome spreads from metaphase-arrested ES 
cells. Mouse chromosomes are acrocentric, with visible regions of DAPI-dense 
heterochromatin around their centromeres (Martens et al., 2005) (see Figure 
1.19). Analysis of H3.3-EYFP and H3.3-HA ES lines demonstrates that H3.3 is 
specifically localized to euchromatic chromosome arms in mouse ES cells, and 
is markedly depleted in DAPI-dense pericentric heterochromatin (Figure 2.8A-B, 
2.9). In addition, telomeric foci of H3.3 are visible on the Y-chromosome in mouse 
ES cells (Figure 2.8A-B, 2.9B-C, K-L, inset). This result is in agreement with 
recent studies that found H3.3 serine 31 phosphorylation (H3.3Ser31p) enriched 
at telomeres in mouse ES cells (Wong et al., 2009).  However, it is notable that 
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Figure 2.7: Misintegrations and mutations in some ZFN targeted lines
A. Uncropped Southern blots as in 2.6C. Some clones (for example, right) show additional genomic 
integrations of donor construct.
B. Alignment of modified H3.3B alleles.  Note examples of point mutation and deletion at the ZFN 
target site. A slightly higher frequency (~10%) of similar deletions and point mutations were  also 
observed upon sequencing the ‘unmodified’ H3.3B allele (not shown).
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Figure 2.8: Genomic localization of histone H3.3 is dependent on amino acid sequence
A-D. H3.3-EYFP and H3.2-EYFP ES cells were treated with 0.2 μg/mL colchicine for 2 hrs at 37˚C. 
Samples were prepared by cytospin, fixed, stained with DAPI, and visualized using DeltaVision 
deconvolution microscopy. EYFP and DAPI overlays of maximum-intensity projections from multiple 
Z-stacks are shown. Bar: 10μm. Panels A and C show EYFP fluorescence. Panels B and D show 
EYFP and DAPI overlays. Inset shows a higher magnification image of the Y-chromosome, which 
wwas. identified by its size and uniform DAPI density .  For complete chromosome sprads including 
DAPI alone, as well as H3.1-EYFP and H3.3-HA, please see the following Figure 2.9.
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Figure 2.9: Complete chromosome spreads of H3.3-EYFP, H3.2-EYFP, H3.1-EYFP, and H3.3-
HA ES cells
A-F. Full representative metaphase chromosome spreads as described in 2.8, including DAPI 
fluorescence (A,D).  
G-I. H3.1-EYFP localization is widespread throughout metaphase chromosomes, similar to H3.2-
EYFP. 
J-L. H3.3-HA localization is similar to H3.3-EYFP localization.  Chromosome spreads were 
performed using anti-HA (HA.11) for immunofluorescence of H3.3-HA (green).  The Y-chromosome 
in all spreads was identified by its size and DAPI pattern, and is shown in the inset of A-L.
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Figure 2.10: Foci of H3.3 serine 31 phosphorylation represent a small subset of overall H3.3 
on metaphase chromosomes
A-F. Metaphase chromosome spreads of H3.3-EYFP ES cells were performed as in previous 
figures, and stained with DAPI (blue), anti-GFP (green), and H3.3Ser31p (red). Inset shows the 
Y-chromosome. Note partial co-localization of H3.3 and H3.3Ser31p on Y-chromosome telomeric 
foci.
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Figure 2.11:  H3.3 significantly colocalizes with H3K4me3, and does not colocalize with 
H3K9me3 pericentric heterochromatin on metaphase chromosomes
A-F.  Metaphase chromosome spreads were stained with DAPI (blue), anti-GFP (green), and anti-
H3K4me3 (red). Note overlap of H3.3 and H3K4me3 (E).
G-L.  Metaphase chromosome spreads were stained with DAPI (bleu), anti-GFP (green), and anti-
H3K9me3 (red).  Note lack of overlap of H3.3 and H3K9me3 (K).
M-N.  Scatterplots depicting colocalization of H3.3-EYFP and H3K4me3 (M) and H3.3-EYFP and 
H3K9me3 (N), as anayzed with DeltaVision software through multiple Z-stacks.  Each dot represents 
a pixel, with red or green signal intensity plotted on the Y or X axes.  The relative intensities of H3.3-
EYFP and H3K4me3  are significantly correlated (Pearson Coefficient of Correlation 0.9146), while 
H3.3-EYFP and H3K9me3 are poorly correlated.
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most H3.3 is found incorporated on chromosome arms, while telomeric foci of 
H3.3Ser31p represent only a small subset of overall H3.3 incorporation, and most 
clearly co-localize with H3.3 at the Y-chromosome (Figure 2.10).
 To determine if H3.3 colocalizes with euchromatic or heterochromatic histone 
modifications, I co-stained H3.3-EYFP ES cell metaphase chromosomes with an 
antibody to H3K4me3 or H3K9me3.  H3K4me3 is associated with transcription 
start sites of active and inactive genes (Guenther et al., 2007; Ruthenburg et al., 
2007a), while H3K9me3 is associated with repetitive pericentric heterochromatin in 
areas such as major and minor satellite repeats (Martens et al., 2005) (see Chapter 
One).  Colocalization analysis revealed that H3.3 is significantly colocalized with 
H3K4me3 on a chromosome-wide level (Figure 2.11, A-F, M, note yellow color 
in E).  In addition, H3.3 does not colocalize with H3K9me3, further indicating 
that H3.3 is largely excluded from H3K9me3-rich pericentric heterochromatin 
(Figure 2.11, G-L, N).  These data provide further evidence that H3.3 is enriched 
in euchromatic chromosome arms, and is largely excluded from H3K9me3-rich 
pericentric heterochromatin.
To establish whether the specific patterns I observed for H3.3 are dependent 
on amino acid sequence, I also performed chromosome spreads from ES cells 
in which one allele of H3.3B was mutated to H3.2-EYFP or H3.1-EYFP (Figure 
2.8A-D, 2.9). Metaphase chromosome spreads demonstrate that while each of 
our EYFP-tagged H3 variants are incorporated into chromatin in ES cells, their 
chromosomal localization is dependent on amino acid sequence (Figure 2.8A-
D). Despite expression of H3.2 or H3.1 from the endogenous H3.3B promoter, 
with identical C-terminal epitope tags, specific patterns of H3.3 enrichment were 
abolished upon mutation of H3.3 to H3.2 or H3.1, and exclusion from pericentric 
heterochromatin is lost (Figure 2.8C-D, 2.9). In contrast to the telomeric localization 
of H3.3 on the Y-chromosome, H3.2 and H3.1 are incorporated throughout the 
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largely heterochromatic Y-chromosome (Figure 2.8C-D, inset, 2.9). Notably, I did 
not observe significant differences in localization between H3.2 and H3.1, both 
of which are broadly distributed throughout metaphase chromosomes (Figure 
2.9). These results demonstrate that the sequence of an endogenous H3.3 gene 
determines its genomic localization in mammalian cells.
ChIP-seq provides genome-wide maps of histone H3 variants
To extend my analysis at higher resolution, I next used ChIP-seq to analyze the 
genome-wide localization of histone H3 variants in mouse ES cells.  As described 
in Chapter One, ChIP-seq provides an enormously powerful, relatively unbiased 
technique for determining genome-wide localization and profiling chromatin state 
(Barski and Zhao, 2009; Mendenhall and Bernstein, 2008).  ChIP-seq provides 
digital, quantitative data regarding genome-wide patterns of enrichment, allows 
for the interrogation of repetitive sequences, and enables mononucleosome level 
resolution (Barski and Zhao, 2009; Mendenhall and Bernstein, 2008).   
As ChIP-seq is a relatively new technique, I performed multiple controls to 
validate these findings, including comparison of native versus crosslinking ChIP-
seq, comparison of HA and EYFP tagged variants, sequencing of input ChIP DNA, 
sequencing of anti-HA ChIP samples from untagged wild-type ES cells, ChIP-seq 
of control histone modifications, and real-time PCR validation of independent ChIP 
samples (see Chapter Five and Appendix for details). I also found remarkably 
similar genome-wide patterns for H3.3 in mouse ES cell lines (C57BL/6J ES and F1 
hybrid ES) of significantly distinct genetic backgrounds (Mikkelsen et al., 2007).
Following alignment of our sequenced ChIP DNA to the reference mouse 
genome, I observed that gene-rich regions of the genome show greater enrichment 
of H3.3 than H3.2 or H3.1S31 (Figure 2.12, 2.13). I also profiled the genome-wide 
localization of H3K4me1, H3K4me3, H3K27me3, and H3K36me3, and compared 
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these results to established profiles for these modifications in ES cells and NPCs 
(Meissner et al., 2008; Mikkelsen et al., 2007). In all cases, histone modification 
profiles from tagged ES cells were nearly identical to previously established 
datasets (Figure 2.14, Figure 2.15).  The remarkable similarity between my 
multiple controls and previous datasets from other laboratories underscores the 
reliability and reproducibility of ChIP-seq, and gives me greater confidence in my 
findings. Moreover, this result suggests that heterozygous mutation of H3.3B to 
CpG
H3K4me3
H3.3-EYFP
H3K36me3
H3.2-HA
H3K4me1
RNAPII Ser5p
H3
anti-HA (WT ES)
H3.3-HA
Input (1,15)
(1,25)
(1,120)
(1,25)
(1,30)
(1,25)
(2,12)
(1,17)
(1,10)
(1,15)
A
100K 120K 140K 160K 180KChr1
genes -
genes +
Figure 2.12: Chromosome-scale map of ChIP-seq data reveals genic enrichment of H3.3
ChIP-seq profiles across a large representative genomic region (120 MB of chromosome 1) in 
mouse ES cells, using antibodies as indicated. Y-axis represents the number of reads spanning 
a genomic position, with scale indicated on the right (baseline, maximum). CpG islands (green) 
and genes (positive strand (+) and negative strand (-)) along with chromosome coordinates are 
shown below plots.  Note the enrichment of H3.3 with genes, CpG islands, and markers of active 
chromatin, including RNAPII Ser5p, H3K4me3, H3K36me3,  and H3K4me1.  Upon mutation of 
H3.3-HA to H3.2-HA, enrichment in gneic regions is significantly reduced.  See later figures for 
higher resolution analyses. Data for general anti-H3 in ES cells is from (Mikkelsen et al., 2007). 
Data for H3.1S31-HA is nearly identical to H3.2-HA, and is not shown.
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H3.2 or H3.1S31 does not significantly alter genome-wide patterns of histone 
modifications.
My collaborators and I found 10,099 total genic and intergenic regions highly 
enriched for H3.3 in crosslinking ChIP-seq of ES cells, in contrast to 1,442 regions 
enriched for H3.2, and we found that gene-rich regions of the genome show greater 
enrichment of H3.3 than H3.2 or H3.1S31 (Figure 2.12., 2.13). On a chromosomal 
scale map, H3.3 enrichment correlated with markers of transcription, including 
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Data produced in collaboration with Deyou Zheng.
Figure 2.13: Genomic locations of H3 variant enriched regions
Enriched regions were identified for H3 variants as described in Chapter Five, and 
their relationship with annotation is plotted. Y-axis represents the number of enriched 
regions, while the X-axis represents different categories of gene annotation and 
transcription factor binding sites (TFBS). Known ES TFBS are from (Chen et al., 2008). 
“Hybrid ES” experiments were performed in a genetically divergent F1 hybrid (castaneus/129) ES 
line, the same ES line described in previous published ChIP-seq studies (Mikkelsen et al. 2007).  I 
have found that genome-wide patterns of H3.3 enrichment are extremely simliar in all analyzed ES 
lines, regardless of genetic background.  See Chapter Five for further details.
105
RNAPII, H3K4me3, H3K36me3, and H3K4me1 (Figure 2.12). Unbiased clustering 
analyses confirmed the genome-wide correlation of H3.3 with active histone 
modifications, particularly H3K4me1 (Figure 2.15). Despite different epitope tags, 
we found extremely similar profiles of H3.3-HA and H3.3-EYFP (Figure 2.12). In 
addition to genes, genome-wide analysis revealed specific enrichment of H3.3 
at previously identified genic and intergenic ES TFBS (Chen et al., 2008b), as 
well as peaks of H3.3 in specific unannotated intergenic regions (Figure 2.13). 
These chromosome-wide patterns of H3.3 were largely eliminated upon mutation 
of H3.3B towards H3.2 or H3.1 (Figure 2.12). Our data demonstrate that the amino 
acid sequence of an endogenous H3.3 gene determines its genomic localization in 
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Figure 2.14: Genome-wide patterns of histone modifications are not affected by heterozygous 
conversion of H3.3B to H3.3-HA or H3.2-HA
Data is shown for a representative region of chromosome 12 containing Esrrb.  H3 variant patterns 
for this gene are shown in 2.26A.  Y-axis represents the number of reads spanning a genomic 
position, with scale indicated on the right.  Genes (+ and - strand) along with chromosome 12 
coordinates are shown below plots.  Data for previously established datasets in mouse ES cells 
and NPC are indicated (Meissner et al., 2008; Mikkelsen et al., 2007), and were downloaded from 
http://www.ncbi.nlm.nih.gov/geo/ . For patterns of histone modifications in H3.3-HA vs H3.2-HA ES 
cells, see also 2.24.
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Figure 2.15: Genome-wide correlation of ChIP-seq datasets
Mouse chromosomes were divided into non-overlapping 2-kb regions and then the number 
of ChIP-Seq reads in each region was counted to generate a vector representing the genome-
wide distribution of each ChIP-Seq experiment. Pearson’s correlation coefficients were computed 
between every pair of ChIP-Seq data and the resulting correlation matrix was clustered and shown 
as a heat map.
Data prodcued in collaboration with Deyou Zheng.
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mammalian cells.
Genome-wide patterns of H3 variants at repetitive elements
Unlike ChIP-chip technologies, which are limited by probe design, ChIP-seq 
enables the localization of proteins to repetitive regions of the genome (Mikkelsen 
et al., 2007). To analyze H3 variant enrichment in different classes of repeats, we 
determined the relative enrichment of specific repeat sequences from our ChIP-seq 
experiments and compared it to that from control input DNA (see Chapter Five). 
H3.3 was reproducibly depleted in satellite repeat sequences and in Y-chromosomal 
repeat DNA, while enriched in rDNA repeats (Figure 2.16). Our ChIP-seq results 
are consistent with the visible exclusion of H3.3 from DAPI-dense pericentric 
heterochromatin (Figure 2.8A-B, 2.9, 2.11), as pericentric heterochromatin is 
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Figure 2.16: Enrichment of H3 variants in different classes of repeats
Analysis of H3 variants in repetitive elements.  Reads from HA-tagged H3 variants were aligned 
directly to a library of mouse consensus repetitive sequences (http://www.girinst.org).  Note 
particular enrichment of H3.3 in the canonical (TTAGGG)n vertebrate telomeric repeat sequence 
(Meyne et al., 1989).  Data are represented as fold enrichment over input.
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enriched in satellite repeats (Martens et al., 2005), and the relative depletion of 
H3.3 from the Y-chromosome. Notably, we found the most significant (5-fold) 
enrichment of H3.3 in the (TTAGGG)n repeat that is the conserved telomeric DNA 
sequence among vertebrates (Meyne et al., 1989) (Figure 2.16). This telomeric 
enrichment of H3.3 is consistent with the telomeric foci of incorporation visible on 
the largely heterochromatic Y-chromosome (Figure 2.8A-B, 2.9B-C, K-L, 2.10, 
inset). Mutation of H3.3B to H3.2 or H3.1S31 demonstrates that repeat-specific 
patterns of H3.3 enrichment or depletion are dependent on amino acid sequence 
(Figure 2.16).
H3.3 is enriched around transcription start sites of both active and repressed 
genes, but is enriched in the bodies of only active protein-coding and non-
coding RNA genes
As there has been some disagreement regarding the patterns of H3.3 at active 
versus repressed genes in vertebrates (Chow et al., 2005; Daury et al., 2006; 
Jin and Felsenfeld, 2006; Sutcliffe et al., 2009; Tamura et al., 2009; Wirbelauer 
et al., 2005), we used ChIP-seq to address the genome-wide patterns of H3 
variant enrichment around gene transcription start sites (TSS) in mouse ES cells. 
Surprisingly, we find that H3.3 is not exclusively a marker of transcriptionally active 
genes.
Mammalian genes can be divided into classes based on the CpG 
dinucleotide content of their promoters. High CpG content promoters (HCP) are 
over-represented in nuclear, metabolic, and transcriptional regulatory genes, and 
HCP genes are likely to be either ubiquitously expressed housekeeping genes or 
to have complex, developmentally regulated patterns of expression (Mikkelsen 
et al., 2007; Saxonov et al., 2006). In contrast, genes with low CpG content 
promoters (LCP) are frequently involved in specific physiological processes and 
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are often highly tissue-specific, such as olfactory receptor genes and keratin genes 
(Saxonov et al., 2006). Previous studies have found that the majority of high CpG 
content promoters in both ES cells and differentiated cells are marked by histone 
H3K4me3 and the presence of RNAPII, regardless of whether the gene is active 
or repressed (Barski et al., 2007; Guenther et al., 2007; Mikkelsen et al., 2007). 
When we divide HCP genes into low, medium, and high expression in ES cells (see 
Materials and Methods), we find that H3.3, like H3K4me3 and RNAPII, is enriched 
around the TSS of both active, highly expressing genes, as well as repressed, low 
expressing genes (Figure 2.17A, D). In both native and crosslinking ChIP-seq, we 
find H3.3 less enriched at the TSS itself (Figure 2.17A, D, 2.18). This depletion of 
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Figure 2.17: H3.3 is enriched around transcription start sites of both active and inactive 
genes with high CpG content promoters, and into the body of active genes
A-I. Profiles of H3 variants, H3, H3 modifications, or RNAPII as indicated above each panel across 
the TSS for highly active (red), medium expressing (black), or low expressing (green) CpG rich 
genes. Y-axis represents the average number of tags per gene per 200 bp per 1 million mapped 
reads. Data for H3 in ES cells is from (Mikkelsen et al., 2007).
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Figure 2.18: Mononucleosome resolution profiles of H3 variants and H3K4me3 at TSS
Y-axis represents the average number of tags per gene per 10 bp per million mapped reads. 
Red represents sequence tags from the sense strand, and green represents sequence tags from 
the antisense strand.  The color bars above profiles mark the estimated nucleosomes around 
TSSs.  The data for H3.3 in panel G (dark blue = sense H3.3, light blue = antisense H3.3, red = 
sense H3K4me3, green = antisense H3K4me3) are scaled by a factor of 50 to match the profile of 
H3K4me3.
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Data produced in collaboration with 
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the -1 nucleosome at the TSS of active and inactive genes has been extensively 
described (Schones et al., 2008), and has been recently attributed both to the 
instability of nucleosome core particles containing H3.3 and H2A.Z, and to the 
presence of specific sequences at CpG promoters that directly reduce nucleosome 
stability (Jin et al., 2009; Ramirez-Carrozzi et al., 2009).
While H3.3 is incorporated around the TSS of both active and repressed 
genes, we find that H3.3 is enriched in the body of active genes, but not that of 
repressed genes (Figure 2.17A, D). Mononucleosome resolution analysis indicates 
that H3.3 is incorporated into the +1 nucleosomes in both activated and repressed 
genes, but up to +3 nucleosomes and further into the coding regions in activated 
genes (Figure 2.18). The level of H3.3 deposition in gene bodies is correlated 
with gene expression, particularly at highly expressed genes (Spearman’s rank 
correlation coefficient ρ = 0.54, p < 2.2e-16; see Figure 2.17A, D, 2.19). Highly 
active genes (Figure 2.17A, D, red) have higher levels of H3.3 in their gene bodies, 
while medium (black) and lower expressed genes (green) have lower levels of 
H3.3. Strikingly, upon mutation of H3.3 to H3.2 or H3.1S31, H3.3 specific patterns 
of enrichment around the TSS and gene body are lost, generating patterns similar 
to general H3 (Figure 2.17B, C, E, F). 
Genome-wide studies recently demonstrated that more than 20% of HCP 
genes in ES cells carry both H3K4me3 and H3K27me3 in their promoters (Bernstein 
et al., 2006a; Mikkelsen et al., 2007). These ‘bivalent’ genes are transcriptionally 
repressed in ES cells, and many encode key developmental TFs and cell surface 
proteins, leading to the model that they represent repressed genes that are poised 
for activation following cell differentiation (Bernstein et al., 2006a; Mikkelsen et 
al., 2007). While bivalent genes are defined by their pattern of H3 modifications, 
the relative distribution and identity of the H3 variants that carry these marks has 
not been established. When we analyzed the pattern of H3 variants at bivalent 
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Figure 2.19: Correlation of H3.3 with gene expression
The left Y-axis represents read density that was computed as average number of ChIP-Seq reads 
per 2-kb genomic sequence per million mapped reads. 
A-D.  Densities of H3.3 and H3K36me3 reads in coding gene bodies are correlated with gene 
expression, particularly for highly expressed genes, in both ES (A-B) and NPC (C-D).  Gene 
expression data are from (Mikkelsen et al., 2007).  For the X-axis, gene expression values were 
uniformly divided into 20 groups to yield genes with low to high levels of expression. Mean gene 
expression values for each group shown on the right Y-axis in B and D.  H3.3 deposition in gene 
bodies is correlated with gene expression, particularly at highly expressed genes (Spearman’s 
rank correlation coefficient ρ  = 0.54, p < 2.2e-16).  By comparison, H3K36me3 shows a greater 
correlation (ρ = 0.76), but H3.1S31 (ρ  = 0.31) and H3.2 (ρ  = 0.25) show significantly smaller 
correlations.
E-H.  Densities of H3.3 and H3K36me3 in lincRNAs are correlated with gene expression at highly 
expressed lincRNAs.  lincRNAs were divided into 5 groups on the basis of lincRNA expression 
data (Guttman et al., 2009) , downloaded from http://www.ncbi.nlm.nih.gov/geo/ , (GSE13765).  
lincRNA expression values are shown on the right Y-axis in F and H.
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TSS by ChIP-seq, we found that H3.3 is enriched around the TSS of H3K4me3/
H3K27me3 bivalent genes in ES cells, while mutation of H3.3 towards H3.2 or 
H3.1 abolishes this enrichment (Figure 2.20A, 2.21E-F). In contrast to repressed 
bivalent H3K4me3/H3K27me3 genes, H3.3 is significantly enriched around the 
TSS as well as into the coding region of active monovalent H3K4me3 genes 
(Figure 2.20B).
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Figure 2.20: Specific examples of H3.3 incorporation at the transcription start sites of active 
and repressed coding genes, and actively transcribed non-coding RNA
A. H3.3 is enriched around the TSS, but not into the gene body of the H3K4me3/H3K27me3 bivalent 
and transcriptionally repressed Zfpm2 gene in ES cells.
B. H3.3 is enriched around the TSS and also in the gene body of the highly expressing ribosomal 
protein S19 gene Rps19.
C. H3.3 is enriched around the TSS and into the body of the non-coding RNA gene Gas5, but less 
enriched in the gene body of the neighboring low expressing Zbtb37 gene in ES cells. The Y-axes in 
J-L are identical (indicated in the right side of panel J), and represent the number of reads spanning 
a genomic position. Gene is shown to scale below plot, with start and direction or transcription 
indicated by arrow. Green rectangles above the gene represent CpG islands.
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Recent studies have also shown that mammalian cells produce over 1600 
large intergenic non-coding RNA (lincRNA) transcripts (Guttman et al., 2009). When 
we examined the genomic loci of lincRNA transcripts, we found that lincRNAs 
known to be expressed in ES cells show enrichment of H3.3 around their TSS, as 
well as into their non-coding RNA gene bodies, similar to the pattern of H3.3 found 
at active genes. Again, these patterns of H3.3 at lincRNAs are dependent on H3.3 
amino acid sequence (Figure 2.19, 2.20C).
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Figure 2.21: Genome-wide profiles of H3.3 at transcription start sites change with cellular 
differentiation and resolution of bivalent domains
A-L. Profiles of H3 variants or H3 modifications as indicated above each panel around the TSS of 
H3K4me3/H3K27me3 bivalent genes in ES cells. ES bivalent genes are classified by resolution in 
NPCs to H3K4me3 only (red), H3K27me3 only (green), or no mark (black). H3K4me3/H3K27me3 
data and bivalent gene definitions are from (Mikkelsen et al., 2007). Y-axes are as in 2.17.
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Transcription end sites of highly expressed genes are marked by peaks of 
H3.3 and phosphorylated RNA polymerase II
When we examined the patterns of H3.3 incorporation at transcriptionally active 
HCP genes, we noticed that enrichment of H3.3 often extended beyond the gene 
body and past the transcriptional end site (TES), particularly at highly active genes 
(Figure 2.20B-C). To determine whether this is a genome-wide phenomenon, we 
used the same division of HCP genes into high, medium, and low expression, and 
analyzed the ChIP-seq patterns of H3 variants and histone modifications around 
TES. In accordance with previous studies in Drosophila and human cells (Henikoff 
et al., 2009; Jin et al., 2009; Mito et al., 2005), we find that the enrichment of H3.3 
beyond the TES is a general phenomenon at highly expressed genes in ES cells 
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Figure 2.22: H3.3 and RNA polymerase Ser5p are enriched after the transcriptional end site 
of highly expressed genes
A-L. Profiles of H3 variants, H3, H3 modifications, or RNAPII as indicated above each panel across 
the TES for highly active (red), medium expressing (black), or low expressing (green) CpG rich 
genes, with data represented as in Figure 3. All data except for D and H are for mouse ES cells. 
Panel D shows data from differentiated NPCs. The data in panel H are for human CD4+ T cells 
(Barski et al., 2007). The data in C and L are from a previous study (Mikkelsen et al., 2007).
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(Figure 2.22A, E) and in differentiated NPCs (Figure 2.22D).
At highly expressed genes such as beta-actin, H3.3 enrichment increases 
immediately after the TES, and peaks at approximately +700 bp ± 200 bp after 
the TES (Figure 2.22A, E, 2.23). This post-TES enrichment of H3.3 was also 
dependent on amino acid sequence, as we did not observe significant enrichment 
of H3.3 mutated to H3.2 or H3.1S31, or of general H3 (Figure 2.22B, C, F, G, 2.23). 
Control ChIP-seq experiments revealed the expected patterns of incorporation 
and lack of post-TES enrichment for H3K4me3, H3K4me1, and H3K36me3, in 
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Figure 2.23: Profiles of H3 variants, H3 modifications, and RNA polymerase around the 
highly expressed housekeeping gene beta-actin
H3.3 and RNAPII Ser5p are enriched in the gene body and after the TES of the highly expressed 
gene Actb (beta-actin) in ES cells. Data for the RNAPII unphos 8WG16 track are from (Mikkelsen et 
al., 2007). Y-axis is indicated on the right as in Figure 2 and 3. RNA-seq data are from (Cloonan et 
al., 2008).  The neighboring Fbx1118 gene is not highly expressed in ES cells, and does not show 
gene body enrichment of H3.3.
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Figure 2.24: TSS and TES enrichment of H3 variants, histone modifications, and RNAPII
Profiles of H3 variants, H3 modifications, or controls as indicated above each panel across the TSS 
and TES for highly active, medium expressing, or low expressing CpG rich genes as shown.  Y-axis 
represents the average number of tags per gene per 200 bp per 1 million mapped reads.  
A,C,E,G.  H3.3 profiles are similar across the TSS and TES for both HA and EYFP-tagged H3.3.
D,F,H.  Mutation of H3.3B towards H3.2 or H3.1 abolishes H3.3 patterns of enrichment.
I.  H3K4me1 patterns are similar to H3.3 around the TSS, though levels of H3K4me1 decline into 
the gene body of highly expressed genes, while H3.3 levels increase and peak beyond the TES.
J.  Background of anti-HA antibody.  Sequencing of anti-HA ChIP from untagged wild-type ES 
cells shows enrichment at the TSS, likely representing the enrichment of nucleosome-poor DNA 
following cross-linking and sonication.
K-N. Profiles of H3K4me3 and H3K36me3 in H3.3-HA and H3.2-HA ES cells.  Heterozygous 
mutation of H3.3 to H3.2 does not alter genome-wide profiles of H3K4me3 or H3K36me3 around 
TSS and TES.
O. Profiles of RNAPII Ser5p in H3.3-HA ES cells at TSS and TES.  P)  Profiles of unphosphorylated 
RNAPII at TSS and TES in ES cells.  Data for P are from (Mikkelsen et al., 2007).
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both H3.3-HA and H3.2-HA ES cells (Figure 2.22J, K, 2.23, 2.24). H3K36me3 has 
been associated with transcriptional elongation in a variety of eukaryotes, from 
yeast to mammals (Bannister et al., 2005; Barski et al., 2007; Mikkelsen et al., 
2007). H3.3 and H3K36me3 are both enriched in the gene body of active genes, 
with levels of both positively correlated with gene expression (Figure 2.17A, D, 
I, Figure 2.19, Figure 2.22A, E, K). Unlike H3.3, however, levels of H3K36me3 
at active genes begin to decline prior to the TES, and decline more significantly 
following the TES (Figure 2.22K, 2.23). While H3.3 is correlated with H3K36me3 
in active gene bodies, H3.3 and H3K36me3 maintain distinctive patterns near the 
TES of active genes.
As a control, we performed ChIP-seq with a mouse monoclonal antibody 
(CTD4H8) to the Ser-5 phosphorylated C-terminal domain (CTD) of RNAPII. To 
our surprise, we observed significant peaks of enrichment of phosphorylated 
RNAPII not only at the TSS of high and low expressing genes (Figure 2.17G), but 
also after the TES of high expressing genes (Figure 2.22I, 2.23). Interestingly, the 
distributions of these post-TES peaks of phosphorylated RNAPII at active genes 
are closely co-localized with the peaks of H3.3, with the phosphorylated RNAPII 
peak slightly downstream (~200 bp) from the H3.3 peak.
Previous studies have shown that the unphosphorylated CTD form of RNAPII 
is enriched in the promoter of both active and inactive genes, while differentially 
phosphorylated CTD forms of RNAPII are associated with elongating polymerase 
in the gene body of actively transcribed protein coding genes and small nuclear 
RNA genes (Guenther et al., 2007; Koch et al., 2008). When we analyzed the 
patterns of unphosphorylated RNAPII CTD (Mikkelsen et al., 2007) in mouse ES 
cells, we observed a peak of unphosphorylated RNAPII CTD at the TSS of high 
and low expressing HCP genes (Figure 2.23, 2.24). However, we did not find any 
significant peak of unphosphorylated RNAPII CTD around the TES of high or low 
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expressing HCP genes (Figure 2.21L, 2.22), providing further evidence that this 
post-TES enrichment of RNAPII is specific to the phosphorylated form of RNAPII.
To determine if the enrichment of H3.3 and the phosphorylated CTD of 
RNAPII is specific to ES cells, we also analyzed their distributions in other cell 
types. Our results indicate that post-TES enrichment of H3.3 and phosphorylated 
RNAPII CTD is not specific to ES cells. When we generated profiles of H3.3 at high, 
medium, and low-expressing genes in differentiated NPCs, we observe that H3.3 
enrichment at highly active genes continues after the TES (Figure 2.22D). While 
it has not previously been used in ChIP-seq studies of ES cells, the monoclonal 
CTD4H8 antibody has also been used in genome-wide studies in human CD4+T 
cells (Barski et al., 2007). When we analyze these datasets, we observe a similar 
enrichment of phosphorylated RNAPII beyond the TES of highly active genes in 
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Figure 2.25: Analysis of H3.3 post-TES at HCP genes without repeats in their TES
HCP genes without repeats (as annotated by the RepeatMasker in the UCSC table browser data) 
in their TES regions (-500 bp to +2kb) were separated into three groups based on their expression 
values, and then the distribution of ChIP-Seq reads around TSSs for these three groups of genes 
were generated as described above in 2.23.
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differentiated human CD4+ T cells (Figure 2.22H).
To ensure that the extension of phosphorylated RNAPII and H3.3 did not 
represent a previously unrecognized extension of transcription beyond the TES of 
high-expressing genes, we analyzed a published RNA-seq dataset from mouse 
ES cells (Cloonan et al., 2008). We observed peaks of transcribed RNA in exons, 
as expected, and did not find significant extension of transcription beyond the TES 
of active genes such beta-actin (Figure 2.23). We were also concerned that the 
H3.3 peak downstream of TESs could be due to the presence of Alu or other active 
repetitive elements in some highly expressed genes. However, this post-TES peak 
remained prominent when we focused our analysis on genes without repeats 
in their TES regions (-500 bp to + 2kb) (Figure 2.25). From these analyses, we 
conclude that both H3.3 and phosphorylated RNAPII are significantly enriched 
beyond the TES of highly expressed genes in undifferentiated and differentiated 
mammalian cell types.
The profile of H3.3 at cell-type specific genes changes with cell 
differentiation
To determine how the genome-wide patterns of H3.3 change with cell differentiation, 
we used an established protocol to differentiate both H3.3-HA and H3.2-HA ES 
cells to NPCs (Conti et al., 2005). To confirm that both H3.3-HA and H3.2-HA NPCs 
were similar in their genome-wide profiles of histone modifications to previously 
analyzed NPCs (Meissner et al., 2008; Mikkelsen et al., 2007), we performed 
control H3K36me3 ChIP-seq experiments from both H3.3-HA and H3.2-HA NPCs 
and found profiles that were extremely similar to established datasets (Figure 
2.14, Figure 2.15).
 Our results demonstrate that the profile of H3 variants changes in 
undifferentiated ES cells and differentiated NPCs at cell-type specific genes. In ES 
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cells, H3.3 was enriched in the gene body of expressed pluripotency genes such as 
Esrrb, Nanog, and Oct4, correlated with H3K36me3 (Figure 2.26A, 2.27). As with 
other high expressing genes, enrichment of H3.3 in the gene body of pluripotency 
genes is dependent on amino acid sequence, as mutation to H3.2 or H3.1S31 
abolishes this enrichment (Figure 2.26A, 2.27). Upon differentiation of ES cells 
to NPCs, the expression of most pluripotency genes is lost (Conti et al., 2005). 
Accordingly, the enrichment of H3.3 and H3K36me3 in the bodies of pluripotency 
Figure 2.26: H3.3 localization changes at cell-type specific genes with cell differentiation 
and resolution of bivalent domains
A. H3.3, H3K4me1, and H3K36me3 are enriched in the gene body of the highly expressed 
pluripotency gene Esrrb in ES cells, and this enrichment is largely lost upon differentiation to 
NPCs.
B. The epidermal growth factor receptor gene Egfr is H3K4me3/H3K27me3 bivalent and 
transcriptionally repressed in ES cells (Mikkelsen et al. 2007). Upon differentiation to NPCs, H3.3, 
H3K4me1, and H3K36me3 are enriched in the Egfr gene body.
C. H3.3, H3K4me1, and H3K36me3 are enriched in the gene body of the highly expressed 
housekeeping gene lactate dehydrogenase A Ldha in both ES cells and NPCs, and are not enriched 
in the low expressed neighboring Ldhc gene. The Y-axes in panels A-C are identical (indicated in 
the right side of panel C).
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genes largely disappeared upon cell differentiation (Figure 2.26A, 2.27).
We next sought to examine how the pattern of H3 variants changes 
at H3K4me3/H3K27me3 bivalent genes (Bernstein et al., 2006a) that are 
transcriptionally repressed in ES cells, but poised for expression in later 
developmental lineages (see Figure 1.14). Analysis of 2,525 HCP genes defined 
as bivalent in mouse ES cells (Mikkelsen et al., 2007) demonstrated that H3.3 is 
enriched around the TSS, but not within the gene body of bivalent differentiation-
specific genes in ES cells (Figure 2.20A, 2.21E). Again, this enrichment of H3.3 
around the TSS of bivalent ES genes is dependent on amino acid sequence, as 
mutation of H3.3 to H3.2 eliminated TSS enrichment at ES bivalent genes (Figure 
2.21F).
Following differentiation of ES cells to NPCs, the profile of H3.3 changes at 
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Figure 2.27: Cell-type specific enrichment of H3.3 at pluripotency genes and transcription 
factor binding sites
A. H3.3 and H3K4me1 are enriched around intergenic and genic TFBS near the Nanog gene in ES 
cells. In all cases, H3.3-specific enrichment is lost upon mutation of H3.3B to H3.2 or H3.1S31. 
B.   H3.3 and H3K4me1 are enriched around intergenic and genic TFBS near the Oct4 (Pou5f1) 
gene in ES cells.
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Figure 2.28: H3.3 is enriched at genes involved in cellular and metabolic processes in both 
ES cells and NPC cells
Genes with H3.3 peaks in their promoter regions were analyzed for enrichment of individual GO 
terms using the program DAVID (Huang da et al., 2009).  The top 25 GO categories are shown here 
with p-values indicated, and the x-axis representing the fraction of H3.3 genes in a GO category.
Produced in collaboration with Deyou Zheng.
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poised TSS with the resolution of bivalent domains. 92% of H3K4me3/H3K27me3 
bivalent genes in ES cells have been shown to resolve to either H3K4me3 only 
(Figure 2.21, red), H3K27me3 only (green), or lose both modifications (black) upon 
differentiation to NPCs (Mikkelsen et al., 2007). In bivalent ES genes that resolve 
to H3K4me3 and become transcriptionally active in NPCs, H3.3 was maintained 
around the TSS and also incorporated into the gene body, in correlation with 
H3K36me3 and H3K4me1 (red, Figure 2.21G, I-K). For example, the epidermal 
growth factor receptor gene Egfr is bivalent and transcriptionally repressed in ES 
cells, yet resolves to H3K4me3 and is expressed in NPCs. Upon differentiation to 
NPCs, H3.3 extended into the gene body of Egfr, correlating with H3K36me3 and 
H3K4me1 (Figure 2.26B). In contrast, for bivalent 
genes that remain transcriptionally repressed and 
resolve to either H3K27me3 or no mark in NPCs, 
H3.3 enrichment was reduced at the TSS upon 
cell differentiation to NPCs (Figure 2.21K). As 
expected, H3.2 remains unenriched at ES bivalent 
TSS following differentiation to NPCs (Figure 
2.21L).
While the pattern of H3.3 changes at cell-
type-specific genes, housekeeping genes that 
remain highly expressed in both ES cells and 
NPCs retain similar enriched patterns of H3.3 
incorporation.  In both ES cells and NPCs, H3.3 
is most highly enriched in genes associated with 
cellular and metabolic processes (Figure 2.28). 
For example, the housekeeping gene lactate dehydrogenase A Ldha is expressed 
in both ES and NPCs (Figure 2.29). In contrast to the cell-type specific genes 
Oct4
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Figure 2.29: Expression of 
pluripotency and differentiation-
specific genes in H3.3-HA and 
H3.2-HA ES cells and NPCs
Whole cell extracts of H3.3-HA and 
H3.2-HA ES cells and NPCs were 
immunoblotted with antibodies as 
indicated.
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Essrb and Egfr, H3.3 remains enriched around the TSS and within the gene body 
of Ldha in both ES cells and NPCs (Figure 2.26C). Our data show that the overall 
relationship between H3.3 incorporation and gene expression is retained in ES and 
NPCs, with H3.3 and H3K4 methylation marking the TSS of active and poised HCP 
genes, and H3.3 enriched in the body and TES of active HCP genes.  However, at 
cell-type specific genes, H3.3 localization changes with cellular state.
Genome-wide enrichment of H3.3 at transcription factor binding sites is 
dependent on amino acid sequence and cellular differentiation state
To determine enriched regions of H3 variants genome-wide, we used a modified 
segmentation algorithm (see Chapter Five). Unexpectedly, we found that 36% 
(3,627) of the enriched regions of H3.3 in mouse ES cells were located outside 
of known annotated genes (Figure 2.13, 2.27, 2.30). Genome-scale studies 
have previously demonstrated that in addition to genes (Mito et al., 2005), H3.3 
replacement marks the boundaries of cis-regulatory elements in Drosophila (Mito 
et al., 2007). Therefore, we considered the possibility that H3.3 might mark genic 
and intergenic TF binding sites in mammalian cells genome-wide.
Significant progress has been made regarding the core transcriptional 
regulatory networks that regulate pluripotency in mammalian cells. We therefore 
compared our genome-wide distributions for histone H3 variants in ES cells and 
NPCs with established genome-wide maps for 13 distinct sequence-specific TFs 
in ES cells (Chen et al., 2008b). Remarkably, 3,878 (38%) of the overall regions 
enriched for H3.3 in ES cells (Figure 2.13) correspond to previously identified 
genic or intergenic TF binding sites (TFBS) (Chen et al., 2008b). As with specific 
patterns of H3.3 at genes, peaks of H3.3 at TFBS are dependent on H3.3 amino 
acid sequence, as mutation of H3.3B to H3.2 or H3.1S31 eliminated these peaks 
of enrichment (Figure 2.27, 2.30, 2.31).
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Figure 2.30: Cell-type specific enrichment of H3.3 
at transcription factor binding sites
A. H3.3 and H3K4me1 are enriched at an intergenic 
region bound by multiple transcription factors (multiple 
transcription factor binding locus, MTL) (Chen et al., 
2008) specifically in ES cells.
B. H3.3 and H3K4me1 are enriched at an intergenic 
region specifically in NPCs, which may represent an 
uncharacterized TFBS.
C. H3.3 is enriched at an intergenic MTL specifically 
in ES cells. In this case, H3K4me1 does not appear 
enriched at this location. The Y-axes in panels A-C 
are identical and indicated in the right side of panel C. 
TFBS identified in mouse ES cells by previous ChIP-
seq studies (Chen et al., 2008) are indicated above 
the plots. NPC H3K4me3 data is from (Mikkelsen et 
al., 2007).
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Data in A-B produced in collaboration with Deyou Zheng.
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Figure 2.31: Genome-wide patterns of H3.3 at transcription factor binding sites are dependent 
on H3 amino acid sequence and cellular state
A-B. H3.3 and H3K4me1 are enriched genome-wide around ES cell TFBS. Genome-wide profiles 
of H3 variants (crosslinking ChIP-seq, HA tagged variants) and H3K4me1 as indicated around 
ES binding sites for Esrrb, Nanog, Oct4, Sox2, and Klf4. TFBS in mouse ES cells were identified 
by a previous study using ChIP-seq (Chen et al., 2008), and classified as promoter (black), gene 
body (dark blue), or intergenic (light blue). Panel A represents data from ES cells, while panel B 
represents data from NPCs at identical regions. Y-axis represents number of tags per binding site 
per 200 bp per 1 million mapped reads. Data for H3 in ES cells is from (Mikkelsen et al., 2007).
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Many of the specific peaks of H3.3 at TFBS are cell-type specific, especially 
those located in intergenic regions. 976 intergenic peaks of H3.3 that co-localize 
with known binding sites for pluripotency-regulating TFs in ES cells are lost 
upon differentiation to NPCs (Figure 2.30A, C). For example, the locus for the 
pluripotency gene Nanog is highly regulated and is a target for multiple transcription 
factors in ES cells (Chen et al., 2008b). Patterns of H3.3 enrichment at the Nanog 
locus correspond with known TFBS in ES cells (Chen et al., 2008b), as well as 
previously identified DNAseI hypersensitive sites (Levasseur et al., 2008) (Figure 
2.27A). These peaks of H3.3 incorporation around Nanog are significantly reduced 
following ES cell differentiation to NPCs (Figure 2.27A). In addition to ES cell 
specific peaks of H3.3 (Figure 2.27, 2.30A, C), we also found peaks of H3.3 that 
are specific to differentiated NPCs (Figure 2.30B). Intriguingly, 2478 (~90%) of 
the intergenic and NPC-specific H3.3 peaks do not overlap with known ES TFBS 
(Chen et al., 2008b) (Figure 2.30B).
Our data suggest that overlapping peaks of H3.3 and H3K4me1 may 
identify known and novel TFBS. H3K4me1has recently been shown to have a 
strong genome-wide co-localization with TFBS, enhancers, and other regulatory 
elements (Heintzman et al., 2007; Robertson et al., 2008; Wang et al., 2008). 
Our analysis found that 30% of the intergenic peaks enriched with both H3.3 and 
H3K4me1 overlap with known TFBS (Figure 2.30A, B, D, 2.31), compared with 
23.7% for all intergenic H3.3 peaks and 26.5% for all intergenic H3K4me1 peaks. 
Genome-wide patterns of H3.3 and H3K4me1 are similar (Figure 2.15). Indeed, 
we note that 26% of H3K4me1 peaks overlap with H3.3 peaks, and peaks of H3.3 
are 5 times more likely to be associated with peaks of H3K4me1 than H3K4me3 (p 
<< 0.00001). Notably, we found 724 intergenic peaks of both H3.3 and H3K4me1 
in NPCs that do not correspond to any known TFBS (Figure 2.30B, 2.32), and 
it is possible that these represent uncharacterized, cell-type specific regulatory 
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Figure 2.32: Genome-wide changes in intergenic peaks of H3.3 and H3K4me1
H3.3 and H3K4me1 intergenic peaks were identified as described in Data Analysis.  Data is for 
crosslinking ChIP-seq with H3.3-HA.  Those intergenic peaks were then defined as ‘known ES 
TFBS’ if they overlap with an intergenic TFBS identified in ES cells (Chen et al., 2008), or ‘unknown’ 
if they do not overlap with known TFBS.  A plots the total number of peaks in each category while B 
plots the relative fraction of peaks in each category.  Note the relative increase in enriched unknown 
intergenic regions in NPCs for H3.3, H3K4me1, and H3.3 and H3K4me1.
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regions. However, there are exceptions to the co-occupancy of TFBS by H3.3 and 
H3K4me1, such as TFBS marked only by peaks of H3.3 but not H3K4me1 (Figure 
2.30C).
To examine the relationship between H3.3 incorporation and TFBS genome-
wide, we took the TFBS identified by ChIP-seq in mouse ES cells for Nanog, Oct4, 
STAT3, Smad1, Sox2, Zfx, c-Myc, n-Myc, Klf4, Esrrb, Tcfcp2l1, E2f1, and CTCF 
(Chen et al., 2008b), and classified those binding sites as gene promoter, gene 
body, or intergenic. Remarkably, we find that H3.3 and H3K4me1 are enriched 
genome-wide at TFBS for all 13 characterized TFs in ES cells, whether these 
binding sites are in the gene promoter, gene body, or intergenic (Figure 2.31A). 
Upon mutation of H3.3B to H3.2 or H3.1S31, the enrichment of H3.3 at all 13 TFBS 
is lost, demonstrating the genome-wide dependence of H3.3 TFBS localization on 
amino acid sequence in mammalian cells (Figure 2.30A). 
When we examine specific peaks of H3.3 at TFBS in ES cells, we find that 
many of them are co-localized with regions bound by multiple TFs (Figure 2.27, 
2.30A, C). Genomic locations bound by more than four TFs have been described 
as multiple transcription factor-binding loci (MTL), and a subset of MTL bound by 
Oct4-Sox2-Nanog have been shown to serve as ES cell-specific enhanceosomes 
(Chen et al., 2008b). Our genome-wide analysis shows that the density of H3.3 in 
ES cell MTL increases significantly with the number of bound TFs (Figure 2.33A). 
Again, this relationship between transcription factor binding and H3.3 incorporation 
is dependent on amino acid sequence, as mutation of H3.3 to H3.2 eliminates 
this correlation (Figure 2.33A). Surprisingly, we do not find a correlation between 
TF binding in MTL and levels of H3K4me1 (Figure 2.33A), despite the strong 
concurrence between H3K4me1 and individual TFBS (Figure 2.31A). These data 
suggest that the level of H3K4me1 at MTL may saturate with lower numbers of 
TFBS, while levels of H3.3 continue to increase with increasing TF binding.
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Following differentiation to NPCs, the genome-wide relationships between 
H3.3, H3K4me1, and TFBS are reduced, but not entirely eliminated (Figure 2.31B, 
2.33B). At some specific TFBS (Figure 2.30A, C), H3.3 and H3K4me1 enrichment 
is lost upon differentiation to NPCs. However, at other TFBS, such as those 5’ and 
3’ of Nanog, H3.3 and H3K4me1 enrichment is reduced, but partially maintained 
(Figure 2.27A). At the genome-wide level, we observe that the overall enrichment 
of H3.3 at TFBS is significantly reduced, but not eliminated, upon differentiation 
from ES to NPCs (Figure 2.31B). At ES MTL, the relationship between multiple 
transcription factor binding and H3.3 enrichment is clearly dependent on cellular 
differentiation state (Figure 2.33A-B). Following differentiation to NPCs, MTL for 
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Figure 2.33: Cell-type specific enrichment of H3.3 at multiple transcription factor binding 
loci
A-B. In ES cells (A) and NPCs (D), levels of H3.3 at ES MTL are dependent on H3 amino acid 
sequence and cellular state. Box-and-whisker plots showing the ChIP-Seq read densities at MTL 
separated by # of TFBS at a locus (x-axis). Y-axis represents # of normalized ChIP-Seq tags at a 
group of MTL with the same # of TFBS, where the central bar is median, box shows 25th and 75th 
percentiles, and whiskers mark the 1.5x interquartile range.
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known ES cell TFs do not show increased levels of H3.3 (Figure 2.33B).
Specific patterns of H3.3 at genes, regulatory elements, and repeats
The data that we have seen in this chapter provide the first genome-wide maps of 
histone H3 variants in mammalian pluripotent cells and NPCs.  I have established 
the normal patterns of histone H3.3 at active and repressed genes, TFBS, and 
specific repeats such as telomeres, and have demonstrated that these genome-
wide patterns are critically dependent on endogenous H3.3 amino acid sequence. 
At cell-type specific genes and regulatory regions, the localization of H3.3 changes 
with cell differentiation.  Therefore, genome-wide patterns of H3.3 enrichment are 
also dependent on cellular state.  These findings raise many questions.  Although 
H3.3 is clearly enriched at a variety of regions, what is the function of H3.3 at these 
elements?  Does H3.3 play a similar role in TSS and gene bodies as it does after 
TES, at TFBS, and at telomeres?  The work that I will describe in Chapter Three 
touches upon a potentially repressive function for H3.3 at telomeres and rDNA.  In 
Chapter Four, I will also discuss ongoing experiments that attempt to address the 
function of H3.3 in mammalian development and cellular differentiation.
In addition to the function of H3.3, another critical question emerges from the 
data presented in this chapter.  What are the factors that are responsible for H3.3 
deposition at these various elements? The histone chaperone HIRA associates with 
H3.3 in HeLa cells, and it has been described to play a critical role in H3.3 deposition 
during Drosophila male pronuclear decondensation (Loppin et al., 2005; Tagami et 
al., 2004).  Is HIRA required for H3.3 deposition at all classes of sites, or are there 
site-specific mechanisms that deposit H3.3 at transcribed sequences, TFBS, and 
telomeres?  After establishing the ‘wild-type’ patterns of H3.3 in mammalian cells, 
I next sought to determine how these genome-wide patterns of H3.3 are altered in 
the absence of Hira.  As we shall see, the results in Chapter Three indicate that the 
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deposition of H3.3 at different genomic regions is significantly more complicated 
than existing models proposed in the literature.  
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CHAPTER 3
HIRA AND ATRx ARE REqUIRED FOR H3.3 DEPOSITION 
AT DISTINCT GENOMIC REGIONS
Summary
In Chapter Two, I described the first genome-wide profiles of histone H3 
variant localization in mammalian embryonic stem (ES) cells and differentiated 
neuronal precursor cells (NPCs).  In this chapter, I establish the dependence and 
independence of these patterns on previously identified as well as novel factors 
involved in H3.3 deposition. To determine the dependence of genome-wide H3.3 
patterns on the putative H3.3 chaperone Hira, I compared the genome-wide 
localization of H3.3 in wild-type and Hira -/- ES cells. These studies are the first to 
demonstrate that Hira is required for genome-wide H3.3 enrichment at active and 
repressed genes. Surprisingly, I found that H3.3 enrichment at specific transcription 
factor binding sites (TFBS), ribosomal DNA, and telomeres is Hira-independent. 
To identify factors that might mediate Hira-independent deposition of H3.3, I used 
a combined immunoprecipitation and mass spectrometry approach. My work 
identifies the chromatin remodeling protein Atrx (alpha thalassemia and X-linked 
mental retardation) and Daxx (death-domain associated protein) as proteins that 
specifically associate with H3.3 in both pluripotent and non-pluripotent cells, both in 
the presence and in the absence of Hira. After generating genome-wide profiles of 
H3.3 in Atrxflox and Atrxnull mouse ES cells, I demonstrate that Atrx is not required for 
H3.3 deposition at genes or TFBS. Finally, I show that Atrx is specifically required 
for enrichment of H3.3 at telomeres and rDNA in ES cells, and for the repression 
of telomeric and ribosomal RNA.
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Results
Hira is required for enrichment of H3.3 at active and repressed genes
After establishing the genome-wide patterns of H3.3 in undifferentiated ES cells 
and differentiated NPCs, I sought to determine whether all of these patterns were 
dependent on the putative H3.3 chaperone Hira.  Hira has been shown to associate 
with H3.3 in human cells, and to be required for assembly of H3.3 nucleosomes 
on paternal chromatin during male pronucleus formation in Drosophila (Loppin 
et al., 2005; Tagami et al., 2004).  Moreover, as described in Chapter One, 
Hira is believed to be required for H3.3-specific deposition, perhaps working 
in combination with CHD1 to engage in replication-independent (RI) chromatin 
assembly (De Koning et al., 2007; Konev et al., 2007) (see Figure 1.22).  Hira -/- 
mice die during early embryogenesis following gastrulation defects and significant 
patterning abnormalities (Roberts et al., 2002).  Although Hira -/- cells are incapable 
of terminal differentiation into functional neurons, Hira -/- ES cells are surprisingly 
viable, proliferate normally in culture, and display normal ES colony morphology 
(Meshorer et al., 2006).  Hira -/- mice and ES cells were generated in the laboratory 
of Dr. Peter Scambler (Meshorer et al., 2006; Roberts et al., 2002).  
 For the next portion of my thesis work, I therefore began a collaboration with 
Dr. Scambler’s laboratory, who generously provided me with wild-type W9.5 and 
Hira -/- ES cells.  Using the techniques described in the previous chapter, I used 
zinc finger nucleases (ZFNs) and my H3.3B-EYFP knock-in donor constructs to 
tag one allele of the endogenous H3.3B gene in Hira -/- ES cells with a C-terminal 
EYFP tag.  Hira -/- ES cells express H3.3B at slightly lower, but comparable levels 
to wild-type ES cells (Figure 3.1).
 To determine the distribution of H3.3 in wild-type and Hira -/- ES cells, I initially 
examined chromosome spreads from metaphase arrested cells. In agreement with 
previous studies in Drosophila embryos and adult cells (Bonnefoy et al., 2007), I 
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find that H3.3 is still globally incorporated into chromatin in the absence of Hira 
(Figure 3.2). In Hira -/- ES cells, H3.3 has a somewhat weaker signal, and is 
concentrated in foci near the end of chromosomes (Figure 3.2).
 I also sought to determine if H3.3 post-translational modifications were 
altered in the absence of Hira. For example, H3.3 serine 31 phosphorylation 
(H3.3S31P) is a post-translational modification that is enriched in mitosis and is 
specific to H3.3 (Hake et al., 2005). H3.3S31P co-localizes with telomeres in ES 
cells, but becomes more localized to pericentromeric heterochromatin following 
cell differentiation (Hake et al., 2005; Wong et al., 2009) (see Figure 1.19). I 
found that H3.3S31P is also Hira-independent, as mitotic enrichment of H3.3S31P 
enrichment is fully maintained in Hira -/- ES cells (Figure 3.3).
 To compare the genome-wide distribution of H3.3 in wild-type and Hira -/- 
ES cells at higher resolution, I again performed native ChIP-seq.  Although Hira has 
been suggested to play a critical role in deposition of mammalian H3.3 (Meshorer et 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
Oct4 Nanog H3.3A H3.3B
R
e
la
ti
ve
 E
x
p
re
ss
io
n
Hira -/- ES expression
 relative to WT W9.5 ES
Hira
GFP
Oct4
H3
H3.3-EYFP
Hira-/-WT
A B
Figure 3.1:  Expression of H3.3 and pluripotency genes in wild-type and Hira -/- ES cells
A. Immunoblots from whole-cell extracts showing expression of H3.3-EYFP in wild-type and Hira 
-/- ES cells, with antibodies as indicated.
B.  Hira -/- ES cells maintain expression of Oct4, Nanog, H3.3A, and H3.3B.  Real-time PCR was 
performed following RNA extraction and cDNA synthesis.  Data were normalized to Gapdh, and 
plotted as expression in Hira -/- relative to W9.5 ES cells.
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Figure 3.2:  Chromosomal localization of H3.3 in wild-type and Hira -/- ES cells
A-F. Metaphase chromosome spreads from WT H3.3-EYFP and Hira -/- H3.3-EYFP ES cells, using 
anti-GFP. Bar: 10μm.
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Figure 3.3:  H3.3 serine 31 phosphorylation is Hira-independent
Immunoblots of whole cell extracts from WT and Hira -/- ES cells grown asynchronously (left two 
lanes) or blocked in metaphase with nocodazole (right two lanes).
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al., 2006; Tagami et al., 2004), this hypothesis has never been rigorously examined 
through ChIP, likely due to the difficulty of raising an antibody to distinguish H3.3 
from the other H3 variants.  As might be expected, my data show that Hira is 
specifically required for genome-wide H3.3 enrichment at active and repressed high 
CpG content promoter (HCP) genes (Figure 3.4A-D). In the absence of Hira, the 
pattern of H3.3 around active and repressed genes (Figure 3.4D) resembles H3.2 
(Figure 3.4C), and general H3 (Figure 2.17C), with no enrichment surrounding 
the TSS, and depletion of H3.3 at the TSS itself. For example, in Hira -/- ES cells, 
the enrichment of H3.3 around the TSS of repressed bivalent genes such as Pparg 
is abolished (Figure 3.4E). At highly expressed housekeeping genes such as the 
ribosomal protein-coding gene Rps19, the enrichment of H3.3 in the gene body 
and after the TES is mostly eliminated in the absence of Hira (Figure 3.4F). These 
data demonstrate that the vast majority of H3.3 enrichment at both active and 
repressed genes in ES cells is Hira-dependent, as expected from the existing 
literature.
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Figure 3.4: Enrichment of H3.3 at active and repressed genes is Hira-dependent
A-D.  Native ChIP-seq profiles of H3 variants, in wild-type ES cells (B-D) and Hira -/- ES cells (E) 
across the TSS and TES for highly active (red), medium expressing (black), or low expressing 
(green) CpG rich genes, with data represented as in Figure 2.
E.  H3.3 enrichment at the TSS of repressed bivalent gene Pparg is Hira-dependent.
F.  H3.3 enrichment at the active, ribosomal-protein coding gene Rps19 is Hira-dependent.
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Hira -/- ES cells maintain global patterns of ES cell gene expression 
Given the lack of genic H3.3 enrichment in the absence of Hira, one possible 
explanation for the alteration in genome-wide patterns of H3.3 at active and 
repressed genes is a significant alteration in patterns of gene expression. 
Therefore, my collaborators and I sought to determine if Hira -/- ES cells show 
genome-wide alterations in gene expression. Remarkably, microarray analysis 
reveals that global patterns of ES cell gene expression are maintained in Hira -/- 
ES cells (Figure 3.5A-C). Moreover, genome-wide patterns of H3K36me3 are also 
extremely similar in wild-type and Hira -/- ES cells (Figure 3.6).  What accounts for 
the strikingly ‘normal’ phenotype of Hira -/- ES cell growth and gene expression, 
but for the significant defects seen upon Hira -/- ES cell differentiation?
 Intriguingly, the phenotype of Hira -/- ES cells is similar to that of CHD1 shRNA 
ES cells (Gaspar-Maia et al., 2009).  Like Hira -/- ES cells, CHD1 shRNA ES cells 
maintain global patterns of ES cell gene expression, but display significant defects 
upon differentiation (Gaspar-Maia et al., 2009).  CHD1 was recently shown to play 
a role in H3.3 deposition during Drosophila pronuclear decondensation, and was 
suggested to work together with Hira (Konev et al., 2007).  It is therefore possible 
that the defects upon differentiation of Hira -/- and CHD1 shRNA ES cells could 
result from impaired replication-independent (RI) H3.3 deposition in more slowly 
dividing or post-mitotic cells.  Rapidly dividing Hira -/- and CHD1 shRNA ES cells 
could be partially ‘rescued’ by replication-dependent (RD) histone deposition, 
enabling global maintenance of the ES cell transcriptome, and I will discuss this 
hypothesis in greater detail in the following chapter.  
 Notably, I cannot at this time rule out more subtle defects in transcription 
that were not detectable by genome-wide microarray studies of Hira -/- ES cells. 
For example, Hira -/- ES cells could still manifest low levels of spurious transcripts, 
as the S. pombe HIRA protein homologs were recently shown to be required for 
145
Figure 3.5:  Microarray analysis of gene expression in wild-type and Hira -/- ES cells
A-C. Triplicate GeneChip® Mouse Gene 1.0 ST Arrays were hybridized with cDNA from three 
independent biological replicates of HIRA-/- ES (cl34) and WT ES (W9.5) cell lines. The data 
was analyzed using the LIMMA package of Bioconductor v2.0 and R v.2.9.2, applying GC-RMA 
normalization and correction for multiple testing (Benjamini-Hochberg) with a significance threshold 
of p<0.05. 
A. Significant differentially expressed genes were binned according to their fold-change. 
B. The number of differentially expressed genes was determined for each low, medium, high 
expression gene sets derived from WT ES cells.  High, medium, and low expression genes were 
determined from a previous microarray of WT ES cells (Mikkelsen et al., 2007) as detailed in 
Materials and Methods.  Overall, only a small number of genes in these gene sets were affected in 
Hira -/- ES cells. 
C. Differential expression of ES cell related genes in wild-type (W9.5) vs Hira -/- ES cells.
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Figure 3.5
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Figure 3.6: H3K4me1 and H3K36me3 are maintained at genes in the presence and absence 
of Hira
A-D. Profiles of H3K4me1 (A-B) and H3K36me3 (C-D) in wild-type (A,C) and Hira -/- (B,D) H3.3-
EYFP ES cells across TSS and TES for highly active, medium, or low expressed CpG rich genes. 
Y-axis represents the average number of tags per gene per 200 bp per 1 million mapped reads.  
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promoter silencing and global repression of cryptic antisense transcripts (Anderson 
et al., 2009).  Overall, my data show that genome-wide enrichment of H3.3 at active 
and repressed genes in ES cells is Hira-dependent.  However, Hira-dependent 
genic deposition of H3.3 is not required for maintenance of the undifferentiated ES 
cell transcriptome.
Hira-independent enrichment of H3.3 at transcription factor binding sites
Due to the significant enrichment of H3.3 at genic and intergenic TFBS, (Figure 
2.28, 2.29), I also examined whether these patterns were dependent on 
Hira. As the ES cell transcriptome is globally maintained in Hira -/- ES cells, I 
reasoned that the overall profile of TFBS would be similar in wild-type and Hira -/- 
ES cells, enabling us to use the same existing dataset of 13 different ES cell TFBS 
(Chen et al., 2008b). Surprisingly, despite the observation that Hira is required for 
genome-wide H3.3 enrichment at active and repressed genes, my collaborators 
and I find that Hira is not essential for genome-wide H3.3 enrichment at TFBS.
 Global profiles of H3.3 are largely maintained at ES cell TFBS in Hira -/- ES 
cells (Figure 3.7, 3.8), demonstrating that H3.3 enrichment at most regulatory 
elements is Hira-independent. For example, H3.3 enrichment at an intergenic 
MTL approximately 30 KB from the Mmp17 gene is maintained in Hira -/- ES cells 
(Figure 3.7B), as is H3.3 enrichment at an intergenic MTL near the repressed 
Foxi3 gene (Figure 3.7C). Indeed, levels of H3.3 are increased at some TFBS 
in Hira -/- ES cells (Figure 3.9). However, we note that levels of H3.3 are also 
reduced at other TFBS in Hira -/- ES cells (Table 3.1, Figure 3.8). Of all previously 
identified ES TFBS (Chen et al., 2008b), 34% show greater than 2-fold more 
H3.3 tags in Hira +/+ than in Hira -/-, while 12% show greater than 2-fold more 
H3.3 tags in Hira -/-, indicating that targeting of H3.3 to the majority (54%) of 
known ES TFBS is Hira-independent (Table 3.1, Figure 3.8).  Global profiles of 
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Figure 3.7: Hira is not essential for 
H3.3 enrichment at transcription 
factor binding sites
A.  Native ChIP-seq genome-wide 
profiles of H3.3 around previously 
described ES TFBS (Chen et al., 2008), 
and data analyzed as in Chapter Two.
B. Deposition of H3.3 in ES cells at 
an intergenic enhancer element near 
Mmp17 is Hira-independent. 
C. Deposition of H3.3 in ES cells at an 
intergenic enhancer element near Foxi2 
is Hira-independent.
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H3K4me1 are very similar in wild-type and Hira -/- ES cells (Figure 3.6A-B, 3.8C), 
indicating that Hira is also not required to maintain the localization of H3K4me1. 
Overall, these data demonstrate that mammalian ES cells utilize Hira-independent 
mechanisms to deposit and enrich H3.3 at many non-genic elements.
Hira-independent association of Atrx and Daxx with histone H3.3
To identify candidates that might mediate Hira-independent deposition of H3.3, I 
began a collaboration with Assistant Professor Ileana Cristea of Princeton University, 
formerly a postdoctoral fellow with Dr. Brian Chait here at Rockefeller University.  Dr. 
Cristea and I used an immunoaffinity purification and mass spectrometry approach 
optimized to help maintain protein complexes in their original state (Cristea et al., 
2005). Using an anti-GFP antibody, proteins interacting with EYFP-tagged H3 
variants in wild-type and Hira -/- ES cells were immunoprecipitated, resolved using 
gel electrophoresis and identified using mass spectrometry (Figure 3.10A, 3.11). 
We also performed immunoblots of immunoprecipitated proteins to confirm specific 
candidates (Figure 3.10B).
 We found many interacting proteins common to all H3 variants in wild-type 
and Hira -/- ES cells, including core histones and previously described members 
common to both RC and RI chromatin assembly complexes, such as Nasp, Asf1a, 
Asf1b, and Rbap48 (a full list of identified proteins is presented in Table 3.2). 
Notably, the previously described H3.3 chaperone Hira (Tagami et al., 2004) was 
identified specifically in proteins isolated with H3.3.
 However, in addition to Hira, we also identified Atrx and Daxx as proteins 
that specifically associate with H3.3 (Figure 3.10, 3.11, 3.12). Atrx is a member of 
the SNF2 family of chromatin remodeling factors (Picketts et al., 1996). Mutations 
of human ATRX give rise to the ATR-X syndrome, a disorder characterized by 
a form of X-linked mental retardation that is frequently associated with multiple 
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Figure 3.8  H3.3 enrichment at ES TFBS  is partially perturbed in Hira -/- ES cells, but is not 
significantly affected in Atrxnull ES cells
A-C.  H3.3 and H3K4me1 read densities at ES TFBS (Chen et al., 2008) were analyzed and plotted 
from anti-GFP and anti-H3K4me1 native ChIP-seq experiments.   TFBS were first separated into 
different groups based on their H3.3 (or H3K4me1) ChIP-seq read densities in wild-type ES cells 
(X-axis). Corresponding ChIP-seq read densities from Hira -/- or Atrx null samples are shown on 
the Y-axis as boxplots.  Upper schematics depict possible results.  H3.3 levels at ES TFBS in 
wild-type and Hira -/- ES cells remain generally correlated, indicating that H3.3 enrichment is not 
completely abolished at ES TFBS in Hira -/- ES cells (A).  However, H3.3 levels at ES TFBS are 
reduced at many ES TFBS in Hira -/- ES cells, and increased at other ES TFBS, particularly at ES 
TFBS with a high density of reads, suggesting that Hira affects H3.3 deposition in some but not all 
TFBS.  H3.3 enrichment at ES TFBS remains highly correlated betwen wild-type and Atrxnull ES 
cells (B), and H3K4me1 enrichment at ES TFBS remains highly correlated between wild-type and 
Hira -/- ES cells (C).
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TF 2-fold decrease of H3.3 in Hira -/- 2-fold increase of H3.3 in Hira -/- No 
change
Tcfcp2l1 0.373 0.105 0.522
CTCF 0.277 0.125 0.598
Klf4 0.387 0.096 0.517
Sox2 0.304 0.201 0.495
Pou5f1 0.312 0.188 0.5
Nanog 0.27 0.216 0.514
Zfx 0.421 0.068 0.511
Smad1 0.265 0.22 0.515
STAT3 0.346 0.146 0.508
E2f1 0.404 0.079 0.517
n-Myc 0.389 0.073 0.538
c-Myc 0.361 0.07 0.569
Esrrb 0.358 0.111 0.531
all 0.344 0.12 0.536
Data analysis performed by Deyou Zheng.
Table 3.1: Global fraction of ES TFBS with differential H3.3 deposition between wild-type 
and Hira -/- ES cells
Significant difference is defined here as 2-fold greater H3.3 tag densities from either wild-type or 
Hira -/- ChIP-Seq analyses.
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Figure 3.9: Real-time PCR confirmation of ChIP-seq results
Real-time PCR of ChIP DNA confirms ChIP-seq results.  Note similar profiles of H3.3 at genes and 
TFBS in Atrxflox (green) and Atrxnull (blue) ES cells.  At genes, particularly active gene bodies and 
TES, H3.3 enrichment is decreased in Hira -/- ES cells (orange), while at TFBS, H3.3 enrichment 
is Hira-independent.  Primer sequences are listed in Appendix.  Data are plotted as fold enrichment 
over intergenic (%input at location / %input at intergenic).
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Figure 3.10: Atrx and Daxx association with H3.3 is Hira-independent
A. H3.3-EYFP, H3.2-EYFP, H3.1-EYFP, and Hira -/- H3.3-EYFP associated proteins were 
immunopurified from heterozygous H3.3B ES cells via the EYFP tag, resolved by SDS-PAGE, and 
visualized by Coomassie Blue. Proteins were identified by mass spectrometry, and those listed in 
red are specific to H3.3. The arrow indicating Hira points to a polypeptide in the H3.3 lane running 
immediately above the polypeptide Nasp (*), which is common to all purified H3 variants. A full list 
of identified proteins is presented in Table 3.2.
B.  Immunoblots of immunopurified H3 variant associated proteins from ES cells with antibodies 
as indicated.
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MS/MS data analysis performed by Ileana Cristea, and used with permission.
ATRX peptide 1 ATRX peptide 2
Figure 3.11: Probing the specificity of Atrx association with H3.3 using hypothesis-driven 
MS/MS analysis 
Hypothesis-driven multistage mass spectrometry (Kalkum et al., 2003) was utilized to obtain a highly 
sensitive detection of specific peptides from proteins of interest, even if these peptide species could 
not be discerned in the primary matrix-assisted laser desorption/ionization  MALDI MS analysis 
because of insufficient signal-to-noise. Even if Atrx peptides were not observed in the H3.2 and 
H3.1 samples at the MS level, their corresponding m/z values ([M+H]+) were selected, subjected to 
collision induced dissociation (CID) fragmentation, and analyzed using MALDI IT MS/MS analyses. 
The expected fragmentation pattern for the Atrx peptides was confirmed only in the sample isolated 
with H3.3 (A-B) as assessed by b and y ion fragments and the preferential cleavages C-terminus 
of Glu and N-terminus of Pro residues.  See also top row of Table 3.2.
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Table 3.2:  List of H3 variant associated proteins identified by mass spectrometry
The presence of the interacting partners in the isolations of the different H3 variants (H3.3, H3.2, 
H3.1, Hira -/- H3.3 and Hira -/- H3.2) is indicated with + (detected) and - (not detected). Only the 
proteins identified as main hits by database searching and confirmed by manual data interpretation 
are illustrated. The specificity of Hira, Atrx, and Daxx association with H3.3 were confirmed by 
western blots and further experiments (see main text for details). The specific association of other 
proteins with particular H3 variants will require further investigation. The number of peptides, protein 
sequence coverage and XProteo d’ (discriminability) score obtained following the analysis of the 
MS data are indicated for each protein isolated with the H3 variants. The XProteo score is based on 
an improved version of the ProFound Bayesian algorithm (Zhang and Chait, 2000) and measured 
as d’—the normalized distance between the score distribution (of the candidate protein) and the 
distribution of randomly matched proteins (in units of standard deviation). A d’=4 correspond to a 
true positive rate of 0.99 and a false positive rate of 0.05. Candidate proteins were confirmed by 
CID MS/MS analyses of the indicated peptides that were acquired and interpreted manually.
*See Figure 3.11 for an example of MS/MS analysis of ATRX peptides.
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Table 3.2
Protein name Protein ID H3.3 H3.2 H3.1 Hira 
-/- 
H3.3
Hira 
-/- 
H3.2
peptides selected for MS/MS
Atrx* gi|6678609|ref|NP_033556.1 + - - + - FGQTKPVYVYR*
FLPPKHEYVLAVR*
WAEEFNDETNVR
EEISDHENNVTILLEDSDLRR
TTSTSNPSSPAPDWYKDFVTDTDAEV-
LEHSGK
Daxx gi|24636788|sp|O35613| + - - + - LEQLLALYVAEIR
TETSDHPEVVPFLHK
ENRTLAMNR
NSEPAEGLR
ELDLSELDDPDSSYLQEAR
hnRNP G-T gi|94381180|ref|XP_914797.2 - - - + - RDPYLGPR
VAQATKPVFESGR
Macf1 gi|94373701|ref|XP_996894.1 - - - + - LQAALASTQQFQQMFDELR
SLNQPTPPPMPILSQSEAKNPR
Hira gi|52426778|ref|NP_034565.2 + - - - - FPEILATLR
YLVNEGFEYR
Dnmt3a gi|13938621|gb|AAH07466.1 + - - - - LFFEFYR
AIYEVLQVASSR
Ssrp1 gi|110283006|sp|Q08943| + - - - - FDEISFVNFAR
NEVTLEFHQNDDAEVSLMEVR
RGS9 gi|2739458|gb|AAC99481.1 + - - - - SPPGMNNVLDYGLDR
EAANTVDITQVMSK
FACTp140 gi|110287968|sp|Q920B9| + - - - - NEGNIFPNPEATFVK
APGEQTVPALNLQNAFR
VEALTKEELEFEVPFR
mHEL-5 gi|71153505|sp|O70133| + + + + + DFVNYLVR
LAHFEPSQR
EGERVEPYK
DINTDFLLVVLR
TTQVPQYILDDFIQNDR
SNF2H gi|14028669|gb|AAK52454.1| + + + + + YLVIDEAHR
QPNVQDFQFFPPR
TPEEVIEYSAVFWER
NASP gi|13384598|ref|NP_058057.2 + + + + + EIEELKELLPEIR
SLQENEEEEIGNLELAWDMLDLAK
5730410I19Rik gi|51261128|gb|AAH79531.1 + + + + + REDIQQFFEEFQSK
DAATYWPLNWR
RBBP-4 gi|90101524|sp|Q60972| + + + + + TVALWDLR
TPSSDVLVFDYTK
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Dnajc9 gi|23956266|ref|NP_598842.1 + + + + + EIPAYSAFVK
ISLEDIQAFEK
Parp1 gi|74144748|dbj|BAE27352.1 + + + + + TLGDFLAEYAK
QPDVEVDGFSELR
DELGFRPEYSASQLK
Ubiquitin gi|51701919|sp|P63049| + + + + + ESTLHLVLR
EGIPPDQQR
ASF1A gi|13384964|ref|NP_079817.1 + + + + + ENPPVKPDFSK
VGYYVNNEYTETELR
ASF1B gi|12859888|dbj|BAB31809.1 + + + + + VGYYVNNEYPDPELR
ENPPPKPDFSQLQR
Atp5b gi|23272966|gb|AAH37127.1 + + + + + VALTGLTVAEYFR
AIAELGIYPAVDPLDSTSR
H2A gi|28316756|ref|NP_783589.1 + + + + + AGLQFPVGR
VTIAQGGVLPNIQAVLLPK
H2B gi|30061385|ref|NP_835507.1 + + + + + LLLPGELAK
AMGIMNSFVNDIFER
H2A.Z gi|7949045|ref|NP_058030.1 + + + + + GDEELDSLIK
AGLQFPVGR
ATIAGGGVIPHIHK
VGATAAVYSAAILEYLTAEVLELAGNASK
YFP gi|3891568|pdb|1YFP| + + + + + FEGDTLVNR
SAMPEGYVQER
H3 gi|53734121|gb|AAH83353.1 + + + + + YRPGTVALR
VTIMPKDTQLAGR
EIAQDFK
STELLIR
H4 gi|85057093|gb|AAI11814.1 + + + + + VFLENVIR
ISGLIYEETR
MCM2 gi|37359742|dbj|BAC97849.1 + + + + + ISHLPLVEELR
IFASIAPSIYGHEDIKR
MCM6 gi|6678832|ref|NP_032593.1 + + + + + DFYVAFQDLPTR
EIPFAKDFYVAFQDLPTR
MCM7 gi|74210112|dbj|BAE21331.1 + + + + + LMMEQRSR
GFTPAQFQAALDEYEELNVWQVNTSR
Hsp1 gi|40556608|ref|NP_032328.2 + + + + + HLEINPDHPIVETLR
HNDDEQYAWESSAGGSFTVR
HAT1 gi|28076885|ref|NP_080391.2 + + + + + FQELVEDYRR
FPEDLENDIR
LLVTDMSDAEQYR
YYISFPTVLDITAEDPSR
HSP70 gi|74211667| + + + + + ARFEELNADLFR
TVTNAVVTVPAYFNDSQR
Table 3.2 continued
Mass spectrometry analysis performed in collaboration with Ileana Cristea, and used with permission.
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congenital abnormalities and alpha thalassemia (Gibbons et al., 2008). ATRX 
has been described to co-exist in a chromatin-remodeling complex with the death 
domain-associated protein Daxx, and these proteins have been localized to 
heterochromatin and promyelocytic leukemia (PML) nuclear bodies in human and 
mouse cells (Ishov et al., 2004; Tang et al., 2004; Xue et al., 2003). As Atrx and 
Daxx specifically associate with H3.3 both in wild-type and Hira -/- ES cells, we 
conclude that this association is Hira-independent (Figure 3.10A-B).
 To determine if the association between H3.3, Atrx, and Daxx was also 
conserved in differentiated human cells, I collaborated with Dr. Peter Lewis, a 
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Figure 3.12:  H3.3 specific association with Atrx and Daxx is conserved in differentiated 
human cells
A.  Immunoblots of Atrx, Daxx and FLAG-HA-H3 from HeLa cells stably expressing H3.3-FLAG-HA 
(FHA) or H3.1-FHA (Tagami et al., 2004).
B.  Oligonucleosomes purified from H3.3-FHA and H3.1-FHA HeLa cells. Micrococcal nuclease 
digested chromatin was incubated with M2 agarose beads in order to purify H3.3-FHA and H3.1-
FHA oligonucleosomes and associated proteins. Two adjacent FLAG elution fractions (FE1 and 
FE2) from each H3.3-FHA and H3.1-FHA purification are shown in B-C. Oligonucleosomal DNA 
was purified and run on a 1% agarose gel, with fragment size indicated.
C.  Immunoblots of eluate from two adjacent FLAG elution fractions (FE1 and FE2) following FLAG 
affinity purification from H3.3-FHA and H3.1-FHA oligonucleosomes (B).
160
postdoctoral fellow in the Allis lab. We isolated oligonucleosomes and chromatin-
associated proteins from human cervical cancer (HeLa) cells carrying stably 
expressed FLAG-HA tagged H3.3 or H3.1 (Tagami et al., 2004) (Figure 3.12). 
Following FLAG affinity purification and FLAG peptide elution, immunoblots 
of H3.3 and H3.1 associated proteins reveal that both Daxx and Atrx are also 
specifically associated with H3.3 but not H3.1 oligonucleosomes in human cells 
(Figure 3.12C).
Atrx is required to maintain H3.3 deposition at 
telomeric DNA and for repression of telomeric 
(TERRA) in ES cells
To determine if Atrx is required for H3.3 enrichment 
in genes, regulatory regions, or telomeres, I 
again used ZFNs to knock-in an epitope tag 
into the endogenous allele of H3.3B, generating 
heterozygous H3.3B / H3.3B-EYFP in the 
background of Atrxflox and Atrxnull mouse ES cells 
(Figure 3.13). Atrxflox and Atrxnull ES cells were a 
generous gift from the laboratory of Dr. Douglas 
Higgs and Dr. Richard Gibbons (Garrick et al., 
2006).  Although Atrxnull  mice die by E9.5 due to 
a defect in trophoblast development, Cre-mediated deletion of Atrx from Atrxflox 
ES cells results in viable Atrxnull  ES cells (Garrick et al., 2006). Immunoblots 
demonstrate comparable expression of H3.3B-EYFP in Atrxflox and Atrxnull  ES cells 
(Figure 3.13).
 I used native ChIP-seq to generate genome-wide profiles of H3.3 in 
the presence and absence of Atrx. My collaborators and I find that Atrx is not 
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Figure 3.13: Expression of H3.3-
EYFP in Atrxflox, Atrxnull, and 
Hira -/- ES cells
Immunoblots showing expression of 
H3.3-EYFP in Atrxflox, Atrxnull, and 
Hira -/- ES cells, with antibodies as 
indicated.
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Data in A-C produced in collaboration with Deyou Zheng and 
Kyung-Min Noh.
Figure 3.14: Similar genome-wide 
profiles of H3.3 in Atrflox and Atrxnull 
ES cells at genes and TFBS
A-B. Native ChIP-seq profiles of H3.3 in 
Atrxflox (B) and Atrxnull ES cells (C) as 
indicated across the TSS and TES for 
highly active (red), medium expressing 
(black), or low expressing (green) CpG 
rich genes.
C.  Genome-wide profiles of H3.3 
around previously described ES TFBS 
(Chen et al., 2008), and data analyzed 
as in 3.7.
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required for H3.3 incorporation at active or repressed genes (Figure 3.14A-B), 
or at regulatory elements (Figure 3.8, 3.14C), as genome-wide profiles of H3.3 
are similar at genes and TFBS in Atrxflox and Atrxnull ES cells. Strikingly, analysis 
of repeats demonstrates that Atrx, but not Hira, is specifically required for H3.3 
enrichment at telomeres (Figure 3.15).
 To determine whether there were any functional consequences of Atrx 
deletion and the loss of Atrx-dependent telomeric enrichment of H3.3, we examined 
the chromatin state and transcriptional output of ES cell telomeres. The chromatin of 
ES and induced pluripotent cell telomeres has previously been shown to have lower 
levels of the heterochromatin marker H3K9me3, increased telomere length, and 
increased transcription of telomeric repeat-containing RNA (TERRA) in comparison 
to differentiated cells (Marion et al., 2009) (see Figure 1.20). In particular, TERRA 
Figure 3.15: Atrx is required for Hira-independent enrichment of H3.3 at telomeres
A.  Analysis of H3.3 enrichment at repetitive elements in Atrxflox, Atrxnull, and Hira -/- ES cells. 
Fold enrichment of repetitive elements in ChIP-seq data are plotted over input.
B.  Dot blot with Sty11 telomeric probe (left) or control Bam repeat probe (right) of ChIP-seq DNA 
from Atrxflox H3.3-EYFP or Atrxnull H3.3-EYFP IPed with indicated antibody (GFP, H3K4me3, or 
H3K9me3) or Input DNA.
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has recently been identified as a component of telomeric heterochromatin and an 
inhibitor of telomerase, and levels of TERRA have been shown to be regulated 
by chromatin modifying enzymes (Azzalin and Lingner, 2008; Azzalin et al., 2007; 
Luke and Lingner, 2009; Schoeftner and Blasco, 2008; Yehezkel et al., 2008). 
Human ATR-X patients have also previously been shown to have altered DNA 
methylation in subtelomeric repeats (Gibbons et al., 2000). ChIP of H3K4me3 and 
H3K9me3 does not show a significant difference in telomeric enrichment between 
Atrxflox and Atrxnull ES cells (Figure 3.15B). However, northern blots from Atrxflox, 
Atrxnull, and Atrxflox ES cells 4 days after treatment with Cre reveal reproducible 
(~1.7 fold) upregulation of TERRA in the absence of Atrx (Figure 3.16A-C).
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Figure 3.16: Atrx is required for repression of 
telomeric RNA
A.  Immunoblots of Atrx in Atrxflox, Atrxnull, and Atrxflox 
ES cells 4 days after treatment with retroviral Cre.
B.  Representative northern blot for TERRA (upper 
panel) and Gapdh (lower panel) in Atrxflox and Atrxnull 
ES cells in the presence and absence of Cre. To ensure 
that signal is from RNA, samples on the right were 
treated with RNase for 30 minutes as indicated.
C.  Quantification of TERRA normalized to Gapdh. 
Error bars represent the standard deviation of three 
independent experiments.
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Atrx is required to maintain H3.3 deposition at ribosomal DNA and for 
repression of ribosomal RNA in ES cells
In addition to subtelomeric repeats, ATRX patients also show alterations in 
DNA methylation at rDNA arrays (Gibbons et al., 2000). Genome-wide and 
immunofluorescence studies in differentiated human cells have previously 
demonstrated that ATRX is localized to rDNA as well as heterochromatin (Law, 
2006; McDowell et al., 1999). To determine whether enrichment of H3.3 at rDNA 
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Figure 3.17: Atrx is required for Hira-independent enrichment of H3.3 at ribosomal DNA, and 
for repression of ribosomal RNA
A. (Top) Scale diagram showing positions of real-time PCR amplicons (blue boxes) across mouse 
rDNA. Numbering is kilobases from the start of transcription. Coding regions are shown in red. 
Yellow bar indicates transcribed region. Location of the real-time PCR amplicon used for rDNA 
primary transcript analysis in H (90F/146R) is indicated. (Bottom) Analysis of H3.3 enrichment 
at mouse rDNA sequences using real-time PCR of H3.3-EYFP ChIP DNA from Atrxflox (green), 
Atrxnull (blue) and Hira -/- (orange) ES cells, plotted as fold enrichment over intergenic region.
B. Total RNA extracted from wild-type and Atrxnull ES cells was reverse transcribed and real-time 
PCR was used to determine levels of ribosomal RNA primary transcript relative to Gapdh mRNA. 
Error bars represent standard deviation from four ES cell subclones.
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might also be dependent on Hira or Atrx, I analyzed ChIP samples from H3.3-EYFP 
Atrxflox, Atrxnull, and Hira -/- ES cells using real-time PCR primers specific for mouse 
rDNA. Intriguingly, H3.3 enrichment at the transcribed region of rDNA is also Hira-
independent and Atrx-dependent (Figure 3.17A). While H3.3 enrichment at rDNA 
transcribed regions is reduced in Atrxnull ES cells, levels of rDNA transcripts are 
also increased in Atrxnull ES cells (Figure 3.17B). Therefore, in both telomeres and 
rDNA, Atrx is required for H3.3 enrichment in these transcribed repetitive elements, 
and the transcription of telomeres and rDNA is increased in the absence of Atrx.
ATRx ADD domain interacts with the histone H3 tail
ATRX associates specifically with H3.3 in the presence and absence of Hira (Figure 
3.10-3.12).  In addition, I have shown that ATRX is required for H3.3 deposition 
at telomeres and rDNA, and for the repression of TERRA and rRNA (Figure 3.15-
3.17).  However, the mechanism by which ATRX directs H3.3 deposition remains 
unknown.  ATRX is a very large protein of approximately 280 kDa, with two highly 
conserved domains (Gibbons et al., 2008).  At its N-terminus, ATRX contains 
an ATRX-DNMT3-DNMT3L (ADD) domain, a PHD finger-like domain, and at 
its C-terminus, ATRX contains an ATPase domain with seven highly conserved 
helicase motifs (Gibbons et al., 2008) (see Chapter Four for further discussion of 
ATRX functional domains).  The ADD domain of DNMT3L was recently shown to 
bind preferentially to the unmodified histone H3 tail (Ooi et al., 2007).
 To determine if the ADD domain of ATRX might mediate a direct association 
between ATRX and histone H3.3, I performed peptide pull-down studies with the 
recombinant ATRX ADD domain (residues 159–296) (Argentaro et al., 2007) and 
biotintylated histone peptides (Figure 3.18).  As controls, I used recombinant 
DNMT3L (Ooi et al., 2007), as well as WDR5, which has been shown to preferentially 
bind to H3K4me2 (Ruthenburg et al., 2006; Wysocka et al., 2005).  I found that the 
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ATRX ADD domain interacts specifically with the histone H3 tail, amino acids 1-20, 
similar to the described interaction of H3 1-20 with DNMT3L (Ooi et al., 2007), 
(Figure 3.18A).  As DNMT3L shows a strong preference for H3 1-20 unmethylated 
at H3K4, I used histone H3 tail peptides methylated at K4 and K9 to determine if 
the ATRX ADD domain displays a similar preference.  I found that the ATRX ADD 
domain shows a slight preference for H3K9 methylation, with increasing binding with 
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Figure 3.18:  ATRx ADD domain interacts with H3 1-20, and does not show a preference for 
H3.3 specific sequences
A-C. Peptide interaction assays with modified or unmodified biotinylated histone H3 peptides as 
indicated, incubated with the human ATRX ADD domain, or full-length DMNT3L and WDR5 as 
controls.
A. The ATRX ADD domain prefers the N-terminal 1-20 amino acids of H3. 
B. The ATRX ADD domain interacts with the N-terminus of H3, is relatively unaffected by H3K4 
methylation, and displays a slight preference for H3K9 methylation. 
C. The ATRX ADD domain does not prefer H3.3-specific peptides, but interacts with the N-terminal 
1-20 amino acids of H3. 
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higher H3K9 methylation states (Figure 3.18B).  DNMT3L binding was completely 
abolished by H3K4 methylation, as previously reported (Ooi et al., 2007), while 
a fraction of the ATRX ADD domain still bound to H3 1-20 peptides methylated 
at H3K4 (Figure 3.18B).   Recent unpublished studies from other laboratories 
confirm that the ATRX ADD domain binds to unmodified H3 tails, and this binding 
is enhanced by di and tri-methlyation of H3K9 (D. Neuhaus, D. Rhodes, Y. Shi, 
personal communication).  However, as described previously, the histone H3 tail 
residues 1-20 are identical in all non-centromeric H3 variants (Figure 1.16), and 
this interaction therefore does not demonstrate why I have seen such a selective 
association of ATRX with H3.3.
 The amino acids that distinguish H3.3 from H3.1/H3.2 are located in the 
N-terminal tail at position 31, as well as in a core region at 87, 90, 90, and 96 
(Figure 1.16).  Therefore, I also used peptide sequences spanning these regions to 
determine if the ATRX ADD domain might show any H3 variant-specific preference. 
Disappointingly, the ATRX ADD domain did not interact significantly with H3 19-38 
or 22-41 from H3.3 or H3.2/H3.1, or with 86-97 from H3.3 or H3.2 (Figure 3.18B). 
Therefore, the mechanism by which ATRX associates with and specifically deposits 
H3.3 remains to be established.
A new perspective on H3.3 deposition pathways
The studies described in this chapter make clear that H3.3 deposition in mammalian 
cells is significantly more complicated than current models suggested by the field 
(De Koning et al., 2007; Loyola and Almouzni, 2007) (Figure 1.22).  Although Hira 
plays an essential role for H3.3 deposition at genes and multiple TFBS, it is only 
responsible for a subset of genome-wide H3.3 deposition patterns in mammalian 
cells.  Deposition of H3.3 at specific TFBS, telomeres, and rDNA is Hira-independent. 
In addition, my work has identified two novel players in H3.3 deposition: ATRX 
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and Daxx.  We have seen that ATRX is required for H3.3 deposition at telomeres 
and rDNA, and for repression of TERRA and rRNA transcription.  Although many 
questions remain, the data in this chapter provide a new perspective on the 
complexity of genomic region-specific H3.3 deposition in mammalian cells.  In 
the following chapter, I will discuss the implications of my work, describe ongoing 
projects and future studies, and discuss the potential functions of H3.3 deposition 
in mammalian development and cellular differentiation.
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CHAPTER 4
GENERAL DISCUSSION, WORK IN PROGRESS, AND 
FUTURE DIRECTIONS
The data presented in the previous chapters represent the first comprehensive 
evaluation of non-centromeric H3 variant localization in undifferentiated mammalian 
embryonic stem (ES) cells and differentiated neuronal precursor cells (NPCs). 
Chromatin immunoprecipitation (ChIP) grade antibodies that distinguish 
H3.3 from the other H3 variants are not available. Therefore, in Chapter Two, 
I introduced a system for the rapid knock-in of epitope tag sequences into the 
endogenous histone H3.3B gene in mouse ES cells.  Using these genetically 
engineered ES cells in combination with point mutagenesis of H3.3B, I have found 
compelling evidence that genome-wide patterns of H3.3 are dependent on H3.3-
specific amino acid sequence. H3.3 displays specific patterns of incorporation in 
the mammalian genome, while H3.2 and H3.1 are much more widely distributed. 
Following the differentiation of ES cells into NPCs, I demonstrated that patterns of 
H3.3 enrichment at cell-type specific genes and transcription factor binding sites 
(TFBS) are dependent on cellular state.  Overall, the data in this thesis identify 
three general categories of H3.3 enrichment in mammalian cells: 1) genes and 
other transcribed non-repetitive sequences, 2) TFBS, and 3) ribosomal DNA (rDNA) 
and telomeres. Remarkably, as shown in Chapter Three, each of these general 
categories of H3.3 enrichment in ES cells are mediated by distinct mechanisms of 
deposition.
In Chapter Three, I examined genome-wide patterns of H3.3 deposition 
in the presence and absence of the histone chaperone Hira. As expected, the 
H3.3 chaperone Hira is required for enrichment of H3.3 at active and repressed 
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genes. Unexpectedly, deposition of H3.3 at specific TFBS, rDNA, and telomeres 
is Hira-independent.  Immunoaffinity purification of H3.3 associated proteins in the 
presence and absence of Hira revealed a specific, Hira-independent association of 
H3.3 with the chromatin remodeling protein Atrx (alpha thalassemia and X-linked 
mental retardation) and the death domain associated protein Daxx.  Using Atrxflox 
and Atrxnull ES cells, my collaborators and I found that Atrx is specifically required 
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Figure 4.1:  Hira and Atrx are required for deposition of H3.3 at distinct genomic regions 
The patterns and levels of H3.3 enrichment at specific elements are represented by green profiles. 
At highly repetitive elements with short repeat length such as telomeres, the precise pattern of 
H3.3 across the element cannot be determined, and the relative enrichment is indicated by a green 
hashed box.
 
H3.3 is enriched in specific patterns at active and repressed genes with high CpG content promoters 
(HCP), genic and intergenic transcription factor binding sites (TFBS), ribosomal DNA (rDNA), and 
telomeres. TSS = transcription start site, TES = transcription end site. The H3.3 chaperone HIRA 
is required for H3.3 enrichment at active genes, repressed genes, and specific TFBS.  Based on 
the described localization of CHD1 to transcription start sites in embryonic stem cells (Gaspar-
Maia et al., 2009), and the cooperative role of Hira and CHD1 in H3.3 nucleosome assembly in 
Drosophila (Konev et al., 2007), it is possible that CHD1 may also play a role in H3.3 deposition 
at these locations, but this possibility has not been examined. Surprisingly, H3.3 enrichment at 
specific TFBS, rDNA, and telomeres is Hira-independent. The boxed question mark denotes as yet 
unidentified factors that are required for Hira-independent and Atrx-independent H3.3 deposition 
at specific TFBS. ATRX is required for H3.3 enrichment at rDNA and telomeres. Although Daxx 
specifically associates with both H3.3 and Atrx, the role of Daxx in H3.3 deposition has not yet been 
established. Note that the profiles shown in this chapter are generalized summary depictions. For 
actual ChIP-seq data, see Chapters Two and Three.
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for H3.3 deposition at telomeres and rDNA.
Overall, these data demonstrate that mammalian cells utilize distinct 
mechanisms to deposit histone H3.3 at different genomic locations (Figure 4.1).   As 
presented in Chapter One, the chromatin field generally accepts a model in which 
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Figure 4.2:  Genome-wide localization of H3.3 requires H3.3-specfic amino acid sequence
Mutation of endogenous H3.3B to H3.2 or towards H3.1 abolishes H3.3 enrichment at TFBS, 
active and repressed genes, rDNA, and telomeres.  Data is summarized in a manner similar to the 
previous figure.
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Hira is the sole H3.3-specific chaperone required for H3.3 deposition.  Therefore, 
the results presented in this thesis provide a significant conceptual advance to 
this overly simplistic paradigm.  The observation that Atrx is required for H3.3 
deposition at telomeres and rDNA opens up a new area of investigation regarding 
the mechanisms, recruitment, and function of genomic region-specific histone 
deposition machinery.   More speculatively, these results may suggest potential 
connections between H3.3 deposition and human genetic disease.  Below, I will 
discuss some of the implications of our findings, describe some current work in 
progress, and suggest some possibilities for future studies.
Genomic localization of H3.3 is specific and requires H3.3 amino acid 
sequence
The data presented in Chapter Two demonstrate that H3.3 is enriched in specific 
patterns at active and repressed coding and non-coding genes, including lincRNA 
(Guttman et al., 2009), as well as TFBS, ribosomal DNA , and telomeres (Figure 
4.1).  Using point mutagenesis of the endogenous H3.3B gene, I provided 
strong evidence that this localization pattern requires H3.3-specific amino acid 
sequence.  Expression of a non-H3.3 variant from the H3.3 promoter is insufficient 
for proper targeting and localization of H3.3, as genome-wide H3.3 patterns are 
abolished upon the mutation of H3.3B to H3.2 or H3.1 (Figure 4.2).  Notably, I 
have not performed the reciprocal experiment that places H3.3 under a replication-
dependent H3.1 or H3.2 promoter. Therefore, it remains possible that the timing of 
H3 variant expression may still play an important role in H3 variant localization if 
the H3 variant is only expressed during the defined window of S-phase. However, 
the results presented in this thesis clearly show that the sequence of the H3 variant 
dictates genome-wide localization when expressed from the endogenous H3.3B 
promoter (Figure 4.2).
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Constitutive incorporation of H3.3 at active and repressed genes with CpG 
rich promoters
In Drosophila, H3.3 is constitutively enriched around poised HSP70 promoters, 
even in the absence of heat shock (Mito et al., 2007). However, in previous studies 
of vertebrates, the profile of H3.3 at repressed genes differed depending on the 
system being studied (see Chapter One) (Jin and Felsenfeld, 2006; Jin et al., 
2009; Sutcliffe et al., 2009).
Our data show that genome-wide patterns of H3.3 around TSS in mammalian 
ES cells and NPCs vary significantly based on the CpG content of gene promoters. 
H3.3 is constitutively enriched around the TSS of both active and repressed high 
CpG content promoter (HCP) genes in ES cells and NPCs, including the TSS 
of bivalent genes in ES cells (Figure 4.2). In contrast to HCP genes, we do not 
observe any significant pattern of H3 variant enrichment at low CpG content 
promoter (LCP) genes in ES cells and NPCs (data not shown). 
LCP and HCP genes have been described to display distinct modes of 
regulation (Mikkelsen et al., 2007; Ramirez-Carrozzi et al., 2009; Saxonov et al., 
2006). Most HCP genes in both undifferentiated and differentiated cells show 
evidence of transcriptional initiation, assemble unstable nucleosomes, and do not 
require SWI/SNF nucleosome remodeling complexes for gene induction, while 
LCP genes assemble stable nucleosomes and require SWI/SNF (Guenther et 
al., 2007; Ramirez-Carrozzi et al., 2009). Indeed, nearly all (99%) of HCP genes 
are marked by H3K4me3 in mouse ES cells, whether they are transcriptionally 
active or repressed, while only 6.5% of LCP genes in ES cells carry H3K4me3 
(Mikkelsen et al., 2007).  Our results are therefore consistent with a model in which 
H3K4 methylation and H3.3 deposition at HCP TSS are coupled to transcriptional 
initiation.
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Gene body deposition and transcription end site peaks of H3.3 in mammalian 
cells are proportional to transcriptional activity
In addition to constitutive TSS deposition of H3.3 at HCP genes, we find enrichment 
of H3.3 in the gene body and after the transcription end site (TES) in proportion 
to transcriptional activity (Figure 4.2).  These gene body and TES patterns of 
H3.3 are distinct from other histone modifications.  While H3.3 and H3K36me3 
are strongly correlated in gene bodies, H3K36me3 begins to decline prior to the 
TES at highly expressed genes (see Figure 1.10), while levels of H3.3 and Ser-
5 phosphorylated RNA polymerase II (RNAPII) increase and are enriched in a 
specific peak beyond the TES of highly expressed genes (Figure 4.2). 
Significant peaks of H3.3 were not initially observed after the 3’ ends of 
genes in Drosophila (Mito et al., 2005, 2007). However, a more recent report found 
a peak of H3.3 at genic 3’ ends of both active and inactive Drosophila genes, 
particularly from chromatin fractions extracted in low-salt (Henikoff et al., 2009). 
Interestingly, a dramatic enrichment of trypanosome-specific histone variants H3V 
and H4V was recently observed at the probable RNAPII transcriptional termination 
sites of polycistronic transcription units (Siegel et al., 2009), leading to the proposal 
that “chromatin-based transcriptional punctuation” in trypanosomes may represent 
an evolutionary adaptation to regulate transcription in eukaryotes that lack 
sophisticated regulatory sequences (Talbert and Henikoff, 2009).  In addition, TES 
peaks of H3.3 were also observed in a recent genome-wide study of HeLa cells 
(Jin et al., 2009). Here, I have shown that “transcriptional punctuation” by histone 
variant H3.3 and phosphorylated RNA polymerase also marks the boundaries of 
highly expressed genes in both undifferentiated and differentiated mammalian 
cells, calling attention to a potentially more universal mechanism for histone variant 
utilization as a genomic “boundary marker.”
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Figure 4.3:  H3.3 localization at cell-type specific genes changes with cell differentiation
Representative ES and NPC profiles for H3.3 are depicted for housekeeping genes, pluripotency 
genes, neural precursor genes, and non-neural genes with HCP promoters. 
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What is the function of H3.3 deposition after transcriptional end sites? Does 
genic and post-TES deposition of H3.3 simply demarcate active genes, or does H3.3 
play a more active role? Previous studies suggest that H3.3 deposition in actively 
transcribed gene bodies may be coupled to transcription, potentially mediated by 
factors associated with elongating polymerase (Daury et al., 2006; Janicki et al., 
2004; Schwartz and Ahmad, 2005; Tagami et al., 2004; Wirbelauer et al., 2005). 
Recent studies in human cells documented accumulation of RNAPII beyond the 
site of RNA transcript cleavage and downstream of H3K36me3, suggesting that 
paused RNAPII may accumulate prior to release at the end of genes (Brodsky 
et al., 2005; Lian et al., 2008). One can speculate that the colocalized post-TES 
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Figure 4.4: H3.3 localization at cell-type regulatory elements changes with cell 
differentiation
H3.3 enrichment at ES cell specific enhancers is decreased in NPCs (top).  In addition, numerous 
unannotated cell-type specific peaks were found, and these represent candidates for possible cell-
type specific regulatory elements.
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peaks of phosphorylated RNAPII and H3.3 at highly active genes in mammalian 
cells represent a site of significant chromatin disruption, as transcription-coupled 
deposition of H3.3 “builds up” with paused RNAPII prior to polymerase release. 
It is also possible that peaks of significant H3.3 replacement may play an active 
role in slowing the extension of RNAPII to facilitate transcriptional termination, as 
nucleosomes have been shown to serve as a barrier to transcriptional elongation 
(Armstrong, 2007).
H3.3 localization changes at specific loci following embryonic stem cell 
differentiation
I chose ES cells as a model system because they would enable me to study how 
patterns of H3 variants change during mammalian cellular differentiation.  I have 
found that the overall pattern of H3.3 enrichment remains consistent in ES cells 
and NPCs, with H3.3 enriched at the TSS of active and inactive genes, within active 
gene bodies and after active TES, as well as TFBS, rDNA, and telomeres (Figure 
4.3).  Notably, my collaborators and I found remarkable genome-wide changes 
of H3.3 localization at cell-type specific genes and TFBS, including pluripotency 
genes, differentiation-specific genes, and known regulatory regions (Figure 
4.3, 4.4). In addition, we also found multiple cell-type specific sites of H3.3 and 
H3K4me1 enrichment that do not correspond to annotated genes or TFBS (Figure 
4.4). When combined with future datasets, it is possible that our data will yield 
additional insights, perhaps as a means of identifying novel ES or NPC regulatory 
and transcribed regions. A similar approach recently used genome-wide patterns 
of H3K4me3 and H3K36me3 to identify novel mammalian lincRNAs (Guttman et 
al., 2009; Mikkelsen et al., 2007), and genome-wide patterns of p300 to identify 
tissue-specific enhancers (Visel et al., 2009).
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Comparison of H3.3 and H2A.Z localization in embryonic stem cells and 
neural precursor cells
As described in Chapter One, the histone variants H3.3 and H2A.Z have been 
found to co-occupy nucleosomes at specific regions of the genome, and such 
H3.3/H2A.Z nucleosomes were found to be relatively unstable in vitro (Jin and 
Felsenfeld, 2006, 2007; Jin et al., 2009).  H3.3 was previously found to be co-
enriched with H2A.Z at active promoters and enhancers of differentiated chicken 
and human cells (Jin and Felsenfeld, 2007; Jin et al., 2009).  However, the 
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Figure 4.5: Predicted genic locations of H3.3 / H2A.Z nucleosomes in ES cells and NPCs 
based on current study and reported literature
Genome-scale patterns of H2A.Z in ES cells and NPCs have been previously reported (Creyghton 
et al., 2008).  Based on this published data and on the data presented in this thesis, H3.3 / H2A.Z 
nucleosomes can be predicted to co-exist at the TSS of repressed genes in ES cells, but active 
genes in NPCs.
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localization of H3.3/H2A.Z nucleosomes has not been previously reported in ES 
cells. Interestingly, the data I have presented in Chapter Two shows that genome-
wide patterns of H3.3 in ES cells differ significantly from the described patterns of 
H2A.Z (Creyghton et al., 2008).  
In ES cells, H2A.Z is enriched in the promoters of repressed polycomb 
target genes, but upon differentiation to NPCs, H2A.Z becomes enriched at the 
promoters of highly expressed genes (Creyghton et al., 2008). I have shown that 
H3.3 is enriched more widely than the reported patterns of H2A.Z in both ES cells 
and NPCs, as H3.3 is enriched around the TSS of both active and repressed 
genes, in addition to expressed gene bodies, TFBS, and telomeres. Moreover, 
while H3.3 enrichment changes at specific locations upon cell differentiation, the 
overall relationship between H3.3 enrichment and gene expression remains similar 
in undifferentiated and differentiated cells. In both ES cells and NPCs, the greatest 
enrichment of H3.3 is found at highly expressed metabolic and housekeeping 
genes (Figure 2.27).  If we integrate the previous results of Boyer, Creyghton, 
and colleagues with the data presented here, one potential implication is that 
destabilizing H3.3/H2A.Z nucleosomes in ES cells would be present specifically 
at the TSS of repressed, poised genes, rather than at active housekeeping genes 
(Figure 4.5).  It is possible that such cell-type specific localization of destabilizing 
nucleosomes may be important to prepare developmental genes in ES cells for 
future expression.  However, no one has yet demonstrated the genome-wide 
localization of H3.3/H2A.Z nucleosomes in any mammalian cell type other than 
HeLa cells (Jin et al., 2009).   Therefore, the first step would be to confirm the 
existence and localization of H3.3/H2A.Z nucleosomes in ES cells and NPCs, an 
experiment which would now be possible by performing a double anti-HA and anti-
H2A.Z ChIP-seq from the H3.3B / H3.3B-HA ES cells described in this thesis.
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Hira-dependent enrichment of H3.3 at active and repressed genes
The data described in Chapter Three represent the first genome-wide study 
to compare chromatin in the presence and absence of a mammalian histone 
chaperone. Previous biochemical experiments showed that Hira specifically 
associates with H3.3 in mammalian cells, and in vivo experiments determined that 
Hira is required for H3.3 deposition and chromatin assembly in the Drosophila 
male pronucleus (Bonnefoy et al., 2007; Loppin et al., 2005; Tagami et al., 2004). 
In addition, biochemical and fluorescence recovery after photobleaching (FRAP) 
studies in wild-type and Hira -/- ES cells showed global increases in unbound H3 in 
the absence of Hira (Meshorer et al., 2006). From these studies, one would expect 
that Hira would play an important role in H3.3 deposition.  However, although 
these experiments were suggestive, the data in this thesis are the first to directly 
show by ChIP that Hira is required for genome-wide H3.3 enrichment at active and 
repressed genes.   How is Hira targeted to these specific genomic regions?
Previous studies hypothesize that H3.3 deposition in actively transcribed 
gene bodies may be coupled to transcription, potentially mediated by factors 
associated with elongating polymerase (Daury et al., 2006; Janicki et al., 2004; 
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Figure 4.6:  Hira -/- ES cells are defective in 
teratoma formation
Teratomas from Hira -/- ES cells are significantly 
smaller than teratomas from wild-type ES 
cells. 5*10^6 W9.5 or Hira -/- ES cells were 
injected into NOD-SCID mice, and teratomas 
were harvested at day 21.  Representative 
teratomas are shown. Experiments were 
performed in collaboration with Jiyeon Kim, Dr. 
Marco Seandel, and Dr. Shahin Rafii.
181
Schwartz and Ahmad, 2005; Tagami et al., 2004; Wirbelauer et al., 2005). Our 
data are consistent with Hira-dependent transcription-coupled deposition of H3.3 
at transcribed non-repetitive sequences.  However, Hira has not been found in 
purifications of the general transcriptional machinery, and the likely association 
between Hira and RNAPII would therefore be mediated through factors that have 
yet to be determined.  Much further work is needed on the recruitment of Hira to 
active and inactive genes. 
Hira-mediated deposition of H3.3 and embryonic stem cell differentiation
Remarkably, although Hira is required for early embryonic development (Roberts 
et al., 2002), my collaborators and I do not observe a significant phenotype in 
Hira -/- ES cells, despite a global lack of H3.3 enrichment at active and repressed 
genes. However, published experiments (Meshorer et al., 2006; Roberts et al., 
2002) as well as recent collaborative data indicates that despite their maintenance 
of the ES cell phenotype in culture, Hira -/- ES cells are significantly defective in 
cell differentiation.  
One test of pluripotency involves the injection of cells into 
immunocompromised mice.  Following injection into non-obese diabetic severe 
combined immunodeficiency (NOD-SCID) mice, pluripotent cells such as ES and 
induced pluripotent stem (iPS) cells will differentiate into multi-lineage tumors known 
as teratomas (Takahashi and Yamanaka, 2006). In collaborative experiments with 
Jiyeon Kim, Dr. Marco Seandel, and Dr. Shahin Rafii, wild-type and Hira -/- ES 
cells were injected into NOD-SCID mice.  Examination of the resulting teratomas 
revealed that Hira -/- teratomas were remarkably smaller than wild-type teratomas 
(Figure 4.6).  It is possible that this defect in teratoma formation could simply be 
due to slower growth of Hira -/- cells.  However, at least in culture, Hira -/- ES cells 
divide as rapidly as wild-type ES cells, and show a similar preponderance of cells 
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in S phase (Ariane Chapgier and Peter J. Scambler, unpublished data). 
Intriguingly, preliminary histological analysis indicated that unlike wild-type 
teratomas, Hira -/- teratomas failed to form fully differentiated tissue such as cartilage 
(data not shown).   This data is also consistent with the reported inability of Hira 
-/- ES cells to fully differentiate into post-mitotic neurons (Meshorer et al., 2006). 
However, it must be noted that these experiments are preliminary, and much work 
will be required to explore the function of Hira in mammalian cell differentiation. 
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Figure 4.7:  Defects in Hira -/- ES cells upon cell differentiation may be due to impaired 
replication-independent histone deposition
Rapidly cycling cells such as ES cells and NPCs are competent for both replication-dependent (RD) 
and replication-independent (RI) histone deposition.  However, post-mitotic neurons are dependent 
upon RI histone deposition.  In Hira -/- cells (bottom), rapidly cycling ES cells and NPCs may be 
rescued by RD histone deposition during frequent S-phases.  However, Hira -/- ES cells do not 
differentiate into post-mitotic neurons (Meshorer et al., 2006), and it is possible that such post-
mitotic cells may be unable to compensate for the loss of Hira-mediated RI histone deposition.
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What might account for the differentiation-specific phenotype of Hira -/- cells?
As both Hira -/- ES cells and Hira -/- embryos display significant patterning 
abnormalities following differentiation (Meshorer et al., 2006; Roberts et al., 
2002), I speculate that rapidly dividing Hira -/- ES cells may be rescued by the 
replication-coupled deposition of histones during the frequent S-phases of ES 
cells (Figure 4.7). ES cells cycle very rapidly, have a short G1 phase, and lack a 
G1/S checkpoint (Burdon et al., 2002).  It is possible that in the absence of Hira-
dependent incorporation of genic H3.3, differentiating cells with slower cell cycles 
may be deficient in replacing histones at active or initiating gene loci. Without H3.3 
or sufficient localized replication-dependent H3.1 or H3.2 as substrates for specific 
post-translational modifications (K4 and K27 methylation) to mark particular loci, 
more slowly-dividing or terminally differentiated cells may become progressively 
incapable of epigenetic memory. 
This hypothesis regarding the developmental importance of RI dependent 
H3.3 deposition by Hira fits with the patterning abnormalities and early lethality 
of Hira -/- embryos, the inability of Hira -/- ES cells to undergo terminal neuronal 
differentiation (Meshorer et al., 2006), the neuromuscular defects seen in H3.3A 
hypomorphs (Couldrey et al., 1999), and with earlier descriptions of H3.3 in the 
literature, in which H3.3 RNA and protein levels were observed to increase during 
models of cell differentiation (Krimer et al., 1993; Lord et al., 1990; Wunsch and 
Lough, 1987). High levels of H3.3 protein have been found in differentiating rat 
neurons, and as noted in Chapter One, H3.3 has been shown to become the dominant 
histone H3 variant in rat brain cortical neurons (Pina and Suau, 1987; Scaturro et 
al., 1995).  In further support of this hypothesis, recent studies in Drosophila have 
determined that surviving H3.3 null flies are ‘rescued’ by upregulation of replication-
dependent histones (see Chapter One) (Sakai et al., 2009).
Future experiments by my colleagues in the Allis laboratory and in Dr. Peter 
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Scambler’s laboratory will further explore the functional role of Hira-mediated 
deposition of H3.3 in ES cell differentiation.  In particular, my colleagues Simon 
Elsaesser and Dr. Ariane Chapgier will use the wild-type and Hira -/- H3.3B-HA 
ES cells I have generated to examine the specific requirements of Hira for H3.3 
deposition in differentiated cells, as my experiments in Hira -/- cells have only 
examined H3.3 incorporation in ES cells.  Although the precise function of Hira 
in cellular differentiation remains to be established, Hira is clearly required for 
early embryonic development (Roberts et al., 2002), and the data presented in 
this thesis are the first to demonstrate that Hira is required for genome-wide genic 
incorporation of H3.3.
CHD1 in mammalian H3.3 deposition
CHD1 is important for H3.3 deposition in the Drosophila male pronucleus, and ChIP-
chip studies show that CHD1 localizes to gene TSS in ES cells (Gaspar-Maia et al., 
2009; Konev et al., 2007).  However, the role of CHD1 in H3.3 incorporation has 
not yet been explored in mammalian cells.  While both CHD1 and Hira are likely to 
play important roles beyond H3.3 incorporation, it is notable that the phenotype of 
CHD1 shRNA and Hira -/- ES cells is similar, with global maintenance of the ES cell 
transcriptome and specific defects upon cellular differentiation (Gaspar-Maia et al., 
2009; Meshorer et al., 2006; Roberts et al., 2002).  For example, CHD1 shRNA ES 
cells appear to be unable to differentiate into post-mitotic cardiomyocytes (Gaspar-
Maia et al., 2009).  Future collaborative studies could use the tagged H3.3B mouse 
ES cells that I have developed in combination with CHD1 shRNA (Gaspar-Maia 
et al., 2009) to examine the potential requirements for CHD1 in mammalian H3.3 
deposition.
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Hira-independent H3.3 deposition at regulatory elements
Recent studies found specific peaks of H3.3 deposition at TFBS in Drosophila and 
human cells (Jin et al., 2009; Mito et al., 2007). Deposition of H3.3 at TFBS has 
been proposed to serve as a mechanism for maintaining regulatory elements in a 
more accessible chromatin conformation (Henikoff, 2008). Thus, while I anticipated 
an evolutionarily conserved role for H3.3 deposition at regulatory elements, the 
extent of H3.3-specific deposition at mammalian ES TFBS was unexpected. 
Close comparison of our data to a recent dataset of 13 different TFs in mouse ES 
cells (Chen et al., 2008b) shows H3.3 enriched in ES cells at all known types of 
TFBS genome-wide, whether in gene bodies, promoters, or intergenic regions. 
My collaborators and I also found a strong positive correlation between previously 
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Figure 4.8:  Hira is required for deposition of H3.3 at active genes, repressed genes, and 
specific transcription factor binding sites
In Hira -/- ES cells, H3.3 enrichment at active and repressed genes, as well as at specific TFBS, is 
lost. Some TFBS show increased H3.3 in the absence of Hira, while other TFBS show decreased 
H3.3, and at most TFBS, H3.3 deposition is unaffected.  Therefore, H3.3 enrichment at many TFBS 
is maintained by Hira-independent factors (boxed question mark).  H3.3 deposition at rDNA and 
telomeres is mediated by ATRX and possibly Daxx, and is Hira-independent.
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identified loci bound my multiple transcription factors (MTL) and H3.3 deposition, 
indicating particular enrichment of H3.3 at enhancer elements. In all cases, patterns 
of H3.3 enrichment at TFBS were abolished upon mutation of H3.3 to H3.2 or 
H3.1S31.
Our data demonstrate that Hira is involved in H3.3 deposition at some genic 
and intergenic TFBS.  However, we also find that genome-wide H3.3 enrichment at 
many regulatory elements is Hira-independent and Atrx-independent.  Collectively, 
these data therefore suggest that H3.3 deposition at TFBS may be mediated by 
multiple and distinct factors, including Hira, with different factors mediating H3.3 
deposition at specific regulatory elements (Figure 4.8). Notably, genome-wide 
patterns of H3.3 correspond closely with H3K4me1, and this correlation between 
H3.3 and H3K4me1 is more apparent at regulatory elements than at genes or 
other genomic regions. Perhaps H3K4me1, potentially in combination with other 
enhancer-enriched histone modifications (Wang et al., 2008), may serve to recruit 
or stabilize as yet unidentified H3.3 deposition machinery at specific regulatory 
elements.
ATRx and Daxx: new histone variant deposition machinery?
Using ChIP-seq in both undifferentiated ES cells and NPCs, the data presented 
in Chapter Two demonstrate that H3.3 is specifically enriched in the canonical 
(TTAGGG)n repeat that is the hallmark of telomeres in vertebrates (Meyne et al., 
1989). Cell imaging studies also show that H3.3 is present in telomeric foci on the 
largely heterochromatic Y-chromosome in ES cells, and H3.3S31 phosphorylation 
is also present on the telomeres of ES cell chromosomes. These results agree 
with a recent report that described the enrichment of H3.3S31 phosphorylation and 
overexpressed MYC-tagged H3.3 on telomeres in ES cells (Wong et al., 2009).
 Surprisingly, the data presented in Chapter Three demonstrate that telomeric 
187
H3.3 deposition, rDNA H3.3 deposition, specific TFBS H3.3 deposition, and mitotic 
H3.3 serine 31 phosphorylation are all Hira-independent.  These observations led 
to a search for factors that might be responsible for Hira-independent deposition of 
H3.3. In collaboration with Drs. Ileana Cristea and Peter Lewis, I have identfied Atrx 
and Daxx as proteins that associate with H3.3 oligonucleosomes in the presence 
and absence of Hira.  Using ChIP-seq, my colleagues and I have demonstrated 
that Atrx is required for H3.3 enrichment at telomeres and rDNA. 
Our results suggest that Atrx is required for the maintenance of telomere 
and rDNA chromatin state in ES cells. Recent studies have shown that the 
Drosophila homolog of Atrx, XNP, co-localizes with H3.3 at sites of nucleosome 
replacement on polytene chromosomes, but is not required for H3.3 localization at 
these sites (Schneiderman et al., 2009).  The data presented in this thesis show 
that Atrx is required for enrichment of H3.3 at mammalian ES cell telomeres and 
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Figure 4.9:  Atrx is required for H3.3 deposition at ribosomal DNA and telomeres, and for the 
repression of ribosomal RNA and telomeric repeat-contaning RNA
In Atrxnull ES cells, H3.3 enrichment at active genes, repressed genes, and TFBS is unaffected. 
However, H3.3 enrichment at rDNA and telomeres is lost in in Atrxnull ES cells.  In addition, rRNA 
and telomeric repeat-containing RNA (TERRA) transcripts are increased in the absence of Atrx.
188
the transcribed regions of rDNA, potentially defining a new category of specifically 
targeted histone variant deposition machinery. Moreover, in the absence of Atrx, 
ES cells show a similar upregulation of both telomeric repeat-containing RNA 
(TERRA) and ribosomal RNA (rRNA) (Figure 4.9). This result is similar to a recent 
finding in human patients with ICF (immunodeficiency, centromeric region instability, 
facial anomalies) syndrome, where mutations in DNMT3B and hypomethylation of 
subtelomeric DNA are also associated with increased levels of TERRA (Yehezkel 
et al., 2008). 
rDNA and telomeres:  specialized, transcribed repetitive regions of 
heterochromatin
Could ATRX and Daxx serve as specific H3.3 variant deposition machinery for 
specialized heterochromatin and repetitive regions such as telomeres and rDNA? 
What might telomeres and rDNA have in common? Transcription of both of these 
repetitive elements is subject to epigenetic regulation by DNA methyltransferases 
and histone modifying enzymes (Luke and Lingner, 2009; McStay and Grummt, 
2008). Although ribosomal RNA synthesis represents the majority of transcriptional 
activity in dividing cells, even in highly proliferative cells, a significant portion of rDNA 
is silenced (McStay and Grummt, 2008).  The ratio of active and silent rDNA clusters 
is regulated by chromatin modifying complexes, and these complexes promote 
distinct patterns of DNA methylation, histone modifications, and nucleosome 
positions at active and silent rDNA repeats (McStay and Grummt, 2008).  Similarly, 
subtelomeric regions and transcribed telomeric repeats share characteristics of 
heterochromatin, including DNA methylation of subtelomeric regions, H3K9me3 
and H4K20me3, and histone deacetylase activity (Blasco, 2007; Luke and Lingner, 
2009; Marion et al., 2009; Schoeftner and Blasco, 2009).
As originally established by Roeder and colleagues and described in Chapter 
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Figure 4.10:  Hypothetical model for Atrx/Daxx-mediated deposition of H3.3 at telomeres and 
ribosomal DNA
A. In wild-type ES cells, Atrx and Daxx mediate H3.3-contaning nucleosome replacement at 
telomeres and ribosomal DNA (rDNA).  Telomeric chromatin is depicted here, though a similar 
model would apply for rDNA.  The ATRX-DMNT3L-DNMT3A (ADD) domain of ATRX interacts 
with an unmodified or H3K9me3 histone tail to stabilize ATRX on chromatin.  Daxx interacts 
specifically with H3.3 as well as ATRX, and Daxx presents H3.3-H4 dimers to ATRX for deposition 
and nucleosome assembly.  rDNA and possibly telomeres are transcribed by RNA polymerase 
I (RNAPI).  The growing pink strand with UUAGG represents telomeric repeat-containing RNA 
(TERRA). Transcription evicts nucleosomes, which are replaced by H3.3-containing nucleosomes 
deposited by the actions of Atrx and Daxx.  It is possible that Atrx/Daxx-mediated deposition of 
H3.3 at telomeres and rDNA may be coupled to RNAPI transcription, though this hypothesis has 
not been tested. 
B.  In Atrxnull ES cells, nucleosomes are depleted at rDNA and telomeres by transcription.  In the 
absence of Atrx-Daxx-mediated nucleosome replacement, nucleosome density at telomeres and 
rDNA decreases, and aberrant spurious TERRA and rRNA transcription takes place.
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One, rDNA is transcribed by RNAPI (Grummt, 2003; McStay and Grummt, 2008; 
Roeder, 2003; Roeder and Rutter, 1969, 1970).  While RNAPII is believed to play 
a major role in TERRA transcription, various data also suggest that that another 
RNA polymerase (RNAPI or RNAPIII) could function in mammalian telomeric 
transcription (Luke and Lingner, 2009). As RNAPI is responsible for transcription 
of rDNA, it is therefore possible that Atrx-dependent H3.3 deposition at telomeres 
and rDNA may both be coupled to RNAPI-mediated transcription.  Like the RNA 
polymerases discovered by Roeder, distinct histone deposition complexes may 
be specialized to perform the same activity (H3.3 deposition) at distinct genomic 
regions.  How might ATRX-mediated deposition of H3.3 serve to repress telomeric 
and ribosomal RNA transcription?
In the absence of Atrx-mediated deposition of H3.3, transcribed telomeric 
and rDNA chromatin might acquire an inappropriately low nucleosome density, 
enabling aberrant upregulation of TERRA and rRNA (Figure 4.10). Just as 
H3K36me3 recruitment of histone deacetylases (HDACs) prevents spurious 
intragenic transcription from initiating within gene bodies (Carrozza et al., 2005; 
Joshi and Struhl, 2005; Keogh et al., 2005; Li et al., 2007b; Li et al., 2007c), Atrx-
mediated replacement of H3.3 containing nucleosomes may be required to prevent 
aberrant upregulated transcription of TERRA and rRNA. Indeed, recent experiments 
show a reduction in total histone H3 occupancy at the human rDNA promoter and 
transcribed region in alpha thalassemia and X-linked mental retardation (ATR-X) 
syndrome patient lymphoblastoid cells (Martin Law, Richard Gibbons, Douglas R. 
Higgs, personal communication).
Daxx as a potential H3.3 binding partner
While this thesis does not explore the role of Daxx, recent data from my laboratory 
colleagues Dr. Peter Lewis and Simon Elsaesser suggest that Daxx is likely to 
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play an important role in H3.3 deposition.  Like Atrx and Hira, Daxx is required 
for embryonic development, and loss of Daxx results in embryonic lethality by 
E9.5 (Michaelson et al., 1999; Salomoni and Khelifi, 2006).  Daxx is a ubiquitously 
expressed ~120 kDa protein with two predicted paired amphipathic helices, an 
acid-rich domain and a Ser/Pro/Thr (SPT)-rich domain (Hollenbach et al., 2002). 
Daxx is known to interact with many proteins in mammalian cells, including various 
transcription factors, and has been shown to function as a transcriptional repressor 
at specific TFBS (Chang et al., 2005; Croxton et al., 2006; Hollenbach et al., 
2002; Huang and Shih, 2009; Mizuta and Kuroda, 2004; Muromoto et al., 2006; 
Puto and Reed, 2008; Wethkamp and Klempnauer, 2009).  As we have seen in 
Chapter Three, the association between Daxx/ATRX and H3.3 is conserved in 
both undifferentiated ES cells and human cervical cancer (HeLa) cells.
The localization of Daxx has been shown to be developmentally regulated. 
Daxx is localized to promyelocytic leukemia (PML) bodies in differentiated human 
cells, but in undifferentiated human ES cells, Daxx localizes to specific foci that 
do not overlap with PML bodies (Butler et al., 2009). Intriguingly, Daxx has been 
specifically localized to the transcriptionally silenced XY body in mid to late stage 
pachytene spermatocytes (Rogers et al., 2004), as has H3.3 (van der Heijden et 
al., 2007). Notably, the timing of Daxx co-localization with the XY body actually 
coincides better with H3.3 (peaking in mid to late pachytene) than the timing of 
Hira localization with the XY body (early pachytene) (Rogers et al., 2004; van der 
Heijden et al., 2007).  Therefore, I speculate that Daxx may be required to mediate 
H3.3 deposition in the XY body.
My colleagues in the Allis laboratory are currently engaged in further studies 
of Daxx and H3.3.  Like Atrxnull ES cells, Daxx -/- ES cell are viable (Michaelson et 
al., 1999).  Therefore, Dr. Kyung-Min Noh and I have recently used the zinc finger 
nuclease method that I described in Chapter Two to generate Daxx -/- H3.3B / H3.3-
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Figure 4.11:  Clinical and molecular features of alpha-thalassemia and x-linked mental 
retardation syndrome
A.  Child of 8 yrs with the characteristic facial features of ATR-X syndrome. Note the upswept frontal 
hair line, hypertelorism, epicanthic folds, flat nasal bridge, small triangular upturned nose, tented 
upper lip, everted lower lip and hypotonic facies. In addition to characteristic facial dysmorphism, 
ATR-X syndrome is generally associated with profound developmental delay and mental retardation, 
genital abnormalities, and alpha thalassemia. Picture and legend adapted from (Gibbons, 2006). 
B.  ATRX mutations cluster in the highly conserved ADD domain and helicase domain.  Top portion 
represents a schematic diagram of the human ATRX gene: boxes represent the 35 exons; thin 
horizontal lines represent introns (not to scale). The 3’ and 5’ untranslated regions (utr) are shown 
flanking the open reading frame.  The locations of mutations described in boys with ATR-X syndrome 
are shown above the gene, and mutations described in ATMDS (myelodysplastic syndrome) are 
shown below the gene. The two protein products ATRX and the alternative splice product ATRXt are 
shown as rectangles. The principal domains, the zinc finger motif (ADD), and the highly conserved 
helicase motif are indicated, as are the P box (P) and a glutamine-rich region (Q). The lower part 
of B provides a graphical representation of the amino acid similarity between human and mouse 
ATRX proteins.  See (Gibbons et al., 2008) for more detail.
C.  The alpha-globin genes downregulated in ATR-X syndrome are located extremely near the 
telomere  of human chromosome 16.  The top of C. depicts a schematic of human chromosome 
16, with the telomeres and centromere indicated. A very small portion (red) near the telomere 
of chromosome 16 is enlarged below, with chromosomal coordinates, genes, CpG islands, and 
mammalian conservation indicated.  Data was downloaded from the UCSC genome browser.
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Figure 4.12:  Speculative model for spreading of telomeric heterochromatin in ATR-x 
syndrome
A.  In the presence of ATRX, H3.3-containing nucleosomes are incorporated at the telomere, 
subtelomeric DNA is methylated, TERRA transcription is regulated, and telomeres maintain localized 
characteristics of heterochromatin such as H3K9me3, HP1 binding, and H4K20me3.  Telomerase 
extends the telomere in pluripotent ES cells.
B.  In Atrxnull ES cells, and possibly in ATR-X patient cells, H3.3 containing nucleosomes are no 
longer enriched at telomeres.  Telomeric nucleosome density decreases, with aberrant increased 
transcription of TERRA.  As TERRA may inhibit telomerase (Luke and Lingner, 2009), it is also 
possible that telomeres may be slightly shorter in Atrxnull cells.  With increased TERRA, telomeric 
heterochromatin spreads to silence susceptible genes such as the alpha-globin locus near 
telomeres.
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HA-IRES-EYFP ES cells (data not shown). Future experiments will involve ChIP-
seq of these targeted Daxx -/- ES cells to examine the genome-wide localization 
of H3.3 in the presence and absence of Daxx.  Remarkably, recent biochemical 
experiments suggest that Daxx may serve as a direct H3.3 binding protein (S. 
Elsaesser and P. Lewis, unpublished data), and additional future studies will 
explore the specific role of Daxx and Atrx in nucleosome assembly using defined 
factors in vitro.
Potential implications for ATR-x syndrome pathogenesis
More speculatively, the results in this thesis raise the possibility that the pathogenesis 
of human ATR-X syndrome might involve an early developmental alteration in 
telomeric chromatin state.  
ATRX has been previously localized to heterochromatin, and the ATRX/Daxx 
complex has been shown to have chromatin remodeling activity (Tang et al., 2004; 
Xue et al., 2003). However, despite significant advances in the characterization 
of the ATRX protein and the specific mutations that occur in ATR-X syndrome, 
the molecular mechanisms underlying the pathogenesis of this syndrome remain 
a mystery (Gibbons, 2006; Gibbons et al., 2008; Higgs et al., 2005). Intriguingly, 
patients with ATR-X syndrome show a downregulation in alpha-globin gene 
expression, but not beta-globin gene expression, and human alpha globin genes 
are located near the telomere of human chromosome 16 (Higgs et al., 2005) 
(Figure 4.11). While it has been speculated that this chromosomal environment 
might be important for the pathogenesis of ATR-X syndrome (Higgs et al., 2005), 
this thesis is the first report to document that Atrx plays a role at telomeres.
One hypothesis is that Atrx-mediated telomeric deposition of H3.3 is required 
to prevent the spreading of heterochromatin and silencing of susceptible genes 
adjacent to telomeres in later development (Figure 4.12).  Better described in lower 
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eukaryotes, this phenomenon of silencing of telomere proximal genes is known as 
telomere position effect (Ottaviani et al., 2008) (Figure 4.12). In support of this 
hypothesis, in addition to the telomere proximal alpha globin genes downregulated 
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Figure 4.13:  Pluripotent embryonic stem cells give rise to chimeras and are competent for 
tetraploid complementation
A.  In conventional generation of mice from ES cells, diploid donor ES cells (green) are injected 
into diploid blastocysts.  The resulting mice are chimeras of the diploid donor ES cells and the 
pluripotent cells from the recipient blastocyst inner cell mass (pink).
B.  Tetraploid complementation provides a rapid method to generate fully ES-derived mice, but this 
procedure is only effective with healthy, pluripotent cells.  Two cell embryos are fused to generate 
a tetraploid cell (4N), and the resulting tetraploid blastocyst is injected with diploid donor ES cells 
(green).  Tetraploid cells of the blastocysts will only give rise to extra-embryonic tissues such as 
the placenta (blue), while injected diploid ES cells will give rise to the entire embryo (green).  See 
(Eggan et al., 2001; Meissner et al., 2009).
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in ATR-X human patients, the top two genes downregulated in a microarray analysis 
of Atrxnull mouse forebrain at E13.5 and P0.5 (Dhrsxy and Csf2ra) are located near 
telomeres (Levy et al., 2008). In the absence of Atrx, TERRA is upregulated, and 
TERRA has been associated with maintenance of the telomeric heterochromatin 
state (Luke and Lingner, 2009). Other histone variants (H2A.Z) in yeast have been 
shown to antagonize spreading of telomeric heterochromatin and the silencing of 
telomere adjacent euchromatin (Meneghini et al., 2003).  To test the hypothesis that 
spreading of telomeric heterochromatin may be important for ATR-X pathogenesis, 
future collaborative experiments will examine the chromatin state of telomeres and 
proximal telomeric regions in wild-type and Atrxnull ES cells, as well as patients 
with ATR-X syndrome.
Localization and function of H3.3B in mammalian development – recent 
progress towards a H3.3B-HA-IRES-EYFP mouse line
Given the nature of the genetic modifications that I have made to ES cells in order 
to track the localization of histone H3.3, it is important to determine whether or not 
these cells remain pluripotent.  Moreover, for future experiments, it is desirable 
to examine the genomic localization of H3.3 in differentiated mammalian tissues, 
as well as to establish the endogenous pattern of H3.3B expression. There are 
a variety of tests to determine the developmental potential of ES cells, including 
embryoid body formation, teratoma formation in immunocompromised mice, and 
the generation of chimeras following injection of ES cells into diploid blastocyst 
embryos (Meissner et al., 2009). The most rigorous test of pluripotency involves the 
injection of diploid ES cells into tetraploid blastocysts (Eggan et al., 2001; Meissner 
et al., 2009) (Figure 4.13).  As tetraploid cells can maintain extraembryonic tissues 
such as the placenta, but are largely incapable of giving rise to the embryo itself, 
the injected diploid ES cells will generate the entire embryo (Eggan et al., 2001; 
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Meissner et al., 2009) (Figure 4.13).
 In collaboration with Dr. Duancheng Wen and Dr. Shahin Rafii, heterozygous 
H3.3B / H3.3-EYFP and H3.3B / H3.3-HA-IRES-EYFP ES cells were injected into 
both diploid and tetraploid blastocysts.  Despite many attempts with several clones, 
H3.3B-EYFP ES cells generated pups with generally poor (<45%) chimerism (data 
not shown).  In addition, none of the of H3.3B / H3.3-EYFP chimeras was found to 
be capable of H3.3-EYFP germline transmission.  
It is possible that the poor chimerism and lack of germline transmission of 
H3.3B-EYFP ES cells could be due to a hypomorphic effect of the EYFP tag. The 
EYFP tag (238aa) is large relative to the H3.3 histone (135aa).  Although the data 
presented in Chapter Two indicate that genome-wide patterns of H3.3-EYFP are 
extremely similar to H3.3-HA, the bulky fluorescent tag could have resulted in a 
mild hypomorphic effect on nucleosome assembly or nucleosome interactions that 
A B
Blastocyst injections and in vivo experiments performed by Duancheng Wen and Shahin Rafii, and data used with permission.
Figure 4.14:  Generation of H3.3B-HA-IRES-EYFP mice
H3.3B / H3.3-HA-IRES-EYFP ES cells injected into diploid B6 blastocysts contribute to mice with 
high chimerism.  Most ES cells described in this study are B6 but maintained on a tyrosinase -/- 
background, and their coat color is therefore albino.
A. H3.3B / H3.3-HA-IRES-EYFP ES cells gave rise to a healthy mouse that is ~100% donor ES-
derived as judged by white coat color and genotyping.  In this case, the chimera is surprisingly from 
diploid blastocyst injection, but healthy H3.3B / H3.3-HA-IRES-EYFP mice were also obtained from 
tetraploid complementation.
B. Other mice from the same litter show significant chimerism.
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is manifested during development.  H2B-GFP fusions have been used in various 
lines of fertile mice (Hadjantonakis; Hadjantonakis and Papaioannou, 2004; Tumbar 
et al., 2004).  However, there is precedent for hypomorphic effects of a H3 family 
GFP fusion in vivo, following knock-in of a GFP tag fused to the H3 centromeric 
variant CENP-A (Kalitsis et al., 2003).  Although Cenpa-GFP heterozygous mice 
were completely healthy and fertile, Cenpa -GFP homozygotes died at E10.5 of 
embryonic development, with significant chromosome missegregation, aneuploidy 
and apoptosis (Kalitsis et al., 2003).
 Despite the lack of success with H3.3B-EYFP ES cells, recent injections of 
H3.3B / H3.3-HA-IRES-EYFP ES cells into diploid blastocysts yielded viable pups 
with extremely high chimerism from several different clones, with almost 100% ES 
contribution in one particular chimera (Figure 4.14).  In addition, several clones 
of H3.3B / H3.3-HA-IRES-EYFP ES cells also gave rise to healthy pups following 
complementation of tetraploid blastocysts, with 100% contribution from the tagged 
ES cells (D. Wen, data not shown).  These results are strong evidence for pluripotency 
of H3.3B / H3.3-HA-IRES-EYFP ES cells. Beyond tetraploid complementation, the 
only further test of pluripotency involves germline transmission.  Once old enough 
for breeding, these mice will be bred to establish a permanent H3.3B / H3.3-HA-
IRES-EYFP mouse line.
The establishment of H3.3B / H3.3-HA-IRES-EYFP mice opens up a wide 
array of experimental possibilities.  The localization of H3.3 during and following 
X chromosome inactivation (Chow and Heard, 2009) can now be assessed using 
female H3.3B-HA mouse embryos, female H3.3B-HA mouse ES cells, and somatic 
cells from adult female H3.3B-HA mice.  H3.3B / H3.3-HA-IRES-EYFP mice will also 
enable analysis of the developmental expression of H3.3B in vivo, a subject that 
has previously only been addressed through northern blots and in situ hybridization 
of select tissues (Bramlage et al., 1997).  Although I have profiled the genome-wide 
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localization of H3.3 in ES cells and NPCs, the establishment of H3.3B-HA mice will 
also allow us to profile the genome-wide localization of H3.3 in other embryonic 
and adult mammalian cell types, including derived cell lines as well as organs such 
as liver and brain (Meissner et al., 2008; Visel et al., 2009; Wederell et al., 2008). 
Multiple H3.3B-HA cell lines can be derived for ChIP-seq and immunofluorescence 
studies, including mouse embryonic fibroblasts, and spermatogonial stem cells 
(SSCs) (Seandel et al., 2007).  
Provided that H3.3B is expressed in primordial germ cells (PGCs), the 
role of H3.3 in germ cell specification during embryonic development can also 
be addressed, as previous studies of PGCs were hampered by the lack of a 
H3.3 antibody (Hajkova et al., 2008).  Moreover, the localization of endogenously 
expressed H3.3B in spermatogenesis can also be determined.  Could H3.3 
localization to the repressive XY body be dependent on Daxx, and not Hira (Rogers 
et al., 2004; van der Heijden et al., 2007)?  In addition, although most sperm 
chromatin is packaged in protamines, specific histone H3 modifications have been 
shown to mark particular developmental genes in sperm, and both H3.3 and H3.1 
have been found at lower levels in human sperm chromatin (Gatewood et al., 
1990; Hammoud et al., 2009).  Are these sperm H3 histone modifications carried 
on H3.3?  ChIP-seq from sperm isolated from H3.3B / H3.3-HA-IRES-EYFP mice 
could be used to address these questions.  Finally, the localization of endogenously 
expressed H3.3B in paternal pronuclear decondensation can also be addressed in 
mammals for the first time (Bonnefoy et al., 2007; Konev et al., 2007; Loppin et al., 
2005; Torres-Padilla et al., 2006).
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Figure 4.15:  Strategy for homozygous targeting of H3.3B
Left.  Zinc finger nucleases (ZFNs) in combination with H3.3B-HA-IRES-EYFP and H3.3B-HA-
IRES-mCherry donors enable homozygous targeting of H3.3B, via double-strand break (DSB) 
potentiated homologous recombination.  Exon coding sequences are thick rectangles, while non-
coding untranslated sequences are thin rectangles. The resulting EYFP and mCherry double-
positive cells have both H3.3B alleles fused to a C-terminal HA epitope tag, with an IRES and 
separately translated EYFP or mCherry reporter. 
Center.  A similar strategy can be used to enable homozygous addition of a destabilizing domain 
(DD) sequence (brown) as well as an HA epitope tag fused to the C-terminus of H3.3B. In the 
absence of shield ligand, DD-tagged H3.3B protein is degraded, but in the presence of shield 
ligand, H3.3B-DD-HA protein expression is maintained. For more details regarding destabilizing 
domains, see: (Banaszynski et al., 2006).
Right. A similar strategy can be used to generate a homozygous knockout of H3.3B, with full 
replacement of coding exons by EYFP and mCherry.
All of these cells can used with and without the addition of lentiviral shRNA vectors for H3.3A 
knockdown.
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Ongoing experiments to probe the function of H3.3 through H3.3B knockout, 
regulated protein expression, and H3.3A shRNA
Although H3.3B-HA-IRES-EYFP mice unlock a wide range of experimental 
possibilities, fundamentally these mice will only enable the tracking of epitope-
tagged H3.3B through development and differentiation. To determine the functional 
significance of H3.3, it is necessary to generate cellular models that reduce, 
eliminate, or regulate H3.3 protein expression.  Recent collaborative experiments 
with Dr. Laura Banaszynski in our laboratory provide significant progress towards 
this goal.
 Mammalian cells contain four alleles that code for H3.3, including two alleles 
of H3.3B and two alleles of H3.3A (Bramlage et al., 1997; Marzluff et al., 2002).  To 
target both copies of H3.3B, Dr. Banaszynski and I devised a strategy to modify my 
H3.3B +/+
H3.3A +/+
ES cells
H3.3B -/-
H3.3A shRNA
ES cells
Embryoid body formation
NPC differentiation
Neuronal differentiation
Teratoma formation
Chimera formation
Tetraploid complementation
Germline transmission
?
H3.3B DD / DD
H3.3A shRNA
ES cells
?+/- shield
Figure 4.16:  Experiments to assess the function of H3.3 in mammalian development and 
cellular differentiation
Wild-type H3.3B +/+ H3.3A +/+ ES cells are pluripotent, and are competent in all of the assays 
listed. The phenotypes of H3.3 ‘null’ (middle) or H3.3B-DD ‘rescue’ ES cells in these assays are 
unknown, and these experiments are currently underway.
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donor construct to include the red fluorescent protein mCherry in place of EYFP. 
Following transfection of cells with zinc finger nucleases and both EYFP and 
mCherry H3.3B donor constructs,  cells that become stably EYFP and mCherry 
double positive are likely to be doubly targeted at both H3.3B  alleles (Figure 4.15). 
This strategy can be used for homozygous tagging of H3.3B with epitope tags 
(Figure 4.15, left). In addition, Dr. Banaszynski modified my donor constructs to 
fuse a destabilizing domain to the C-terminus of H3.3B (Banaszynski et al., 2006). 
Such destabilizing domains (DD) were developed by Dr. Banaszynski during her 
graduate work, and they enable rapid, reversible, and tunable regulation of protein 
levels through the use of a small molecule  (Banaszynski et al., 2006).  Targeting 
of both H3.3B alleles with H3.3B-DD-HA-EYFP and H3.3B-DD-HA-mCherry donor 
constructs will allow total control over H3.3B protein expression (Figure 4.15, 
center).  To generate a full H3.3B knockout, I also modified my donor constructs 
to fully replace the coding exons of H3.3B with the open reading frame of EYFP 
and mCherry (Figure 4.15, right).  To knock-down expression of H3.3A, we have 
validated several lentiviral shRNA vectors that enable greater than 90% H3.3A 
mRNA knock-down (data not shown).
 H3.3 ‘null’ (H3.3B -/- + H3.3A shRNA, or H3.3B-DD-HA + H3.3A shRNA) 
ES cells have recently been established, and they are being used for a variety of 
experiments.  Preliminary experiments suggest that H3.3 null ES cells are viable, 
but display a mild growth defect in culture (data not shown). Most immediately, Dr. 
Banaszynski is examining the expression of rRNA and TERRA in the absence of 
H3.3. If the function of ATRX-mediated H3.3 nucleosome replacement at rDNA and 
telomeres is to repress transcription of these heterochromatic repeats, then loss 
of H3.3 may also lead to aberrant upregulation of rRNA and TERRA (Figure 4.10). 
In addition, my colleagues will use whole transcriptome profiling (RNA-seq) (Wang 
et al., 2009a) to examine whether loss of H3.3 leads to any global alterations in 
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transcriptional regulation.
To assess the function of H3.3 in mammalian development and cellular 
differentiation, wild-type and H3.3 null ES cells will be used in several experiments 
(Figure 4.16). In vitro cell differentiation assays will include embryoid body formation, 
retinoic acid differentiation, NPC formation, and differentiation into post-mitotic 
neurons (Conti et al., 2005).  In collaboration with Dr. Shahin Rafii’s laboratory, 
H3.3 null ES cells will also be injected into immunocompromised mice in teratoma 
formation experiments, as well into diploid and tetraploid blastocysts to assess the 
requirements for H3.3 in vivo (Figure 4.16).  In addition, Dr. Duancheng Wen has 
already generated chimeras from heterozygous H3.3B / H3.3B-KO-EYFP ES cells 
into diploid blastocysts (data not shown), and these chimeras will be bred with 
wild-type mice in an attempt to establish a heterozygous H3.3B +/EYFP line.
Perspective, predictions, future questions, and challenges
This thesis provides the first genome-wide profiles of histone H3 variants in 
mammalian pluripotent cells. My collaborators and I have shown that Hira is 
required for H3.3 deposition at genes, and we identify Atrx as required for Hira-
independent H3.3 deposition at telomeres and rDNA. Our data also suggest the 
existence of Hira and Atrx-independent specific machinery responsible for H3.3 
deposition at specific regulatory elements. Overall, the work presented in this 
thesis raises the prospect that distinct, region-specific chaperone and remodeling 
complexes mediate the targeting of a single histone variant (H3.3) to particular 
genomic regions.
These findings raise multiple questions. What is the function of H3.3 at 
these different genomic sites? Does H3.3 play a similar role at genes, TFBS, 
rDNA and telomeres? I predict that H3.3 has largely evolved to function in 
nucleosome replacement and ‘chromatin repair’ in a variety of genomic, cellular, 
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H3.3 replacement nucleosomes mediate
‘chromatin repair’ and maintain chromatin
dynamics.
In the absence of H3.3, RD H3.2 and H3.1 
nucleosome assembly partially rescues chromatin.
spurious transcripts?
H3.3
nucleosome
replacement
nucleosome
eviction
nucleosome
eviction
A
B
H3.2 / H3.1
Figure 4.17: Speculative model: the primary non-reproductive functions of H3.3 are 
nucleosome replacement and chromatin repair at regions of chromatin disruption
A. In wild-type cells, nucleosome replacement with H3.3-containing nucleosomes enables 
‘chromatin repair’ at regions of chromatin disruption, while the intrinsic instability of H3.3-containing 
nucleosomes also promotes dynamic chromatin. At regions of chromatin disruption such as genes 
and regulatory elements, H3.3 containing nucleosomes strike an ideal balance between overly 
exposed naked DNA and overly stable H3.2 or H3.1 nucleosomes.
B.  In the absence of H3.3, nucleosome replacement at regions of chromatin disruption is impaired. 
Nucleosome replacement and chromatin ‘rescue’ can be partially mediated by H3.2 or H3.1 
containing nucleosomes, most likely through replication-dependent (RD) nucleosome assembly 
(Sakai et al., 2009). However, nucleosome replacement in mammalian cells may be inadequate in 
the absence of H3.3. Loss of H3.3 could potentially result in progressive defects such as spurious 
transcripts, particularly in post-mitotic cells that lack the capacity for RD nucleosome assembly.
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and developmental contexts, and that this nucleosome replacement function 
is critically important in the large-scale chromatin remodeling that takes place 
during specific developmental transitions in multicellular organisms (Orsi et al., 
2009).  In addition, recent data shows that H3.3-containing nucleosomes are 
more sensitive to salt-sensitive disruption than H3.1-containing nucleosomes, 
suggesting intrinsic differences in stability that could reduce the energy required 
for nucleosome mobilization (Jin and Felsenfeld, 2007).  Therefore, it is likely that 
H3.3 nucleosomes do not only serve a replacement function, but also contribute to 
chromatin dynamics (Figure 4.17).
What is the function of H3.3 in mammalian development?  Recent studies 
have shown that H3.3 plays a role in Drosophila transcription regulation, and is 
essential for fly fertility (Hodl and Basler, 2009; Ng and Gurdon, 2008; Sakai et al., 
2009).  As lower levels of H3.3A already lead to partial neonatal lethality, fertility 
defects, and neuromuscular deficits in mice (Couldrey et al., 1999), it is likely that 
H3.3 many play an even more important role in mammals.  Do cellular requirements 
for H3.3 differ in dividing versus post-mitotic cells, where replication-independent 
deposition might play a larger role? 
Recent studies from yeast may be informative regarding the possible 
phenotypes of H3.3 deletion.  The yeast homologs of HIRA also play a role in 
replication-independent histone deposition, and localize to transcribed regions in S. 
cerevisiae (Green et al., 2005; Nourani et al., 2006).  Intriguingly, the S. pombe HIRA 
homologs were recently shown to be required for genome-wide promoter silencing 
and for the repression of cryptic antisense transcripts (Anderson et al., 2009).  The 
HIRA complex has therefore been proposed to restore chromatin structure in the 
wake of RNAPII (Anderson et al., 2009). Intriguingly, H2A.Z has also recently been 
observed to suppress spurious antisense transcripts in S. pombe (Zofall et al., 
2009). Therefore, I predict that H3.3 containing nucleosomes may also serve to 
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replace nucleosomes disrupted by a variety of processes, including transcription 
and transcription factor binding, and that this ‘chromatin repair’ function of H3.3 
may be critical for the repression of spurious transcripts (Figure 4.17). It is likely 
that such a ‘chromatin repair’ function of H3.3 would be particularly important for 
post-mitotic cells that are incapable of RD histone deposition during S-phase.
The surprising finding that distinct factors are required to deposit H3.3 at 
specific genomic regions also raises many questions.  How are Hira and Atrx 
targeted to specific genomic regions?  Neither Hira nor Atrx have been shown 
to interact directly with transcription machinery, and significant work remains 
regarding the recruitment of these complexes to distinct regions.  It is likely that 
like many chromatin-mediated processes, the targeted recruitment of Hira and Atrx 
may depend significantly on an interaction with site-specific DNA binding factors 
(Farnham, 2009).  As Daxx interacts with multiple transcription factors (Chang et 
al., 2005; Croxton et al., 2006; Hollenbach et al., 2002; Huang and Shih, 2009; 
Mizuta and Kuroda, 2004; Muromoto et al., 2006; Puto and Reed, 2008; Salomoni 
and Khelifi, 2006; Wethkamp and Klempnauer, 2009), it is possible that Daxx-
mediated interaction with both H3.3 and cell-type specific TFs may be important 
for targeting of H3.3 to specific regions.  
Finally, what is the mechanism by which H3.3 is deposited?  Despite the 
biochemical requirement of Hira for replication-independent nucleosome assembly, 
we have very little insight into how Hira, much less Atrx and Daxx, mediate H3.3 
deposition into chromatin.  Is Atrx-mediated deposition of H3.3 also replication-
independent, like Hira, or does it occur during replication?  Why are there site-
specific mechanisms that deposit H3.3 at transcribed sequences, TFBS, rDNA and 
telomeres?  Many of these questions regarding the mechanism of H3.3 deposition 
are the subject of active work by my laboratory colleagues, and I am confident that 
we can look forward to significant advances in the near future.
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Overall, the data presented in this thesis make clear that the existing paradigm 
of Hira-dependent deposition of H3.3 is too simplistic for mammalian cells. While 
many questions remain, these findings lay the groundwork for a more nuanced 
understanding of H3 variants in mammalian cells, and provide a foundation for 
future studies of H3.3 in mammalian development.
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CHAPTER 5
MATERIALS AND METHODS
Mouse embryonic stem cells
The parental “C6” embryonic stem (ES) cell line was derived from tyrosinase 
-/- (white, albino) homozygous mouse embryos of B6(Cg)-Tyrc-2J/J C57BL/6J 
background.  http://jaxmice.jax.org/strain/000058.html  The parental “965” ES line 
is an F1 hybrid 129SVJae x M. m. castaneus (Eggan et al., 2001; Mikkelsen et al., 
2007), and was a gift from Dr. Rudolf Jaenisch.  Parental W9.5 and Hira -/- (cl34) 
ES cells were a gift  from Dr. Peter Scambler, and have been described previously 
(Meshorer et al., 2006).  Parental Atrxflox and Atrxnull ES cells were a gift from Drs. 
David Garrick, Richard Gibbons, and Douglas Higgs, and have been described 
previously(Garrick et al., 2006). 
ES cell culture and neural precursor cell differentiation
Undifferentiated mouse ES  cells were cultured under standard conditions in the 
presence of leukemia inhibitory factor (LIF) (Meissner et al., 2009).   For early 
passages, undifferentiated ES cells were maintained on a feeder layer of mitomycin 
C treated or irradiated mouse embryonic fibroblasts (MEFs) in standard ES cell 
media, KO-DMEM (Invitrogen 10829-018), 2mM L-glutamine (Sigma G7513) 
and pen-strep, 15% ES grade fetal bovine serum (Gibco 10439-024), 10-4 mM 
2-mercaptoethanol, and leukemia inhibitory factor (LIF) (Meissner et al., 2009).  To 
remove feeders for ES cell whole cell extracts, chromosome spreads, chromatin 
immunoprecipitation, and NPC differentiation, ES cells were passaged at least 
two passages off of feeders on to gelatin-coated plates.  Neural precursor cell 
(NPC) differentiation was performed as described (Conti et al., 2005).  NPCs 
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were cultured and expanded on gelatin-coated plates in NeuroCult® NSC Basal 
Medium (Mouse, Stem Cell Technologies, cat#05700) supplemented with 2mM 
final L-glutamine and pen-strep (Omega Scientific PG-30), modified N2 supplement 
freshly prepared in house as described (Conti et al., 2005), and 10ng/ml of both 
mouse EGF (Peprotech 315-09) and human FGF-2 (Peprotech 100-18B).
Zinc finger nuclease design, targeting, and verification
Zinc finger nucleases (ZFNs) directed against the mouse H3.3B (h3f3b) gene 
were designed using an archive of validated two-finger modules (Doyon et al., 
2008; Urnov et al., 2005).  Zinc finger nucleases (ZFNs) were designed against 
a region immediately upstream of the H3.3 stop codon (see Figure 2.2), since 
gene conversion tracts from DSBs induced by I-SceI (Elliott et al., 1998) and by 
ZFNs in somatic mammalian cells are rather narrow.  My goal was to both tag 
the native H3.3B open-reading frame (ORF) at the C-terminus (Figure 1B) as 
well as co-convert the H3.3B coding region to a H3.2 or H3.1 allelic form (Figure 
S1D-E).  ZFNs were designed using an archive of validated two-finger modules 
(Doyon et al., 2008; Shukla et al., 2009; Urnov et al., 2005), assembled using a 
PCR-based method, cloned into expression vectors and validated as described 
(Urnov et al., 2005). The ZFNs used carried obligate heterodimer forms of the FokI 
endonuclease (Miller et al., 2007).  ZFN target sequences and the recognition 
helices are provided below.
Locus ZFN Binding Sequence (underlined) ZFN Finger 1 Finger 2 Finger 3 Finger 4
h3f3b #25000#25001
GACATCCAGTTGGCTCGCCGGATACGGGG
CTGTAGGTCAACCGAGCGGCCTATGCCCC
RSDHLSE 
DRSALSR 
RNDTRKT 
TSANLSR 
QSSNLAR 
RSDVLSE
RSDDRKT
QRNHRTT
ZFN target site and designed zinc finger helices sequences
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H3.3B EYFP and HA-IRES-EYFP donor plasmid construction
Briefly, a PCR fragment of genomic DNA from mouse H3.3B was cloned out of a 
genomic bacterial artificial chromosome (BAC) from C57BL/6J mouse chromosome 
11 using Phusion polymerase (NEB F-530L) and into a pCR2.1 vector (pCR2.1-
H3.3B) using TA-TOPO cloning (Invitrogen K4500-02).  To generate the H3.3B-
EYFP donor construct (pCR2.1-H3.3B-EYFP), a 6 amino acid (SRPVAT) linker 
(Ahmad and Henikoff, 2002) followed by the open-reading frame of EYFP 
(Clontech) was inserted in-frame into the last coding exon of H3.3B, using ligation-
independent cloning  (LIC) (Geiser et al., 2001) The H3.3B-EYFP donor included 
no H3.3B promoter sequence, containing approximately 0.6kb of 5’ homologous 
genomic sequence starting at the second H3.3B codon, including introns, until 
the last H3.3B coding amino acid, followed by the linker and EYFP, a stop codon, 
and approximately 1.3kb homologous to the H3.3B 3’UTR (see Figure 2.4).   To 
generate the H3.3B-HA-IRES-EYFP construct (pCR2.1-H3.3B-HA-IRES-EYFP), a 
C-terminal HA-IRES sequence was cloned out of the vector pMSCV-F-del Casp9.
IRES.GFP (Straathof et al., 2005), Addgene Plasmid 15567, and inserted in-frame 
using LIC into the pCR2.1-H3.3B-EYFP vector.  To generate H3.2-EYFP, H3.1-
EYFP, H3.2-HA-IRES-EYFP, and H3.1-HA-IRES-EYFP donors, point mutations 
were made in pCR2.1-H3.3B-EYFP and pCR2.1-H3.3B-HA-IRES-EYFP using the 
Quick-Change Mutagenesis II kit (Stratagene).
ZFN targeting and verification
To deliver ZFNs and donor constructs, mouse ES cells were transfected by Amaxa 
nucleofection.  In brief, immediately prior to transfection, ES cells were feeder 
depleted by harvesting the ES cells, plating on a feeder-free dish for 30min, and 
then collecting the ES-enriched non-adherent cells for transfection.  2-5*10^6 
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cells ES cells were resuspended in 90μl solution, mixed with two non-linearized 
plasmids (1 μg of ZFN plasmid with both ZFNs separated by a 2A peptide sequence 
+ 10μg of donor plasmid) in 10μl nucleofection solution, and transfected using 
program A-013 as described in the Amaxa manufacturer’s protocol for mouse 
ES cells.  Following transfection, we used sterile plastic pipettes to transfer the 
cells to warm ES media in tissue culture dishes that were already prepared with 
feeders.  After transfer, ES cells were cultured in standard conditions on treated 
feeders for 3-5 days prior to fluorescent activated cell sorting (FACS) (Figure 2.3, 
2.5) or fluorescent colony picking.  Following colony picking, clonal isolation and 
expansion, we prepared genomic DNA using the Qiagen DNeasy Blood & Tissue Kit 
(Qiagen 69504).  Individual clones were screened by PCR using a forward H3.3B 
primer (TTGGTGGAGTATCTGCCCGTTCTG) outside of the donor construct and 
reverse primer (GTTCTTCTGCTTGTCGGCCATGATA) within EYFP (see Figure 
2.6).  To verify that the wild-type H3.3B allele remained intact, we also amplified 
both H3.3B alleles by using the same forward primer above, and a reverse primer 
(TGAAGCCAACCTGCTGCTCTACAGT) outside the donor construct, performed 
gel electrophoresis, and isolated the smaller band corresponding to the wild-type 
H3.3B allele (data not shown).  PCR products from both wild-type and modified 
H3.3B alleles were sequenced using standard methods (Figure 2.6).  To confirm 
heterozygosity, we used the primers described above to sequence both H3.3B 
alleles from all ES lines used in this study.  For further confirmation of heterozygosity, 
we performed Southern blotting on a subset of the ES lines.  To perform Southern 
blotting, we digested genomic DNA from wild-type and targeted ES cells with 
BsrBI, and used a labeled 638bp AvaII fragment of the H3.3B donor as probe to 
visualize wild-type H3.3B and integrated H3.3B donors.  All targeted C6 ES lines 
used for manuscript were found to be pure heterozygotes (Figure 2.6).  The hybrid 
H3.3-HA ES line and the Hira -/- H3.3-EYFP ES lines were heterozygous, with one 
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H3.3B allele targeted, but also had additional donor integrations by Southern blot. 
Western blot analysis indicates that the hybrid ES H3.3-HA is not overexpressed 
relative to the pure heterozygote hybrid H3.1S31-HA ES line (data not shown), and 
global patterns of H3.3 were extremely similar to patterns in the pure heterozygous 
C6 H3.3-HA and H3.3-EYFP ES lines.  H3.3-HA and H3.2-HA ES cells were also 
fully karyotyped, and found to have normal male mouse karyotypes (data not 
shown).
RT-PCR
Total RNA from ES cells and NPCs was isolated using TRIzol Reagent 
(Invitrogen) or RNeasy (Qiagen). 1μg of RNA from each sample was used to 
generate cDNA using the Superscript First-Strand Synthesis kit (Invitrogen). 
Real-time PCR was performed with SYBR Green PCR master mix (Applied 
Biosystems) according to the manufacturer’s instructions.  Pooled cDNA was 
used to generate a standard curve from which the relative amount of cDNA 
amplified in each sample was determined as indicated.  Primer sequences for 
RT-PCR are as follows.  Gapdh_F: GGTTGTCTCCTGCGACTTCAACAGC, 
Gapdh_R: CGAGTTGGGATAGGGCCTCTCTTGC (Chew et al., 
2005), Pou5f1 _F: TTGGGCTAGAGAAGGATGTGGTT, Pou5f1 -
_R: GGAAAAGGGACTGAGTAGAGTGTGG (Chew et al., 2005), 
Nanog_F: CCTCTTCAAGGCAGCCCTGATTCT, Nanog_R: 
AGAGTTCTTGCATCTGCTGGAGGCT, Olig1_F: GCTCGCCCAGGTGTTTTGT, 
Olig1_R:  GCATGGAACGTGGTTGGAAT (Boyer et al., 2006), h3f3a_F: 
ACAAAAGCCGCTCGCAAGAG, h3f3a_R: ATTTCTCGCACCAGACGCTG, 
h3f3b_F: TGGCTCTGAGAGAGATCCGTCGTT, h3f3b _R: 
GGATGTCTTTGGGCATGATGGTGAC, 
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Flow cytometry
FACS and analysis was performed on a BD FACSAriaII-2. In brief, ES cells were 
trypsinized and gently separated to single cells for FACS, and resuspended in 
PBS + 5% ES quality FBS (Gibco 10439-024). FACS collection tubes were pre-
coated with ES quality FBS for at least 30 minutes prior to the sort. To prevent 
clumping during the sort, cells were gently filtered into a single cell suspension 
through a cell-strainer mesh (Polystyrene Round-Bottom Tube with Cell-Strainer 
Cap, Falcon #352235).  Following sort, cells were immediately plated on feeders 
with ES media.
Isolation of protein complexes and mass spectrometric analysis
Immunoaffinity purications of GFP-tagged H3.3, H3.2, H3.1, H3.3 HIRA-/-, and 
H3.2 HIRA -/- were performed as previously described (Cristea et al., 2005), and 
MALDI MS and MS/MS analyses were performed as described (Luo et al., 2009). 
Briefly, for each isolation, ~2.5g cryogenically ground cells were extracted in 9 ml 
of 20 mM K-HEPES, pH 7.4, 110 mM K-acetate, 0.1% Tween 20, 0.5% Triton, 300 
mM NaCl, and 1/100 (v/v/) protease inhibitor cocktail (Sigma-Aldrich). Resulting 
cell homogenates were incubated with 12 mg M-270 epoxy magnetic beads (Dynal, 
Oslo, Norway), conjugated with in-house developed rabbit polyclonal anti-GFP 
antibodies (5µg antibodies/mg beads) for one hour at 4°C. Isolated proteins were 
eluted in 700 µl 0.5N NH4OH, 0.5mM EDTA for 20 minutes at room temperature, 
dried by vacuum centrifugation, suspended in protein electrophoresis sample buffer, 
resolved by 1-D SDS-PAGE (4–12% NuPAGE Novex Bis-Tris gel, Invitrogen), and 
stained with Coomassie Blue (GelCode Blue, Pierce). The entire gel lanes were cut 
into sections (~30 sections per gel lane), and proteins were digested with 12.5ng/
μl sequencing grade modified trypsin (Promega, WI, USA). Resulting peptides 
were extracted on reverse phase resin (Poros 20 R2, PerSeptive Biosystems), 
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eluted in 2 mg/ml α-cyano-4-hydroxycinnamic acid, 70% (v/v) acetonitrile and 0.1% 
(v/v) trifluoroacetic acid, and deposited onto an in-house made magnetic MALDI 
target, as described (Blethrow et al., 2007). MALDI MS and MS/MS analyses 
were performed using prOTOF (Perkin Elmer), vMALDI LTQ XL (Thermo Electron, 
Bremen, Germany), and MALDI LTQ Orbitrap XL (Thermo) mass spectrometers, 
as described (Blethrow et al., 2007; Luo et al., 2009). Protein candidates were 
identified by database searching against the most recent version of the National 
Center for Biotechnology Information nonredundant protein database using the 
XProteo computer algorithm (http://www.xproteo.com). The MS/MS CID data was 
acquired and interpreted manually to confirm the candidate peptides.
Antibodies
Antibodies used for western blotting, immunofluorescence, and ChIP-seq were 
as follows.  H3K4me1 (Abcam ab8895), H3K4me3 (Abcam ab8580), H3K27me3 
(Upstate/Millipore #07-449), H3K36me3 (Abcam ab9050), C-terminal H3 (Abcam 
ab1791), anti-HA (mouse monoclonal 12CA5, western and ChIP-seq), anti-HA 
(mouse monoclonal HA.11, Covance MMS-101R, immunofluorescence), Oct-3/4 
(BD Biosciences 611202), affinity-purified rabbit polyclonal anti-GFP (Cristea et 
al., 2005), Ldha (Santa Cruz H-160, sc-33781), Atrx (mouse monoclonal 23c) 
(McDowell et al., 1999). The mouse monoclonal antibody to the RNA polymerase 
CTD phosphorylated on Ser5 CTD4H8 (Upstate/Millipore #05-623) was raised 
against a chemically synthesized phospho-Ser 5 peptide sequence from the CTD 
of the largest RPB1 subunit of RNAPII, and has been extensively characterized 
previously (Stock et al., 2007). The anti-Nestin hybridoma (Rat-401) developed by 
Susan Hockfield was obtained from the Developmental Studies Hybridoma bank 
developed under the auspices of the NICHD and maintained by the University of 
Iowa, Dept. of Biological Sciences, Iowa City, IA 52242.  Mouse monoclonal anti-
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HA (12CA5) antibody was a gift from Dr. Christina Hughes, and mouse monoclonal 
anti-Hira (WC119) antibody was a gift from Dr. Peter Adams.
Cellular extract preparation and metaphase chromosome spreads
Whole cell extracts were prepared by resuspending cell pellets in SDS-Laemmli 
sample buffer, followed by brief sonication and boiling. Chromosome spreads were 
performed as described (Perez-Burgos et al., 2004).
Gene expression analysis of wild-type and Hira -/- ES cells
RNA expression data for W9.5 and Hira -/- ES cells was generated from polyA 
RNA and random primers using the GeneChip Mouse Gene 1.0 ST Array kit 
(Affymetrix).
TERRA analysis
RNA was isolated using RNeasy Mini Kit (Qiagen), and TERRA analysis was 
performed as described (Azzalin et al., 2007; Sfeir et al., 2009).
Peptide pull-downs and protein expression
Histone peptide pull-downs were performed as described (Ooi et al., 2007). 
Recombinant ATRX ADD domain was a gift from Dr. Daniela Rhodes (Argentaro et 
al., 2007), DNMT3L was a gift from Dr. Emily Bernstein (Ooi et al., 2007).  WDR5 
plasmid was a gift from Dr. Alex Ruthenburg, and recombinant WDR5 protein was 
expressed as previously described (Ruthenburg et al., 2006).  
ChIP and ChIP-seq
Crosslinking and native ChIP were performed as described (Barski et al., 2007; 
Lee et al., 2006), with minor modifications as described in Appendix A.  Please 
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see Appendix A for detailed native and crosslinking ChIP and ChIP-seq methods 
and protocols.  Purified ChIP DNA was used for cluster generation on Illumina/
Solexa flow cells, and sequencing analysis was performed on an Illumina/Solexa 
Genome Analyzer 2 following manufacturer protocols.  Primer sequences for ChIP 
validation are listed in Table 5.1.   Table 5.2 lists ChIP-seq assays performed and 
total tag# for each experiment.
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Genomic position Description H3.3 
enrich-
ment
Forward primer Reverse primer Primer 
sequence 
previously 
published
chr7:25668795-
25669006
Rps19-1 3.39 TGGGGGATCATGAGT-
TCAAAGCC
TGCCGGAGTCTGGT-
TGTTCA
chr7:25669207-
25669375
Rps19-2 2.18 GCCACATGTCATAGTGC-
CTTTTCCC
CGGGAACAAGGAGGCG-
GAAA
chr7:25669916-
25670076
Rps19-4 4.64 TGAGGGAGCGGGGTGTG-
GAG
CGTCGCCAGTCCAC-
CCCAAA
chr7:25671099-
25671315
Rps19-5 9.68 ATGTCCACGGGATCCA-
CTTTGTTTC
TGCACGCTTGCTTC-
CAAGAG
chr7:25672343-
25672506
Rps19-6 17.03 GCTGTCTTGCTGCTTA-
CAGCCTCTAAATAG
TGCAATGGGGAT-
TCTAGCCG
chr7:25674153-
25674369
Rps19-7 17.69 TCTGCAGAGTGAGTGCCA-
GGACTATACA
CCATCCCAAGCTGTG-
TAAACCTGG
chr7:25674989-
25675167
Rps19-8 18.19 TTGTCCTCAAGACACCAGT-
GGAGCT
ATCTGCTCAACCGCACT-
TGG
chr7:25675686-
25675847
Rps19-9 7.46 AATTCCAGCTCCTAGT-
TCGTTGGGA
AACCCCCTTCCAT-
GAGCTTG
chr5:143667188-
143667378
Actin-3 6.15 TTGATAGTTCGCCATGGAT-
GACGA
ATCGATCCCCAA-
GAAAACCCCA
chr5:143665065-
143665289
Actin-5 3.75 TTAAAAACTGGAACGGT-
GAAGGCG
ATGGACGCGACCATC-
CTCCTCTTA
chr5:143664523-
143664714 
Actin-6 17.39 TGGGCTAGGCCTTGCTGAT-
GGTAT
TGCAGATGGAG-
GCAAAGGGT
chr5:143664113-
143664319
Actin-7 17.57 AGCTCCAGCCTTTGT-
CAGTCGTGA
TTGTTTGGGTGGGT-
GAAGGG
chr5:143663236-
143663455
Actin-8 16.62 GTAACAGAGGCCCAGGTAA-
CACAGACA
TGGCAAAGATG-
GAAGGCGCA
chr17:35640919-
35641088
Oct4-4 11.84 GGAACTGGGTGTGGGGAG-
GTTGTA
AGCAGAT-
TAAGGAAGGGCTAGGAC-
GAGAG
Chew et al. 
2005
chr17:35644291-
35644494 
Oct4-10 5.62 GGAGTCCCCTAG-
GAAGGCATTAATAGTTT
GGATTCTCTCGGCTTCA-
GACAGACTTT
Chew et al. 
2005
chr17:35646759-
35646950
Oct4-12 13.88 CCCTTCCAGAGC-
CCCTTTCAGTAA
GCACCAGGGTCTC-
CGATTTGCATA
chr6:122660079-
122660280
Nanog-6 4.48 TCTGCTGCCTAAGCTCT-
TGTGCTGT
CTGCTCTTTCCAATC-
CCTTCTCCC
chr18:11051739-
11051976
Gata6 5.54 CCTTCCCATACACCACAACC CCCCTCCTTCCAAAT-
TAAGC
Boyer et al. 
2006
chr15:40487513-
40487666
Zfpm2 6.47 GGATGAAGTTCTCAGAGCT-
GGT
GCGCGAACTTTTACAC-
CTACTT
Bernstein et 
al. 2006
chr3:87773491-
87773703 
Nestin-4 1.64 TTTGCTATGTAGAGGCTG-
GCCTCAA
GCATGGTGCACCTGTA-
CACACACA
chr3:87774987-
87775219
Nestin-6 3.75 TCAGCTCGCTGCTGGAATC-
CTCCG
TGCTCCTCCAGCGTCT-
TGACCC
chr3:87781155-
87781365
Nestin-10 1.50 ATGAGACCCAGGGTTCAT-
TGAGGC
TCGTTCTCTAGCTT-
GCTCTCAGCCA
chr5:130137827-
130138046
TF5-2 10.78 ACTACCCCATTGTG-
GCAGTCGATG
GATGGCACA-
CAAAAGGAAGCATGG
chr5:130139506-
130139707
TF5-4 12.51 TGTGATGGCAGAATGCT-
CAATCCTG
GAGCCAAATGAAC-
CTTTTCCTCCC
Table 5.1:  Real-time PCR primers and validation of ChIP-seq
Sequence of forward and reverse primers and mouse genomic position (mm9) is provided.  Data 
is presented as fold enrichment over chr8 intergenic (%input at location / % input at intergenic). 
Primers with Hira-independent enrichment of H3.3 (TFBS and rDNA) are indicated in bold.
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chr2:172342091-
172342310
TF2-4 10.13 TGGCGGCTAGAGCTTCTT-
TAATGCA
TCGAAATCTCCGCCTGC-
CAA
chr1:72275693-
72275847
TF_Oct4-43 10.34 GCAATGGTTAAGCGAGGT-
TACAGGAACACA
AACCCTAAGGCCAG-
GATGGTCAGTAG
Chen et al. 
2008
chr1:182854966-
182855138
TF_Nanog-34 7.46 GGGGAAATACAGTAATT-
GACCAATCAGC
CCAAGACCACCAAAGT-
TCCACCTACCCTCA
Chen et al. 
2008
repeat rDNA_90F_146R 3.42 CTTTTTACTGGCTTG-
GGTCTGTCG
GGAAGCGTGGCTCG-
GGGAC
repeat rDNA_743F_811R 2.17 CTCTTCTCGTTCTGCCA-
GCG
TGCCTTCCACACAC-
CACCG
repeat rDNA_2801F_2860R 1.90 CGAGGGCAAAGGGAAA-
GAGGC
CAACAGACCACCACAC-
CGTCG
repeat rDNA_5319F_5451R 4.41 GATTCCGTGGGTGGTG-
GTGC
AGAAGTTGGGGGACGC-
CGAC
repeat rDNA_6007F_6060R 1.64 AAGGGGTGGGTGGGGTCG AGGGGAAATCGGAG-
GCGG
repeat rDNA_6814F_6878R 1.80 GGTCGTTGGGGGACTGT-
GCC
CGTATCGGTATTTCG-
GGTGTGAGC
repeat rDNA_7147F_7200R 1.20 GGCGGTTGTCGGTGTGGC GGCGGAGCGGGAA-
GAAGC
repeat rDNA_9752F_9862R 2.99 CGGGCGTGGAATGC-
GAGTG
GGGGTCTGAT-
GAGCGTCGGC
repeat rDNA_13366F_13419R 1.40 GTGTGGAGGCGGAGAG-
GGTC
TTGGGGGGGAAAAAAT-
GGAAG
chr1:136431721-
136431906
TF_Nanog-37 9.16 TTCAAAACCTTTTCTAATGT-
TAAGTATGGG
GCAGGCTAAAACAATTG-
GTGCTCTGACATC
Chen et al. 
2008
chr4:135702804-
135702993
TF_Nanog-36 (lincRNA) 7.75 ACACCTACGAGGCATTAT-
TAAGCTAATTCC
GCCCATAAATGATTACAA-
CAGCAGACTAA
Chen et al. 
2008
repeat MajSat 1.17 GACGACTTGAAAAATGAC-
GAAATC
CATATTCCAGGTCCT-
TCAGTGTGC
Martens et 
al. 2005
repeat MinSat 1.03 CATGGAAAATGATAAAAACC CATCTAATATGTTCTA-
CAGTGTGG
Martens et 
al. 2005
Table 5.1 continued
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sample number ChIP, method, cell-type 
as listed in Figure S5
Antibody GEO sample name Tag-
Size
totalRead MappedRead
1 H3.3-HA, x-link, H3.3-
HA ES
anti-HA 
(12CA5)
ES_H33_HA_antiHA_
xChIPSeq
36 9035477 5459510
1 H3.3-HA, x-link, H3.3-
HA ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 7879052 3746969
1 H3.3-HA, x-link, H3.3-
HA ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
35 6936913 4505457
2 H3K36me3, x-link, H3.3-
HA ES
H3K36me3 
(Abcam 
ab9050)
ES_H33_HA_
H3K36me3_xChIPSeq
36 6022772 3521419
3 H3K4me1, x-link, H3.3-
HA ES
H3K4me1 
(Abcam 
ab8895
ES_H33_HA_
H3K4me1_xChIPSeq
36 9101416 6203945
4 RNAPII CTD4H8, x-link, 
H3.3-HA ES
RNAPII 
CTD4H8 
(Upstate/
Millipore 
#05-623)
ES_H33_HA_RNAPII_
CTD4H8_xChIPSeq
36 10380059 5466893
5 H3.2-HA, x-link, H3.2-
HA ES
anti-HA 
(12CA5)
ES_H32_HA_antiHA_
xChIPSeq
36 7175197 4189238
5 H3.2-HA, x-link, H3.2-
HA ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
35 7662575 4667154
5 H3.2-HA, x-link, H3.2-
HA ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 8022943 3754658
6 H3K36me3, x-link, H3.2-
HA ES
H3K36me3 
(Abcam 
ab9050)
ES_H32_HA_
H3K36me3_xChIPSeq
36 8258652 4128488
7 H3.3-HA, x-link, H3.3-
HA NPC
anti-HA 
(12CA5)
NP_H33_HA_antiHA_
xChIPSeq
36 10468958 6374820
7 H3.3-HA, x-link, H3.3-
HA NPC
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
35 6507833 4593473
7 H3.3-HA, x-link, H3.3-
HA NPC
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 8474427 4224225
8 H3K36me3, x-link, H3.3-
HA NPC
H3K36me3 
(Abcam 
ab9050)
NP_H33_HA_
H3K36me3_xChIPSeq
36 6099447 4124703
9 H3K4me1, x-link, H3.3-
HA NPC
H3K4me1 
(Abcam 
ab8895)
NP_H33_HA_
H3K4me1_xChIPSeq
36 10408633 6652275
10 RNAPII CTD4H8, x-link, 
H3.3-HA ES
RNAPII 
CTD4H8 
(Upstate/
Millipore 
#05-623)
NP_H33_HA_RNAPII_
CTD4H8_xChIPSeq
36 10340552 4836974
11 H3.2-HA, x-link, H3.2-
HA NPC
anti-HA 
(12CA5)
NP_H32_HA_antiHA_
xChIPSeq
36 8424873 3587825
Table 5.2:  Summary of ChIP-seq experiments
ChIP-seq method, cell type, antibody, and read numbers are indicated. Data correspond to files 
deposited in GEO (late 2009, accession number GSE16893).
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11 H3.2-HA, x-link, H3.2-
HA NPC
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 6438827 2946810
11 H3.2-HA, x-link, H3.2-
HA NPC
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
35 6935320 4006635
12 H3K36me3, x-link, H3.2-
HA, ES
H3K36me3 
(Abcam 
ab9050)
NP_H32_HA_
H3K36me3_xChIPSeq
36 6639414 4283010
13 Input, x-link, H3.3-HA 
hybrid ES
x-link 
ChIP input 
control.  No 
antibody.
ESHyb_H33_HA_In-
put_xChIPSeq
36 9110275 5371094
14 H3.3-HA, x-link, H3.3-
HA hybrid ES
anti-HA 
(12CA5)
ESHyb_H33_HA_an-
tiHA_xChIPSeq
36 9676064 5894951
14 H3.3-HA, x-link, H3.3-
HA hybrid ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 9784425 5997655
14 H3.3-HA, x-link, H3.3-
HA hybrid ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
34 6268370 3836705
15 H3K36me3, x-link, H3.3-
HA hybrid ES
H3K36me3 
(Abcam 
ab9050)
ESHyb_H33_HA_
H3K36me3_xChIPSeq
34 6463354 3789693
16 Input, x-link, H3.1S31-
HA hybrid ES
x-link 
ChIP input 
control.  No 
antibody.
ESHyb_H31S31_HA_In-
put_xChIPSeq
36 9173252 5397974
17 H3.1S31-HA, x-link, 
H3.1S31-HA hybrid ES
anti-HA 
(12CA5)
ESHyb_H31S31_HA_
antiHA_xChIPSeq
36 5780596 3603934
17 H3.1S31-HA, x-link, 
H3.1S31-HA hybrid ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 10048249 6076492
17 H3.1S31-HA, x-link, 
H3.1S31-HA hybrid ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 8300087 4699124
18 H3K36me3, x-link, 
H3.1S31-HA hybrid ES
H3K36me3 
(Abcam 
ab9050)
ESHyb_H31S31_HA_
H3K36me3_xChIPSeq
36 8371173 4773789
19 H3.3-HA, native, H3.3-
HA ES
anti-HA 
(12CA5)
ES_H33_HA_antiHA_
nChIPSeq
36 11966966 6541403
19 H3.3-HA, native, H3.3-
HA ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 11704727 7346788
20 H3K4me3, native, H3.3-
HA ES
H3K4me3 
(Abcam 
ab8580)
ES_H33_HA_
H3K4me3_nChIPSeq
36 8200550 5167942
21 Input, native, H3.3-HA 
ES
native 
ChIP input 
control.  No 
antibody.
ES_H33_HA_input_
nChIPSeq
36 11427929 6039408
22 H3.2-HA, native, H3.2-
HA ES
anti-HA 
(12CA5)
ES_H32_HA_antiHA_
nChIPSeq
36 2133418 1361872
22 H3.2-HA, native, H3.2-
HA ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
36 13362561 7074823
Table 5.2 contd.
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22 H3.2-HA, native, H3.2-
HA ES
anti-HA 
(12CA5)
deeper sequencing 
replicate within sample 
directory above
32 9664647 5528131
23 H3K4me3, native, H3.2-
HA ES
H3K4me3 
(Abcam 
ab8580)
ES_H32_HA_
H3K4me3_nChIPSeq
32 6402480 4415020
24 H3K27me3, native, 
H3.2-HA ES
H3K27me3 
(Upstate/
Millipore 
#07-449)
ES_H32_HA_
H3K27me3_nChIPSeq
32 8741662 5428037
25 Input, native, H3.2-HA 
ES
native 
ChIP input 
control.  No 
antibody.
ES_H32_HA_input_
nChIPSeq
32 8715354 5479449
26 H3.3-EYFP, native, 
H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
ES_H33_EYFP_anti-
GFP_nChIPSeq
36 5193695 3744380
26 H3.3-EYFP, native, 
H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
deeper sequencing 
replicate within sample 
directory above
36 5595554 3395192
26 H3.3-EYFP, native, 
H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
deeper sequencing 
replicate within sample 
directory above
36 6047143 3191111
27 Input, native, H3.3-
EYFP ES
native 
ChIP input 
control.  No 
antibody.
ES_H33_EYFP_Input_
nChIPSeq
36 5726370 3531774
28 H3K4me1, native, H3.3-
EYFP ES
H3K4me1 
(Abcam 
ab8895)
ES_H33_EYFP_antiH-
3K4me1_nChIPSeq
36 5780578 4385502
29 H3K36me3, native, 
H3.3-EYFP ES
H3K36me3 
(Abcam 
ab9050)
ES_H33_EYFP_antiH-
3K36me3_nChIPSeq
36 8600269 5174908
30 H3.3-EYFP, native, Hira 
-/- H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
Hiranull_ES_H33_
EYFP_antiGFP_
nChIPSeq
36 11564437 6590765
30 H3.3-EYFP, native, Hira 
-/- H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
deeper sequencing 
replicate within sample 
directory above
36 12460001 5457471
31 H3K4me1, native, Hira 
-/- H3.3-EYFP ES
H3K4me1 
(Abcam 
ab8895)
Hiranull_ES_H33_
EYFP_antiH3K4me1_
nChIPSeq
36 8915573 6420547
32 H3K36me3, native, Hira 
-/- H3.3-EYFP ES
H3K36me3 
(Abcam 
ab9050)
Hiranull_ES_H33_
EYFP_antiH3K36me3_
nChIPSeq
36 7999631 4416253
33 Input, native, Hira -/- 
H3.3-EYFP ES
native 
ChIP input 
control. No 
antibody.
Hiranull_ES_H33_
EYFP_Input_nChIPSeq
36 8156833 5292703
34 H3.3-EYFP, native, Atrx-
flox H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
Atrxflox_ES_H33_
EYFP_antiGFP_
nChIPSeq
36 6476017 4304375
34 H3.3-EYFP, native, Atrx-
flox H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
deeper sequencing 
replicate within sample 
directory above
36 9088918 5313474
34 H3.3-EYFP, native, Atrx-
flox H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
deeper sequencing 
replicate within sample 
directory above
36 9236425 6207716
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35 Input, native, Atrxflox 
H3.3-EYFP ES
native 
ChIP input 
control. No 
antibody.
Atrxflox_ES_H33_
EYFP_Input_nChIPSeq
36 6060126 4117751
36 H3.3-EYFP, native, Atrx-
null H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
Atrxnull_ES_H33_
EYFP_antiGFP_
nChIPSeq
36 7806156 4811353
36 H3.3-EYFP, native, Atrx-
null H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
deeper sequencing 
replicate within sample 
directory above
36 9685286 6402420
36 H3.3-EYFP, native, Atrx-
null H3.3-EYFP ES
anti-GFP 
(Cristea et 
al., 2005)
deeper sequencing 
replicate within sample 
directory above
36 8575771 5495831
37 Input, native, Atrxnull 
H3.3-EYFP ES
native 
ChIP input 
control. No 
antibody.
Atrxnull_ES_H33_
EYFP_Input_nChIPSeq
36 7102030 4758929
38 anti-HA, x-link, W9.5 
wild-type ES
anti-HA 
(12CA5) 
control. No 
HA epitope 
in untagged 
ES cells
ES_wild_type_antiHA_
control_xChIPSeq
36 7099906 3065689
Table 5.2 contd.
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Data Analysis
All ChIP-seq data analysis was performed in collaboration with Dr. Deyou Zheng. 
ChIP-seq or input reads were mapped to the mouse genome (build 37, or mm9) 
using the ELAND alignment software within the Illumina Analysis Pipeline. Profiles 
in specific genomic regions were displayed in the Affymetrix Integrated Genome 
Browser. For analysis of repetitive elements, reads were aligned directly to a library 
of mouse consensus repetitive sequences (http://www.girinst.org). For analysis 
at TSS and TES, we segregated reference gene (refSeq) annotation into low, 
medium and high expression based on a previous microarray analysis (Mikkelsen 
et al., 2007). For analysis of TFBS, binding sites for 13 TFs in mouse ES cells 
were obtained from a previous ChIP-seq analysis (Chen et al., 2008). To generate 
density profiles ± 5kb around TSS, TES, bivalent genes, and TFBS, we used a 
sliding window method which summed the number of ChIP-seq reads in each 200 
bp window. The sums were then normalized by the number of genes or TFBS in 
each group and the total mapped reads obtained in a ChIP-seq experiment. 
Genome-wide density maps of H3 variants and determination of enriched regions. 
All reads were mapped to the mouse genome (build 37, or mm9) using the ELAND 
alignment software within the Illumina Analysis Pipeline in multi/extended mode. 
Unique reads mapped to a single best-matching location with no more than two 
mismatches were kept.  During our data analysis, each read was extended 100 nt 
in its 3’ direction to account for the estimated ChIP DNA fragment size of ~300 bp. 
Using these extensions, we generated genome-wide distributions of H3 variants, 
histone modifications, and RNAPII represented by the number of reads spanning 
individual genomic locations.  These profiles were displayed in the Affymetrix 
Integrated Genome Browser (IGB) and also used for the determinations of genomic 
regions enriched with ChIP-Seq signals. Like H3K36me3, the signals for H3.3 are 
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very dispersed and often found in large extended regions (Figure 2.11, 2.19., 2.22, 
2.26). As a result, my collaborators and I tried several existing peak identification 
programs and found that they were not very effective in identification of H3.3 
enriched regions.  We therefore employed a simple segmentation algorithm. We 
first applied a Poisson distribution to model the genome-wide ChIP-Seq profile, and 
then selected positions with read coverage above a threshold that was determined 
for each experiment specifically at the p-value of 0.1.  Adjacent positions above 
this threshold and less than 600 bp apart were then merged to form genomic 
blocks, which were subsequently filtered by a minimal length of 300 bp to generate 
candidates of enriched regions.  The final enriched regions, furthermore, must also 
have twice more reads in a ChIP assay than its control input run (after normalization 
by read depths).  As a comparison, 95% and 97% of the peaks identified by our 
method for H3K4me1 and H3K4me3 ChIP-Seq experiments, respectively, were 
also determined as peaks by a popular ChIP-Seq peak analysis program, MACS 
(Zhang et al., 2008), suggesting that we only called peaks of high confidence. 
Figure 2.12 and Figure 2.14 summarize the numbers of enriched regions for 
selected ChIP-experiments and their spatial relationships to gene annotation and 
transcription factor binding sites.
The relative depositions of H3 variants in repetitive elements.  Reads were aligned 
directly to a library of mouse consensus repetitive sequences (http://www.girinst.
org).  The proportion of reads aligning to each class of repeats was computed for 
H3.3, H3.2, and H3.1S31, on the condition that the alignment length and sequence 
identity must be ≥ 25-bp and ≥ 90%, respectively. The resulting numbers were 
compared to the corresponding proportions calculated for input controls to yield 
relative fold-enrichments. 
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Distributions of H3 variants in transcription start and end sites.  The reference gene 
(refSeq or known genes) annotation was downloaded from the UCSC browser 
(http://genome.ucsc.edu), and genes were segregated into low, medium and high 
expression based on expression data obtained from a previous microarray analysis 
(Mikkelsen et al., 2007) . The expression values for these three categories were 
defined as 5~20, 50~200, and >500, respectively. Based on the CpG contents 
in their promoters, genes were further divided into three types: high (HCP), 
intermediate (ICP) and low CpG (LCP) promoters (Mikkelsen et al., 2007).  Data 
shown here are mostly for low, medium and high expression HCP genes (~1800 
genes in each group).  The three groups of genes were comparatively analyzed 
for density profiles of H3 variants or modifications around their transcription start 
sites (TSSs) and transcription end sites (TESs).  Briefly, after dividing the ± 5kb 
regions across TSSs (or TESs) into 50 non-overlapping windows (200-bp in size), 
we summed the number of ChIP-Seq reads ending in each window over all genes. 
The sums were then normalized by the gene number in each group and the total 
of mapped reads obtained in a ChIP-Seq experiment to generate final aggregated 
ChIP-Seq profiles of H3 variants or modifications. This sliding window method was 
also applied to analyze a set of genes with “bivalent” marks at their promoters in 
mouse ES cells but not in mouse NPC (Mikkelsen et al., 2007). 
The relative enrichment of H3 variants in TFBS.  The lists of binding sites for 13 
transcription factors in mouse ES cells were obtained from a previous ChIP-Seq 
analysis (Chen et al., 2008).  RefSeq gene annotation was used to segregate 
TFBS into three groups: promoter (± 5 kb of TSS), intergenic (5 kb away from 
genes), and otherwise gene body. After extending each of these TFBS from its 5’ 
and 3’ direction to span 10-kb sequence, we applied a sliding-window approach, 
similar to the one for TSSs, to generate density profiles over TFBS for different 
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H3 variants or histone modifications.  (Chen et al., 2008) has also defined a set 
of multiple transcription factor-binding loci (MTL) that were bound by more than 
four different transcription factors. For these MTL, we computed the read density 
(number of reads per 5-kb sequence) to characterize the correlation between 
number of bound factors and the abundance of different H3 variants. 
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APPENDIx
CHROMATIN IMMUNOPRECIPITATION (CHIP) AND 
DETAILED PROTOCOLS FOR CHIP-SEq
The crosslinking ChIP-seq protocol described below was adapted from a ChIP-
chip protocol originally published by the laboratory of Dr. Richard Young (Lee et 
al., 2006b). In addition, a number of the steps in this protocol grew out of detailed 
discussions with Dr. Tom Milne, Sarah Whitcomb, and Dr. Nicolai Siegel. For native 
ChIP-seq, I adapted a native ChIP protocol from Dr. Keji Zhao’s laboratory (Barski 
et al., 2007). 
Crosslinking and native ChIP
ChIP is generally performed with either formaldehyde-mediated crosslinking of 
proteins and nucleic acids within living cells followed by sonication (crosslinking, 
x-ChIP) or by micrococcal nuclease digestion of harvested cell nuclei and isolation 
of solubilized mono or short oligonucleosomes (native ChIP).  Crosslinking 
ChIP ‘freezes’ protein and nucleic acid interactions and enables the analysis 
of nucleosomal as well as non-nucleosomal proteins such as TFs and RNA 
polymerase, while native ChIP is more suitable for the analysis of core chromatin 
and nucleosomal components such as histones and histone modifications (Kuo and 
Allis, 1999; O’Neill and Turner, 2003) (See Figure 1.8).  I used a slightly modified 
version of described protocols (Barski et al., 2007; Lee et al., 2006b) to perform 
both native and crosslinking ChIP.  Both protocols use Invitrogen Dynal magnetic 
beads (Invitrogen Dynabeads anti-mouse M-280 #112-02, or Dynabeads anti-
rabbit M-280 #112-04, or Dynabeads Protein A #100-02D).  I have found that these 
magnetic beads generate low background when washed as described (Barski et 
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al., 2007; Lee et al., 2006b), and also are free of salmon sperm DNA which might 
otherwise contaminate ChIP-seq results.  The use of a protocol that omits salmon 
sperm or other non-specific DNA blocking agents is absolutely critical for ChIP-
seq, as such non-specific nucleic acids overwhelm the actual sequence reads 
from specifically immunprecipitated DNA (D Zheng, personal communication). 
 For x-ChIP, I harvested embryonic stem (ES) cells and neural precursor cells 
(NPCs) immediately prior to fixation with 1% paraformaldehyde, as I found that 
crosslinking on gelatin-coated plates also crosslinks gelatin. Approximately 1*10^7 
cells were used for each ChIP.  For sonication, I used a Bioruptor (Diagenode) 
and optimized sonication conditions to generate DNA fragments of approximately 
300-500bp.  Following a published x-ChIP protocol (Lee et al., 2006b) through 
overnight crosslink reversal at 65˚C, RNase digestion, and proteinase K digestion, 
I then isolated ChIP DNA and ChIP input DNA using the Qiagen Qiaquick PCR 
purification kit (28104), eluting in 50μl 10mM Tris pH8.5.  For native ChIP, I used 
the published protocol (Barski et al., 2007) as described, with slight modifications. 
Following the final wash, I eluted off of magnetic beads using 50mM Tris-HCl pH 
8.0, 10mM EDTA, and 1% SDS, as described in the x-link ChIP protocol (Lee 
et al., 2006b).  Following elution, I digested proteins with proteinase K (Roche, 
recombinant, PCR grade, 03115828001), and isolated DNA with Qiagen PCR 
purification kit as described for x-ChIP protocol. Following DNA isolation from 
native ChIP, ChIP-seq library preparation is largely identical to the crosslinking 
ChIP-seq protocol.
Validation of ChIP prior to ChIP-seq
To validate the ChIP, I used real-time PCR with SYBR Green PCR master mix 
(Applied Biosystems) to amplify ChIP samples and ChIP inputs, determining % 
input of ChIP samples at target locations and control intergenic locations.  Real-
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time PCR is critical for ChIP quality control prior to ChIP-seq. Primer sequences 
and ES % inputs are listed in Table 5.1.  To confirm telomere enrichment, ChIP-
seq DNA libraries were also probed with a TTAGGG repeat probe and BamHI 
repeat probe as described (Sfeir et al., 2009).
ChIP-seq library preparation
For ChIP-seq of x-link or native ChIP DNA, I took 30 ul of remaining ChIP DNA 
or ~180ng of input DNA, repaired DNA ends to generate blunt-ended DNA using 
the Epicentre DNA ENDRepair kit (Epicentre Biotechnologies, cat# ER0720), and 
purified repaired DNA using Qiagen PCR purification kit (28104).  Following DNA 
END Repair, I added A bases to the 3’ end of the DNA fragments using Klenow 
Fragment (NEB M0212L), and purified DNA using Qiagen MinElute (28004).  I ligated 
Illlumina/Solexa adapters (#FC-102-1003) to DNA fragments overnight, using T4 
DNA ligase (NEB M0202L).  Following overnight ligation, I purified adapter-ligated 
DNA fragments with Qiagen MinElute.  To generate libraries for Solexa sequencing, 
I performed 18 cycles of PCR with Illumina/Solexa primers 1.1 and 2.1, checked 
the fragment size for 1/10 of the amplified library on an agarose gel, and purified 
the remaining ChIP-seq library using Qiagen MinElute.  I did not use gel purification 
to isolate the ChIP-seq library, as standard methods of gel purification have been 
shown to decrease the representation of A+T-rich sequences (Quail et al., 2008), 
and I have also found decreased DNA yield following gel purification (data not 
shown).  Detailed protocols for all of these steps are provided below.  For details of 
Solexa sequencing and ChIP-seq data analysis, please see Chapter Five.
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Detailed protocols for crosslinking ChIP-seq
Prepare cells and paraformaldehyde
For ChIP-seq, seed cells so as to reach ~1*10^7 cells / IP. 1. 
Prepare 10% paraformaldehyde stock as follows:
Microwave 18ml of PBS in a 50ml tube placed in a beaker with water until water 
starts to boil (leave lid of tube slightly ajar). Do the subsequent steps in a hood.  Add 
2 grams of paraformaldehyde (wear a mask when weighing this out) and 140λ of 
1M KOH. Vortex (be careful since this is a hot solution) and the paraformaldehyde 
should dissolve. QS to 20 ml. Cool to 370 before use. Can be stored frozen 
indefinitely.
Cross-link and fix cells
Fix cells for 10 minutes with 1% freshly made or frozen paraformaldehyde in 2. 
media @ 370.  Count another plate in parallel to have some idea of cell #.
* aside for BM  (and other non-adherent) cells - fix in a small volume of Pf/media 
(~5ml) and then dilute 10X with 45 ml RPMI.  
Fix trypsinized ES or non-adherent cells in 10ml warm media +1ml 10% PF, rotating 
in a 50ml conical tube at RT.  (Fixing ES cells on a gelatinized plate crosslinks 
the gelatin, and generates a goopy, disastrous mess.  Hence, trypsinize ES cells 
first.)
     For adherent cells grown on tissue culture dishes without gelatin, add 1 ml 
10% paraformaldehyde to 10 ml media for 10 min at 37.  
Quench unreacted paraformaldehyde with 2.5M glycine, 5 min @ RT, 3. 
rotating if the cells are already out of the tissue culture dish.  (2.5M glycine is ~20X, 
ie 500µl / 10ml media with  1% paraformaldehyde.)
Dilute with 40ml cold media with FBS.  This step may neutralize any residual 4. 
trypsin or formaldehyde, but is not required.
Spin fixed cells down.  Remove media/paraformaldehyde and rinse and 5. 
resuspend cells with 5ml PBS + protease inhibitors (PI).  Add PI just before use. 
Transfer to a new tube (15ml or 1.5 ml tube). Cold PBS + inhibitors rinse.  (Make 
sure to include protease inhibitors in last PBS rinse prior to flash freeze.  I use 1 
tablet of PI / 7ml of PBS. Roche, complete mini EDTA-free 11-836-170-001)
Pellet cells @ 1200rpm, 5’.  Flash-freeze pellet in liquid nitrogen and store 6. 
@-800 .  Alternately, you can continue with protocol. If continuing, note that a single 
freeze/thaw helps break up cells.
Bind antibody to Dynabeads/ block beads (afternoon prior to ChIP)
Block Solution (for 1 ChIP)
500ml  1x PBS
2.5g BSA  --> 0.5% w/v
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1. 150uL Dynabeads (anti-mouse M-280, cat# 112-02, or anti-rabbit M-280 
cat#112-04, to eppendorff (for 2 ChIPs)
2. 3x wash 1ml block solution: gently mix, collect beads, remove sup
3. resuspend beads in 500uL block solution + ~15ug antibody (20ul H3K4me3 
ab8580) (scale antibody and beads accordingly: 100ul beads, ~10ug antibody – 
aim for more rather than less antibody – you will wash any remaining antibody 
away after binding to the beads).  Per IP, you will use > 50ul of antibody bound 
beads, >5ug antibody, for ~ 1*10^7 cells.
4. O/N rotating @ 4 deg
5. 3x wash in 1ml block solution
6. resuspend beads in 150uL block solution
Lysis and Sonication
LB1 for 100mL
5mL  1M Hepes-KOH, pH 7.5 --> 50mM
2.8mL   5M NaCl   --> 140mM
0.2mL  0.5M EDTA   --> 1mM
20mL  50% glycerol   --> 10%
5mL  10% NP-40   --> 0.5%
2.5mL  10% Triton x-100  --> 0.25%
64.5mL ddH2O 
1.  pipette resuspend x-linked cell pellet in 1mL LB1 + protease inhibitors (PI) 
(per1*10^7 cells! ie, for 9*10^7 cells, use 9ml) -- if using large cell #s, the next few 
steps can be done in a conical -- just make sure to sufficiently resuspend pellet.
2. 10 min rotating @ 4deg
3. spin 5 min @ 1,350g @ 4deg
LB2 for 100mL
1mL  1M Tris-HCl, pH 8.0  --> 10mM
4mL  5M NaCl   --> 200mM
0.2mL  0.5M EDTA   --> 1mM
0.1mL  0.5M EGTA   --> 0.5mM
94.7mL ddH2O 
1. pipette resuspend pellet in 1mL LB2 + PI
2. 10 min rock @ RT
3. spin 5 min @ 1,350g @ 4deg
LB3 for 100mL
1mL  1M Tris-HCl, pH 8.0  --> 10mM
2mL  5M NaCl   --> 100mM
0.2mL  0.5M EDTA   --> 1mM
0.1mL  0.5M EGTA   --> 0.5mM
1mL  10% Na-Deoxycholate --> 0.1%
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2.5mL  20% N-lauroylsarcosine --> 0.5%
93.2mL ddH2O
1. resuspend pellet in 600µl LB3 + PI, for 1*10^7 cell# ChIP-seq)
 Note: for multiple ChIPs from the same sample, resuspend in more LB3, 
  for ChIP-seq, ~600ul LB3 / 1*10^7 cells / IP, pool resuspended 
cells.
 pass through 27 gauge needle 2-3x to break up cell clumps
 -split into aliquots for Bioruptor sonication, no more than 300ul per tube
2. sonicate BioRuptor 7x 30”/30” in ice water, high power, replace ice, repeat 
7x sonication.
3. Pool sonicated chromatin from one sample in a 15ml conical.  Add 1/10 
volume of 10% Triton X-100 to sonicated lysate  (DO NOT FORGET TO ADD 
TRITON OR YOU WILL NOT SOLUBILIZE YOUR NUCLEAR MEMBRANE) (for 
ex., 80ul for 800ul).
4. Aliquot and spin 10min @ 20,000g @ 4deg to crack nuclei; save sup = IP 
input
 Aliquot 600µl sup for each IP.  
 save 30uL (5%) freeze for sonication check (agarose) 
 save 30uL (5%) freeze for ChIP INput (compare w/ChIP elute)
 Freeze remaining sup in aliquots for future IPs.
IP Chromatin
1. add 70uL antibody bound bead mix to sonication sup (600ul) – if you are 
using fewer than 1*10^7 cells per IP, you can scale your antibody and beads down 
accordingly
2. rotate O/N @4deg
Wash
RIPA Wash Buffer (for 250mL)
12.5mL 1M Hepes-KOH, pH 7.6 --> 50mM
125mL 1M LiCl   --> 500mM
0.5mL  0.5M EDTA   --> 1mM
25mL  10% NP-40   --> 1%
17.5mL 10% Na-Deoxycholate --> 0.7%
69.5mL ddH2O
 @ 4 deg
0. start water bath to 65deg for elution and rev X-link!
1. 3-7x (Suggestion: 8x !) wash 1mL RIPA wash buffer - on magnetic stand
2. wash 1mL TE +  50mM NaCl
3. spin (3 min @ 960g @ 4deg and carefully remove residual TE with a pipet 
– (do NOT attempt to use magnet at this step or you will lose your sample)
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Elute
Elution Buffer (for 100mL)
5mL 1M Tris-HCL, pH 8.0 --> 50mM
2mL 0.5M EDTA   --> 10mM
10mL 10% SDS   --> 1%
83mL ddH2O   
1. add 210uL elution buffer
2. elute 30 min @ 65deg- resuspend beads every 2 min by briefly vortexing 
– make sure caps on tubes are not loose – also, the 65 degree water bath can 
bleed the marker – write in strong marker and keep track of tubes
3. spin down 1 min @ 16,000g @ RT
4. remove 200uL sup transfer to new eppendorff
 
Reverse Crosslinks
1. bring ChIP IN samples (30uL) and sonication check samples (30uL) frozen 
yesterday to  200uL with elution buffer
2. ChIP elutions (IP), ChIP IN, sonication check samples O/N @ 65 deg
Digest RNA and protein
1. add 2uL 500 ug/ml RNase (Roche, RNase, DNase free, Cat. No. 11 119 915 
001), vortex briefly to mix
2. 1 hour @ 37deg  (bring water bath to 55 deg) 
3. add 2uL 14-22 mg/mL Proteinase K (Roche, proteinase K, recombinant, 
PCR grade, Cat. No. 03 115 828 001) proteinaseK --> 0.2ug/mL final, vortex 
briefly.
4. 2 hours @ 55 deg
DNA purification
5. Recover DNA by Qiagen PCR purification kit.  Add 1ml of Binding reagent 
PBI to each RNased, PK digested sample.  Mix.  
6.  Bind DNA through Qiagen spin columns as described in protocol, using 
no more than 0.75ml of sample at one time / column.  Ie, apply the first 0.7ml, 
spin, discard flow-through, then apply then second ~0.5ml, spin, etc.  Continue as 
described in Qiagen PCR purification protocol.  Elute with 50µl qiagen elution 
buffer EB.  Take 5 ul of ChIPed, purified DNA for real-time PCR analysis. 
Store remaining 45ul at -20, and use for ChIP-seq only pending real-time 
PCR analysis.
Real-time PCR analysis
Make 1:100 dilution of each input and sample (5ul + 495ul H2O) for real-time 
PCR.  I use SYBR green (Applied Biosystems SYBR Green PCR Master Mix, 
#4309155) for real-time quantification.
For each primer set, make the appropriate mix.  Keep on ice until adding to plate. 
Use 15λ of each mix / well of 96-well real-time PCR plate.  Add 10λ of appropriate 
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1:100 dilution to each well for 25λ total.  Make sure to pipet up and down.  Quick 
spin 96 well plate for 30 sec. at 450rpm to make sure mix is even in all wells.
  
   1:100 DNA  10.0 λ
2X SYBR Mix:  12.5 λ  
   Fwd primer    0.5 λ
   Rev primer    0.5 λ
   H20     1.5 λ
   Total   25.0 λ
Preparing ChIP samples for ChIP-seq
Note on yield of ChIP DNA: ChIP DNA amounts are generally <10ng / ul, and not 
accurately quantifiable by nanodrop.  Therefore, I do not base my decision about 
whether to use the sample for ChIP-seq on the relative DNA yield, but rather on 
real-time PCR analysis, looking at % input at an enriched location vs % input at 
an unenriched location.  Antibody quality and the relative biological abundance of 
their epitopes can be variable, but the real-time PCR analysis is critical to make 
sure that you are sequencing high quality, specifically IPed material.  
Note on yield of input DNA:  Typical yields of purified input DNA (pre-IP) are ~50-
100+ ng / µl, with 50 µl EB representing 5% (2.5 to 5 µg) of the original input (~ 
50-100 µg.)
DNA end repair
1.  Repair DNA ends to generate blunt-ended DNA using the Epicentre DNA 
ENDRepair
kit (Epicentre Biotechnologies, cat# ER0720)
 1-34 μl DNA (0.3 μg)
 5 μl 10x End repair buffer (330 mM Tris-acetate, pH7.8, 660 mM
 potassium acetate, 100 mM magnesium acetate, 5 mM DTT)
 5 μl 2.5 mM each dNTPs
 5 μl 10 mM ATP
 x μl H2O to adjust the reaction volume to 49 μl
 1 μl End-Repair Enzyme mix (T4 DNA Pol + T4 PNK)
For ex.:
 30 μl ChIP DNA from remaining 45ul (~180ng of input DNA, add H20 to 
reach 30µl)
 Make mix qs to 19µl 5 μl 10x End repair buffer
    5 μl 2.5 mM dNTP mix
    5 μl 10 mM ATP
    4 μl H2O to adjust the reaction volume to 49 μl
 1 μl End-Repair Enzyme mix (T4 DNA Pol + T4 PNK)
 Keep at room temperature for 45 min.
2. Use QIAquick PCR purification kit and elute in 34µl Qiagen EB
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Add ‘A’ bases to the 3’ end of the DNA fragments
3. Add “A” to 3′ ends
 34 μl DNA from above
 Make mix qs to 13µl  
  5 µl Klenow buffer NEB2 (10X)
  1 µl dATP (10mM)
  7 µl dH20
 3µl Klenow enzyme (Klenow Fragment (3´→ 5´ exo- ), NEB M0212L 5000 
un/ml)
 Total volume: 50 μl
 Incubate for 30 min at 37°C. 
4.  Purify DNA with Qiagen MinElute (cat. 28004) and elute in 11µl Qiagen EB.
Figure A1:  Gel image of crosslinking ChIP-seq DNA pre and post-amplification for Solexa 
sequencing
Sonicated ChIP inputs and ChIP samples were amplified and prepared for Solexa sequencing. 
~180ng of ChIP input DNA and 35μl of each ChIP sample were used in end repair, A addition, 
adapter ligation, and amplification (see detailed steps above).  300 ng of ChIP input DNA was loaded 
for comparison (pre-amplification, left).  Following 18 cycle PCR amplification with Solexa primers 
1.1 and 2.1, 4μl  of unpurified 50ul PCR reaction was loaded in each lane to assess fragment sizes 
of the amplified ChIP-seq libraries (post-amplification, right).  DNA ladder (center) indicates that the 
ChIP-seq libraries are predominantly between 300-500bp.  The remaining 46μl post-amplification 
PCR reaction was then directly purified with Qiagen MinElute (without gel purification) and eluted 
into 15μl EB for Solexa sequencing.
Inputs
H3.3  H3.1
 HA    S31
       HA
Pre-
amplification Post-amplification
H3.3-HA ES H3.1S31-HA ES----------------------- -----------------------
Inp HA  K36me3  nIgG Inp HA   K36me3 nIgG
1    2     3      4      5     6      7     8
1000
850
100
650
500
400
300
200
2000
1850
------------ Size-------
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Ligate adapters to DNA fragments
5. Linker ligation. The oligo mix should contain 10x molar excess of the DNA
templates.
 10 μl DNA
 Make mix qs to 17µl   
  3 µl 10x T4 DNA ligase buffer
  13 μl H2O (nuclease free)
  1 μl Solexa adapter oligo mix (try 1:10 dilution)
   3 μl T4 DNA ligase (NEB M0202L, 400 units/μl)
 Total volume: 30 μl
Incubate at room temperature for 15 min and then overnight in PCR program 
below.
1) 4°C for 2 hrs.   2) 0.1° / s to 16°C.  3) 16°C for 20min.  4) 0.1° / s to 4°C.  
5)  Go to 1, 6 times.  6)  4°C forever.
6.  Purify DNA with QIAGEN MinElute and elute in 11µl Qiagen EB.
Amplify adapter-modified DNA fragments by PCR to generate ChIP-seq 
library
7. Amplify the DNA using Solexa primers and enzyme mix
 10 μl of DNA
  Make mix qs to 39.5µl 10 μl of 5X Phusion HF buffer
      1.5 μl of dNTP mix (10mM dNTP)
      0.75 µl Solexa primer 1.1
      0.75 µl Solexa primer 2.1
      1.5 µl DMSO
      25 µl dH20 (nuclease free)
 0.5 µl Phusion
 Total volume: 50 μl
 Denature at 98°C for 30 sec.  98°C, 10sec; 65°C, 30sec; 72°C, 30sec. (18 
 cycles)  72°C, 5 min. hold @ 4 degrees.
8.  Try 18 cycles first, check 4 μl of product on 2% gel. If the band is not
clearly visible, do 3 more cycles. Check again. 
9.  Purify remaining 46µl DNA with Qiagen MinElute (cat. 28004) and elute in 15µl 
Qiagen EB.  
10.  Nanodrop and store at -20 prior to Solexa sequencing.  Typical nanodrop 
yields post amplification and MinElute purification are 170-270 ng / µl, 15 µl total 
volume in Qiagen EB.
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